WO2004052280A2 - Anti-angiogenic compounds and their use in cancer treatment - Google Patents

Anti-angiogenic compounds and their use in cancer treatment Download PDF

Info

Publication number
WO2004052280A2
WO2004052280A2 PCT/US2003/038512 US0338512W WO2004052280A2 WO 2004052280 A2 WO2004052280 A2 WO 2004052280A2 US 0338512 W US0338512 W US 0338512W WO 2004052280 A2 WO2004052280 A2 WO 2004052280A2
Authority
WO
WIPO (PCT)
Prior art keywords
compound
formula
optionally substituted
group
nmr
Prior art date
Application number
PCT/US2003/038512
Other languages
French (fr)
Other versions
WO2004052280A3 (en
Inventor
Evgueni Piatnitski
Alexander Kiselyov
Jacqueline Doody
Yaron Hadari
Shawn Ouyang
Xiaoling Chen
Original Assignee
Imclone Systems Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imclone Systems Incorporated filed Critical Imclone Systems Incorporated
Priority to AU2003293376A priority Critical patent/AU2003293376A1/en
Publication of WO2004052280A2 publication Critical patent/WO2004052280A2/en
Publication of WO2004052280A3 publication Critical patent/WO2004052280A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Definitions

  • the present invention relates to novel five-membered ring heterocycles that inhibit the tyrosine kinase activity of VEGF receptors and are useful in the treatment of cancers, processes for making the heterocycles, pharmaceutical compositions and dosage forms that contain them, methods of treating angiogenic dependent diseases in mammals using them, and methods of manufacturing the compositions and dosage forms.
  • Angiogenesis is the process by which new blood vessels develop in an organism. During angiogenesis, capillary endothelial cells proliferate and migrate f om pre-existing blood vessels into other tissues where they assemble into tubular structures and join to form tubular assemblies and closed-circuit vascular systems. These vascular systems undergo maturation to form new capillary vessels connected to the vascular network.
  • Angiogenesis is important to normal physiological processes like embryonic development, follicular growth, and wound healing. Angiogenesis also is necessary to the progression of some pathological conditions like neoplastic diseases (cancers) and non-neoplastic diseases that involve abnormal neovascularization like some inflammatory diseases and vascular proliferative diseases like atherosclerosis, restenosis and neovascular glaucoma (Folkman, J. and Klagsbrun, M. St ⁇ eflee 235:442-447 (1987)). In neoplastic diseases, the vascularization provides nourishment to the neoplasm and enables the migration of tumor cells through the vasculature.
  • cancers neoplastic diseases
  • non-neoplastic diseases that involve abnormal neovascularization like some inflammatory diseases and vascular proliferative diseases like atherosclerosis, restenosis and neovascular glaucoma (Folkman, J. and Klagsbrun, M. St ⁇ e
  • Inflammatory diseases whose progression is accompanied by blood vessel proliferation include rheumatoid arthritis, psoriasis, diabetic retinopathy and age-related macular degeneration. These and other pathological conditions that are aggravated by persistent or uncontrolled angiogenesis are known as angiogenic dependent diseases.
  • Angiogenesis like many other biological mechanisms requiring regulation of cellular proliferation, is dependent on the phosphorylation of proteins by protein tyrosine kinases. Overexpression or aberrations in the pathways coupled to these kinases can produce pathological outcomes (like uncontrolled angiogenesis and tumor growth). Inhibitors, modulators or regulators of kinase activity have the potential to be therapeutically relevant agents in the treatment of tumor growth and other angiogenic dependent diseases.
  • VEGF Vascular endothelial growth factor
  • VEGF is a homodimeric glycoprotein consisting of two 23 kD subunits.
  • Four different monomeric isoforms of VEGF resulting from alternative splicing of mRNA have been identified. These include two membrane bound forms (VEGF 206 and VEGF lg9 ) and two soluble forms (VEGF 165 and VEGF 121 ).
  • VEGF 165 is the most abundant isoform in all human tissues except placenta.
  • VEGF is a potent endothelial-cell specific mitogen (ED 50 2-10 pM), specifically promoting proliferation of endothelial cells.
  • VEGF is expressed in embryonic tissues (Breier et al., Development (Camb.) 114:521 (1992)), macrophages, and proliferating epidermal keratinocytes during wound healing (Brown et al., J. Exp. Med., 176:1375 (1992)), and may be responsible for tissue edema associated with inflammation (Ferrara et al, Endocr. Rev. 13:18 (1992)).
  • VEGF expression in situ hybridization studies have demonstrated high levels of VEGF expression in a number of human tumor lines including glioblastoma multiforme, hemangioblastoma, other central nervous system neoplasms and ALDS-associated Kaposi's sarcoma (Plate, K. et al. (1992) Nature 359: 845-848; Plate, K. et al. (1993) Cancer Res. 53: 5822-5827; Berkman, R. et al. (1993) J Clin. Invest. 91:
  • VEGF vascular endothelial growth factor
  • VEGF receptors are class HI receptor-type tyrosine kinases characterized by having several, typically 5 or 7, immunoglobulin-like loops in their amino-terminal extracellular receptor ligand-binding domains (Kaipainen et al, J. Exp. Med., 178:2077-88 (1993)).
  • the other two regions include a transmembrane region and a carboxy-terminal intracellular catalytic domain interrupted by an insertion of hydrophilic interkinase sequences of variable lengths, called the kinase insert domain (Terman et al., Oncogene, 6:1677-83 (1991)).
  • VEGF receptors include fms-Vke tyrosine kinase receptor (flt-1), or VEGFR-1, sequenced by Shibuya et al., Oncogene, 5:519-24 (1990), kinase insert domain-containing receptor/fetal liver kinase (KDR/flk-1), or VEGFR-2, described in WO 92/14248, filed February 20, 1992, and Terman et al., Oncogene, 6:1677-83 (1991) and sequenced by Matthews et al., Proc. Natl. Acad. Sci. USA, 88:9026-30 (1991), although other receptors can also bind VEGF.
  • Another tyrosine kinase receptor, VEGFR-3 (flt-4) binds the VEGF homologues VEGF-C and VEGF-D and is important in the development of lymphatic vessels.
  • KDR/VEGFR-2 is the main VEGF signal transducer that results in endothelial cell proliferation, migration, differentiation, tube formation, increase of vascular permeability, and maintenance of vascular integrity.
  • VEGFR-1 possesses a much weaker kinase activity, and is unable to generate a mitogenic response when stimulated by VEGF, although it binds to VEGF with an affinity that is approximately 10-fold higher than KDR.
  • VEGFR-1 has also been implicated in VEGF and placenta growth factor (P1GF) induced migration of monocytes and macrophages and production of tissue factor.
  • P1GF placenta growth factor
  • VEGF+ tumor cells will up-regulate expression of VEGF receptor molecules, e.g., VEGFR-1 and VEGFR-2.
  • High levels of VEGFR-2 are expressed by endothelial cells that infiltrate gliomas (Plate, K. et al., (1992) Nature 359: 845-848), and are specifically upregulated by VEGF produced by human glioblastomas (Plate, K. et al. (1993) Cancer Res. 53: 5822-5827).
  • VEGR-2 expression in glioblastoma associated endothelial cells suggests that receptor activity is induced during tumor formation, since VEGFR-2 transcripts are barely detectable in normal brain endothelial cells, indicating generation of a paracrine VEGF/VEGFR loop. This upregulation is confined to the vascular endothelial cells in close proximity to the tumor.
  • Blocking VEGF activity with neutralizing anti-VEGF monoclonal antibodies (mAbs) results in inhibition of the growth of human tumor xenografts in nude mice (Kim, K. et al. (1993) Nature 362: 841-844), suggesting a direct role for VEGF in tumor-related angiogenesis.
  • VEGFR antagonists have been developed to treat vascularized tumors and other angiogenic associated diseases. These have included neutralizing antibodies that block signaling by VEGF receptors expressed on vascular endothelial cells to reduce tumor growth by blocking angiogenesis through an endothelial-dependent paracrine loop. See, e.g., U.S. Patent No. 6,365,157 and International Publications Nos.
  • VEGF receptors also have been found on some non-endothelial cells, such as tumor cells producing VEGF, wherein an endothelial-independent autocrine loop is generated to support tumor growth. It has been demonstrated that a VEGF/human VEGFR-2 autocrine loop mediates leukemic cell survival and migration in vivo. Dias et al., "Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration," J. Clin. Invest. 106:511-521 (2000); Witte et al., “Treatment of non-solid mammalian tumors with vascular endothelial growth factor receptor antagonists;” and International Publication No. WO 01/74296. Similarly, VEGF production and VEGFR expression also have been reported for some solid tumor cell lines in vitro. (See Tohoku, Sato, J. Exp. Med., 185(3):
  • VEGFR-1 Mabs inhibit an autocrine VEGFR/human VEGFR-1 loop in breast carcinoma cells.
  • Wu, et al. "Monoclonal antibodys against VEGFR1 inhibits fltl -positive DU4475 human breast tumor growth by a dual mechanism involving anti-angiogenic and tumor cell growth inhibitory activities," AACR_NCI_EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 29-November 2, 2001, Abstract #7; and Carmeliet et al. (International PCT application filed June 20, 2002).
  • inhibitors of VEGF receptor tyrosine kinase activity can interrupt the paracrine and/or autocrine VEGF/ VEGFR loop.
  • Such inhibitors hold the potential to disrupt pathological angiogenisis and influence the progression of angiogenic dependent diseases.
  • vascular endothelial cells in particular vascular endothelial cells adjacent to cells affected by a disease that needs neo vascularization in order to advance to a life threatening stage.
  • agents that are useful for the treatment of cancer Novel small molecules have been discovered which have an inhibitory effect on the tyrosine kinase activity of VEGFR-2 receptors and utility in cancer treatment. These compounds share a 1,3-disubstituted five-membered heterocyclic ring scaffold represented by Formula (I):
  • X j and X 2 are atoms or radicals independently selected from the group consisting of oxygen, sulfur, nitrogen, radicals of formula C-R 3 and radicals of formula N-R 3 , with the proviso that at least one of X j and X 2 is oxygen, sulfur, nitrogen or a diradical of formula N-R 3 , wherein:
  • R 3 is an atom or radical selected from the group consisting of: 1) hydrogen, 2) halogen,
  • R 4 is an atom or radical selected from the group consisting of: a) halogen; b) alkyl, which may be optionally substituted with one or more halogen, hydroxy or lower alkoxy; c) alkenyl, which may be optionally substituted with one or more halogen, hydroxy or lower alkoxy; d) nitro; e) cyano; f) oxo; g) vinyl; h) styryl; i) a group of formula -C(O)R 5 , -CO 2 R 5 , -OR 5 , -SR 5 , -SOR 5 , -
  • R 5 and R 6 are atoms or radicals independently selected from the group consisting of hydrogen, lower alkyl, aralkyl, aryl and heteroaryl;
  • X 3 is selected from the group consisting of oxygen, sulfur, nitrogen and diradicals of formula N-R 3 ,
  • Y j and Y 2 are atoms independently selected from the group consisting of nitrogen and carbon,
  • R j is a radical selected from the group consisting of:
  • Wj is nitrogen or C-R ⁇ ,
  • W 2 is nitrogen or C-R ⁇
  • W 3 is nitrogen or C-R w3
  • W 4 is nitrogen or C-R ⁇
  • W 5 is nitrogen or C-R ⁇
  • W 6 is nitrogen or and
  • W 9 is nitrogen or C-R ⁇
  • each R ⁇ , R w2 , R w3 , R w4 , R w5 , R ⁇ , R ⁇ , R ⁇ and R ⁇ being an atom or radical independently selected from the group consisting of: 1) hydrogen, 2) halogen,
  • alkyl optionally substituted with one or more substituents selected from R 4
  • alkenyl optionally substituted with one or more substituents selected from R 4
  • X 4 is O, S, or N-R 4 , a is 0 to 3, b is 0 to 2, c is 0 or l, or together, one or more of the combinations R ⁇ and R ⁇ , R w2 and R w3 , R w3 and R ⁇ , R, v5 and R w6 , R w6 and R w7 , R ⁇ and R ⁇ , and R w8 and R ⁇ form a fused 5- or 6- membered carbocyclic ring or heterocyclic ring having one or two heteroatoms selected from nitrogen, oxygen and sulfur, Z is selected from the group consisting of oxygen, sulfur, -S(O)-, -S(O) 2 -, -
  • CR 5 R 6 -, -CR 5 R 6 O-, CR 5 R 6 NR 3 - and -NR 3 - R 2 is a radical of formula -OR 7a , -SR 7a , -S(O)R 7a , -CR 5 R 6 -OR 7a wherein R 7a is a radical selected from the group consisting of: 1) -CH 2 -R 8 ,
  • R 8 is a cyclic radical selected from the group consisting of: a) aromatic carbocyclic radicals, optionally substituted with 1 to 5 substituents wherein the substituents are selected from
  • R 4 or two adjacent substituents can form a 5, 6 or 7 membered fused carbocyclic or heterocyclic ring optionally substituted with one or more substituents selected from R 4 , and b) aromatic and non-aromatic heterocyclicyl radicals, optionally substituted with 1 to 5 substituents wherein the substituents are either selected from R 4 or two adjacent substituents can form a 5, 6 or 7 membered fused carbocyclic or heterocyclic ring optionally substituted with one or more substituents selected from R 4 , or R 2 is a radical selected from the group consisting of -CR 5 R 6 NR 7a R 7b , and -N ⁇ R,,, and: R 7a and R ⁇ are both hydrogen,
  • R 7a and R ⁇ together form a 6 membered ring heterocycle, optionally substituted with one or more substituents selected from the group R 4 , or R- Tb is hydrogen or a radical selected from R 4 and R 7a is a radical selected from the group consisting of: 1) -CH 2 -R 8 ,
  • R 8 is a cyclic radical selected from the group consisting of: a) aromatic carbocyclic radicals, optionally substituted with 1 to 5 substituents wherein the substituents are selected from R 4 or two adjacent substituents can form a 5, 6 or 7 membered fused carbocyclic or heterocyclic ring optionally substituted with one or more substituents selected from R 4 , and b) aromatic and non-aromatic heterocyclicyl radicals, optionally substituted with 1 to 5 substituents wherein the substituents are either selected from R 4 or two adjacent substituents can form a 5, 6 or 7 membered fused carbocyclic or heterocyclic ring optionally substituted with one or more substituents selected from R 4 .
  • the active agents may be incorporated into pharmaceutical compositions and dosage forms in accordance with further teachings of this disclosure.
  • the active agents, compositions and dosage forms may be used independently or together to treat angiogenic dependent diseases according to the method aspect of the invention.
  • a “hydrocarbyl” radical means a fragment of a molecule that contains carbon and hydrogen. As used in this disclosure, the term is intended to include fragments that contain, in addition to carbon and hydrogen, any number of heteroatoms. Heteroatoms may be pendant, such as the carbonyl oxygen of acetone or the fluorine atoms of 2,2- difluoropropane. Heteroatoms also may be incorporated into a hydrocarbyl fragment, such as the nitrogen of N,N-dimethylaminomethyl, the oxygen atom of diethyl ether or a polyethyleneglycol fragment.
  • alkyl refers to a saturated hydrocarbyl radical that may be unsubstituted or substituted with one or more substituents.
  • the alkyl radical may be straight, branched or cyclic.
  • lower alkyl is reserved for alkyl radicals containing from 1 to 6 carbon atoms.
  • Linear and branched lower alkyl substituents include methyl, ethyl, propyl, isopropyl, butyl and t-butyl, and the like.
  • Cyclic lower alkyl radicals include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
  • alkenyl refers to a straight, branched or cyclic non- aromatic hydrocarbyl radical containing at least one carbon to carbon double bond.
  • lower alkenyl as used herein is reserved for an alkenyl radical containing from 2 to 6 carbon atoms. Lower alkenyl groups include ethenyl, propenyl, butenyl cyclohexenyl, and the like.
  • alkynyl refers to a straight, branched or cyclic hydrocarbyl radical containing at least one carbon to carbon triple bond.
  • lower alkynyl as used herein is reserved for an alkynyl radical containing from 2 to 6 carbon atoms. Lower alkynyl groups include ethynyl, propynyl and butynyl, and the like.
  • Alkyl, alkenyl and alkyl radicals typically have between 1 and 40 carbon atoms.
  • aryl as used herein refers to carbocyclic and heterocyclic radicals that are "aromatic,” i.e.
  • Aryl radicals can be distinguished by those skilled in the art from other radicals having cyclic ⁇ electron systems by applying the Huckel rule which states that resonance stabilization will occur when the number of electrons that are delocalized in the ⁇ electron system is 4n+2 where n is an integer.
  • Aryl radicals include unsubstituted or substituted 6-membered aromatic rings, such as, phenyl, substituted phenyl and like, as well bicyclic rings, such as naphthyl, and polycyclic rings, such as anthracenyl, and heterocyclic radicals, such as pyridinyl as well as, imidazolyl, oxazolyl, thiazolyl, indazolyl and the like (wherein the Huckel rule is satisfied by the contribution by a heteroatom of a pair of electrons to the aromatic stabilization).
  • heterocycle means a stable 5- to 6-membered mono- or 7- to 10-membered fused bicyclic ring system, any ring of which may be saturated or unsaturated, aromatic or non-aromatic, provided that from one to three ring atoms are selected from the heteroatoms N, O and S while the other ring atoms are carbon.
  • the nitrogen and sulfur heteroatoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized.
  • heterocycles includes the abovementioned heteroaryls, as well as reduced (e.g. dihydro and tetrahydro) analogs thereof.
  • Heterocycles include any bicyclic group in which any of the above-defined rings is fused to a benzene ring.
  • the heterocyclic ring may be attached at any heteroatom or carbon atom, which results in the creation of a stable structure.
  • heterocyclic components include piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolodinyl, 2-oxoazepinyl, azepinyl, pyrrolyl, 4-piperidonyl, pyrrolidinyl, pyrazolyl, pyrazolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, oxazolidinyl, isoxazolyl, isoxazolidinyl, mo holiny
  • alkoxy refers to a radical containing a straight, branched or cyclic hydrocarbyl radical attached via an oxygen atom.
  • Substituents on the hydrocarbyl group may include for example, a phenyl ring, in which the alkoxy may be for example, a benzyloxy group.
  • alkoxy groups are methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, tertiary butoxy, pentoxy, isopentoxy, hexoxy, isohexoxy allyloxy, propargyloxy, vinyloxy, and the like.
  • aralkyl as used herein contemplates a lower alkyl group which has as a substituent an aryl group.
  • halo or halogen as used herein is intended to include the halogen atoms fluorine, chlorine, bromine and iodine.
  • the present invention provides novel compounds that inhibit tyrosine kinase activity of vascular endothelial growth factor receptors.
  • the present invention is not intended to be limited to any particular mechanism of VEGF receptor kinase inhibition.
  • the compounds of the present invention are certain appropriately 1,3-disubstituted five- membered ring heterocycles that are encompassed by Formula (I).
  • X, and X 2 are atoms or radicals independently selected from the group consisting of oxygen, sulfur, nitrogen, radicals of formula C-R 3 and radicals of formula N-R 3 , with the proviso that at least one of X j and X 2 is oxygen, sulfur, nitrogen or a diradical of formula N-R 3 , wherein:
  • R 3 is an atom or radical selected from the group consisting of:
  • alkenyl optionally substituted with one or more substituents selected from R 4 ;
  • R 4 is an atom or radical selected from the group consisting of: a) halogen; b) alkyl, which may be optionally substituted with one or more halogen, hydroxy or lower alkoxy; c) alkenyl, which may be optionally substituted with one or more halogen, hydroxy or lower alkoxy; d) nitro; e) cyano; f) oxo; g) vinyl; h) styryl; i) a group of formula -C(O)R 5 , -CO 2 R 5 , -OR 5 , -SR 5 , -SOR 5 , -
  • R 5 and R 6 are atoms or radicals independently selected from the group consisting of hydrogen, lower alkyl, aralkyl, aryl and heteroaryl;
  • X 3 is selected from the group consisting of oxygen, sulfur, nitrogen and diradicals of formula N-R 3 ,
  • Yj and Y 2 are atoms independently selected from the group consisting of nifrogen and carbon, R ⁇ is a radical selected from the group consisting of:
  • Wj is nitrogen or C-R ⁇
  • W 2 is nifrogen or C-R ⁇
  • W 3 is nitrogen or C-R ⁇
  • W 4 is nifrogen or C-R ⁇
  • W 5 is nifrogen or C-R ⁇
  • W 6 is nitrogen or C-R w6
  • W 7 is nitrogen or C-R ⁇
  • W 1 is nitrogen or C-R ⁇
  • W 9 is nitrogen or C-R ⁇ , each R ⁇ , R ⁇ , R ⁇ , R ⁇ , R w5 , R w6 , R ⁇ , R ⁇ and R w9 being an atom or radical independently selected from the group consisting of:
  • X 4 is O, S, or N-R 4 , a is 0 to 3, b is 0 to 2, c is 0 or 1, or together, one or more of the combinations R ⁇ and R w2 , R ⁇ and R w3 , R w3 and R ⁇ , R w5 and R w6 , R w6 and R ⁇ , R ⁇ and ⁇ , and R w8 and R ⁇ form a fused 5- or 6- membered carbocyclic ring or heterocyclic ring having one or two heteroatoms selected from nitrogen, oxygen and sulfur, Z is selected from the group consisting of oxygen, sulfur, -S(O)-, -S(O) 2 -, - CR 5 R 6 -, -CR 5 R 6 O-, CR 5 R 6 NR 3 - and -NR 3 - R 2 is a radical of formula -OR 7a , -SR 7a , -S(O)R 7a , -CR 5 R 6 R 7a ,
  • R 8 is a cyclic radical selected from the group consisting of: a) aromatic carbocyclic radicals, optionally substituted with 1 to 5 substituents wherein the substituents are selected from R 4 or two adjacent substituents can form a 5, 6 or 7 membered fused carbocyclic or heterocyclic ring optionally substituted with one or more substituents selected from R 4 , and b) aromatic and non-aromatic heterocyclicyl radicals, optionally substituted with 1 to 5 substituents wherein the substituents are either selected from R 4 or two adjacent substituents can form a 5, 6 or 7 membered fused carbocyclic or heterocyclic ring optionally substituted with one or more substituents selected from R 4 , or R 2 is a radical selected from the group consisting of -CR 5 R 6 -NR 7a R 7b , and -NR ⁇ R ⁇ and:
  • R 7a and R ⁇ are both hydrogen
  • R 7a and R ⁇ together form a 6 membered ring heterocycle, optionally substituted with one or more substituents selected from the group R 4 , or R- Tb is hydrogen or a radical selected from R 4 and R 7a is a radical selected from the group consisting of: 1) -CH 2 -R 8 ,
  • R 8 is a cyclic radical selected from the group consisting of: a) aromatic carbocyclic radicals, optionally substituted with 1 to 5 substituents wherein the substituents are selected from R 4 or two adjacent substituents can form a 5, 6 or 7 membered fused carbocyclic or heterocyclic ring optionally substituted with one or more substituents selected from R 4 , and b) aromatic and non-aromatic heterocyclicyl radicals, optionally substituted with 1 to 5 substituents wherein the substituents are either selected from R 4 or two adjacent substituents can form a 5, 6 or 7 membered fused carbocyclic or heterocyclic ring optionally substituted with one or more substituents selected from R 4 .
  • substituent R 2 is preferably a radical of formula -NH-R 8 , -NHCH 2 -R 8 , - NHCH 2 CH 2 -R 8 or -NHCH 2 CH 2 CH 2 -R 8 , wherein R 8 is an optionally substituted phenyl radical, optionally substituted bicyclic aromatic carbocyclic radical, optionally substituted polycyclic aromatic carbocyclic radical, optionally substituted monocyclic aromatic heterocyclic radical, optionally substituted bicyclic aromatic heterocyclic radical or optionally substituted polycyclic aromatic heterocyclic radical.
  • R 8 substituents are phenyl, optionally substituted with 1 to 5 substituents selected from R 4 ; pyridinyl, optionally substituted with 1 to 4 substituents selected from R 4 ; pyrazinyl, optionally substituted with 1 to 3 substituents selected from R 4 ; pyrimidinyl, optionally substituted with 1 to 3 substituents selected from R 4 ; indazolyl, optionally substituted with 1 to 5 subsitutents selected from R 4 ; tetrazolyl;or an aromatic heterocyclic radical of formula:
  • the present invention is directed to these compounds in all states of purity.
  • the compounds of this invention exist in different physical states as well, such as dissolved states and condensed states. Condensed states include salts and solvates of the compound (particular salts suitable for pharmaceutical use are described below).
  • the present invention also relates to "prodrugs" of compounds of Formula (1).
  • a "pro-drug” is a compound that is administered to a patient and is converted within the patient's body into a second compound that exerts a therapeutic effect.
  • the present invention encompasses pro-drugs that are transformed in vivo to yield the Formula (I) compound or a protein conjugate of it. Pro-drugs are thoroughly discussed in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems Vol. 14 of the A. C. S. Symposium Series, and in Edward B. Roche, ed.,
  • VEGF receptor antagonists of the invention are readily prepared by general methodologies described in compendia and freatises on heterocycles and organic synthesis methods. In particular, there may be mentioned Comprehensive Heterocyclic Chemistry
  • Triazoles are 5- membered ring heterocycles containing three nitrogen atoms. Triazoles exist in two distinct classes-l,2,3-triazoles and l,2,4-triazoles ⁇ differentiated by the positions of the nitrogen atoms in the aromatic ring. Both classes have aromatic character. 1,2,3- Triazoles characteristically have a annular nifrogen atom bonded to two other annular nifrogen atoms. The 1,2,4-triazoles characteristically have only one direct bond between annular nitrogen atoms. The triazoles that have been discovered to have VEGF receptor kinase inhibitory activity are 1,2,4-triazoles. Accordingly, one preferred class of 1,2,4- triazoles of the present invention are those that are encompassed by Formula (la):
  • R l5 R 2 , R 3 , W,, W 2 , W 3 and W 4 are as previously defined with respect to Formula
  • R 3 is hydrogen.
  • R 2 is -NH-R 7a
  • R 3 is hydrogen
  • W 2 is C-
  • R w2 , W 3 , W 4 , W 5 and W 9 are CH, W 7 is C-R ⁇ and W 8 is C-R ⁇ . Accordingly, more preferred 1,2,4-triazoles of the present invention are those encompassed by Formula (la'):
  • W ]5 W 6 , R ⁇ , R ⁇ , R w8 and R 7a are as previously defined with respect to Formula
  • W ]3 R ⁇ -R ⁇ , R 7a , ⁇ and Z are as previously defined with respect to Formula (I).
  • Yet more preferred 1,2,4-triazoles of Formula (la") are those wherein Z is -NH-, -CH 2 O-, or -CH 2 -.
  • 1,2,4-Triazoles whose annular nitrogens are unsubstituted as they are in Formulae (la') and (la") are likely to exist as a rapidly equilibrating mixture of three isomers, a phenomenon called protofropy.
  • 1,2,4- triazole is best represented as a proton associated with a resonance stabilized triazole anion. Ainsworth et al. J. Med. Pharm. Chem. 1962, 5, 383. Representations of the three isomers, or tautomers, may be generated by attaching the hydrogen atom whose point of attachment is unspecified to each of the annular nitrogen atoms and adjusting the positions of the two double bonds to obtain proper valency.
  • 1,2,4-Triazoles are readily prepared by methods described in Comprehensive Heterocyclic Chemistry Part 4a (Alan Katritzky and Charles Rees eds., Pergamon Press: Oxford 1984); Heterocyclic Compounds Vol. 37 (John Wiley & Sons: New York 1981) stndMethoden der Organishchen Chemie (Houben-Weyl: Stuttgart 1974).
  • Methodologies for making 1,2,4-triazoles from acyclic starting materials include (1) condensation of a hydrazine (R-NHNH 2 ) with an imide (R'-C(O)NHC(O)-R”), known as the Einhorn-Brunner reaction. Einhorn et al. Liebigs
  • N C(R")NH 2 ).
  • Conversion of these compounds to 1,2,4-triazoles is generally performed in a polar organic solvent, like a lower alcohol or THF, under neutral or mildly basic conditions at a concentration of about lmM to about 2 M.
  • a polar organic solvent like a lower alcohol or THF
  • the reaction may proceed at reduced, ambient or elevated temperatures.
  • reaction conditions of about IM in refluxing anhydrous ethanol may be tried as a starting point for optimization of any particular ring closing reaction.
  • Ethanol may be replaced with a high boiling solvent if the reaction does not proceed at a practicable rate.
  • the Pellizzari reaction suffers in comparison to some of the other methods because high reaction temperatures are frequently required.
  • the 1,2,4-triazoles of this invention are prepared by contacting a hydrazide of Formula (II)
  • the ring closure is effected under basic conditions which can be established using a strong base, with alkali metal hydroxides and alkoxides being preferred.
  • bases that may suitable include sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, trialkylamines, such as trimethylamine and triethylamine, dialkylanilines, such as N,N-diethylaniline, pyridines, such as 2,4,6-trimethylpyridine, pyridine, and dimethylaminopyridine, DBU, or DABCO,
  • the molar amount of the base to be used is 1 to 20, preferably 1 to 5, times the amount of limiting reagent.
  • Compounds (TJ) and (III) can be contacted in a melt (if at least one is a liquid at the reaction temperature) or in an inert diluent.
  • Diluents include water and organic compounds that are liquid at ambient temperature like certain lower alcohols, such as methanol, ethanol, 1-propanol, 2-propanol, 1-butanol, 2-butanol and zjo-butanol; aliphatic and aromatic hydrocarbons, such as hexane, pefroleum ether, benzene, toluene, and xylene; halogenated hydrocarbons, such as dichloromethane, chloroform and Freons; ethers, such as diethyl ether, methyl t-butyl ether, 1,2-dimethoxyethane, dioxane and tetrahydrofuran;
  • N,N-dialkyl amides such as dimethylformamide and dimethylacetamide; ketones, such as acetone and methyl ethyl ketone; nitriles, such as acetonitrile and acrylonitrile; and sulfoxides, such as dimethylsulfoxide.
  • compounds (H) and (III) are contacted in a lower alcohol diluent, with a preferred lower alcohol being ethanol.
  • the ring closure is conducted in a lower alcohol using an alkali metal salt of the corresponding alkoxide anion or different alkoxide anion as base.
  • hydrazides and amidines may be prepared conventionally by known synthetic pathways.
  • Scheme I depicts a process whereby commercially available and readily accessible nitriles may be converted into an amidine (HI) salt that can be used in the making of the 1,2,4-triazoles of this invention.
  • an anhydrous lower alcohol solvent e.g. ethanol
  • an appropriately substituted nitrile undergoes addition by a molecule of solvent when treated with anhydrous hydrochloric acid to form an imidate.
  • the imidate may be conveniently isolated as an acid addition salt with the acid catalyst.
  • the imidate salt may be carried forward in the next step of the process. Treatment of the imidate or imidate salt with ammonia transforms the imidate group into an amidine group.
  • Ort o-alkylamino substituted benzoic acid hydrazides can be prepared by condensation of an ester of anthranilic acid and a lower alcohol with an aldehyde followed by reduction of the so-formed imine. The resulting ort/zo-methylamino substituted benzoic acid is then contacted with hydrazine to yield hydrazide (H), as shown in Scheme H
  • the aldehyde and anthranilic acid lower alcohol ester are contacted under mildly acidic conditions.
  • Preferred acid catalysts are acetic acid, methanesulfonic acid, trifluoroacetic acid, pivalic acid, hydrochloric acid, hydrobromic acid, with the most preferred acid being acetic acid.
  • the imine group is reduced with a suitable reducing agent.
  • suitable reducing agents include sodium cyanoborohydride, sodium borohydride, lithium aluminum hydride, DIBAL, diborane and the like and catalytic reducing agents such as Raney nickel, and palladium on carbon.
  • the most preferred reducing agent is sodium cyanoborohydride. Additional reducing agents that are known to reduce imines to amines can be found in Larock R.C. Comprehensive Organic Transformations 2nd ed. (Wiley-
  • Hydrazide (II) may be prepared by reacting the carboxylic acid group of the reduced product with a hydrazine. Unsubstituted hydrazine is conveniently available as a solid hydrate (Aid. Cat. Nos. 22,581-9 and 20,794-2) and in solutions in THF and water (Aid. Cat. Nos. 43,363-2 and 30,940-0). Substituted hydrazines may be readily prepared from NH 2 NH 2 by methods well known to those skilled in the art.
  • compounds (II)-(V) may bear functionality that inhibits one or more reactions used in making the compounds of the present invention.
  • Compounds (II)-(V) may be derivatized to a form that modifies interfering chemical functionality using well established techniques of functional group protection. For instance, if necessary, hydroxy groups, carboxylic acids, and primary and secondary amine groups on substituents R ⁇ may be protected as desired as silyl ethers, esters, carbamates, carbonates and the like using techniques well known to the skilled artisan.
  • a second preferred class of 1,3-disubstituted five-membered ring heterocycles of Formula (I) is 2,5-disubstituted oxadiazoles.
  • Oxadiazoles are 5-membered ring heterocycles containing two double bonds, one oxygen atom and two nitrogen atoms.
  • Oxadiazoles are potentially capable of existing in three distinct classes, 1,2,3-, 1,2,4-, 1,3,4- and 1,2,5-oxadiazoles. However, few unfused 1,2,3-oxadiazoles are stable.
  • R l5 R 2 , W 1? W 2 , W 3 and W 4 are as previously defined with respect to Formula (I).
  • R j is a substituted or unsubstituted aniline group (-NH-Aryl) and R 2 is a radical of formula -NR ⁇ ⁇ .
  • yet more preferred 1,3,4-oxadiazoles of the present invention are those that are encompassed by Formula (lb')
  • Wj is nitrogen and W 2 , W 3 and W 4 are each CH.
  • This addition reaction is generally performed in an organic solvent, like dichloromethane, under neutral conditions and at ambient or elevated temperature at a concenfration of about ImM to about 2 M.
  • the intermediate is then cyclized by treating it with a coupling agent like dicyclohexylcarbodiimide.
  • Isothiocyanate starting materials of Formula (VI) are either commercially available or can be conveniently prepared using well-establish techniques of functional group interconversion starting from the corresponding unsubstituted benzene derivative by electrophilic aromatic substituted with, e.g., ammonium thiocyanate; the corresponding nitro derivative by reaction with carbon disulfide; or the corresponding trialkylsilylamine, or amide by treatment with carbon disulfide and many other techniques described in Comprehensive Organic Functional Group Transformations Vol. 5 pp. 1021-1045 (Katritzky, A.R. et al. editors, Elsevier Science Ltd: Oxford 1995) which is hereby incorporated by reference in its entirety and, in particular, for its description of methods of making isothiocyanates contained in the cited pages of the reference.
  • a third preferred class of 1,3-disubstituted five-membered ring heterocycles of Formula (I) are oxazoles.
  • Oxazoles contain two double bonds, one oxygen atom and one nitrogen atom that is not adjacent to the oxygen atom in the five-membered heterocyclic ring.
  • One preferred class of 1,3-disubstituted oxazoles are 2,5-disubstituted oxazoles (absolute numbering) encompassed by Formula (lc):
  • R l5 R 2 , W lt W 2 , W 3 and W 4 are as previously defined with respect to Formula (I).
  • R j is optionally substituted phenyl
  • W l5 W 2 , W 3 and W 4 are each CH and R 2 is -NH-R 7a .
  • Especially preferred 2,5-disubstituted oxazoles are those encompassed by Formula (lc'):
  • R w5 , R v ⁇ 6 and R w7 are as previously defined with respect to Formula (I) and X, and
  • X 2 are as previously defined with respect to Formula (lc).
  • a fourth preferred class of 1,3-disubstituted five-membered ring heterocycles of Formula (I) are 2,4-disubstituted imidazoles. Imidazoles contain two double bonds and two non-adjacent nifrogen atoms. in the five-membered heterocyclic ring. Accordingly, one preferred class of 2,4-disubstituted imidazoles of the present invention are those that are encompassed by Formula (Id):
  • W l9 W 2 , W 3 and W 4 are as defined with respect to Formula (I).
  • X ! is CR 3 (more preferably CH or CH 3 )
  • X 2 is nifrogen
  • R j is optionally substituted phenyl
  • R 2 is -NH 2
  • W l5 W 2 , W 3 and W 4 are each CH.
  • Yet more preferred imidazoles of the present invention are those encompassed by Formula (Id').
  • the imidazoles of this invention are prepared by contacting an amidine of Formula (V) with an -halo carboxyl compound of Formula (VIII) :
  • R 2 is NH 2
  • R 2 is an interfering functionality.
  • DC (2-aminoaryl) ⁇ -halo ketone
  • imidazoles of Formula (Id') may be prepared by a variation of the reaction expressed in Scheme HI.
  • the cyclization reaction is generally performed in a polar aprotic solvent like DMF or THF, under basic conditions at a concentration of about ImM to about 2 M. If the starting halide is a bromide, it can be activated by addition of sodium iodide to the reaction mixture. In addition, the reaction mixture may be refluxed to accelerate the reaction.
  • the nitro group is reduced using conditions well known in the art for reducing aryl nitro groups to amines. Such conditions are summarized and citations to primary references are given in Larock, R.C. Comprehensive Organic Transformations 2nd ed. pp. 823-827 (Wiley- VCH: New York 1999), which pages and the primary references to which they refer are hereby incorporated by reference for their teachings how to reduce nitroarenes to aminoarenes.
  • compositions and dosage forms containing at least one compound of Formula (I) or a pharmaceutically acceptable salt, hydrate or pro-drug thereof, in combination with a pharmaceutically acceptable carrier.
  • the terms "pharmaceutically acceptable salts” and “hydrates” refer to those salts and hydrated forms of the compound that would favorably affect the physical or pharmacokinetic properties of the compound, such as solubility, palatability, absorption, distribution, metabolism and excretion. Other factors, more practical in nature, which those skilled in the art may take into account in the selection include the cost of the raw materials, ease of crystallization, yield, stability, solubility, hygroscopicity and flowability of the resulting bulk drug.
  • a compound of the present invention is present as a salt or hydrate that is not pharmaceutically acceptable, that compound can be converted in certain circumstances to a salt or hydrate form that is pharmaceutically acceptable in accordance with the present invention.
  • a counterion such as, an alkali metal cation such as sodium or potassium.
  • suitable counterions include calcium, magnesium, zinc, ammonium, or alkylammonium cations, such as teframethylammonium, tetrabutylammonium, choline, triethymydroammonium, meglumine, triethanol-hydroammoniiim, and the like.
  • An appropriate number of counterions are associated with the molecule to maintain overall charge neutrality.
  • salts of bases may be prepared by the addition of an appropriate acid.
  • the compounds of the present invention can be used in the form of salts derived from inorganic or organic acids. Examples include acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxy-ethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, pamoate, pectinate, persulfate, 3-phenylpropionate, pi
  • Base salts include ammonium salts, alkali metal salts such as sodium and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases such as dicyclohexylamine salts, N-methyl-D-glucamine, and salts with amino acids such as arginine, lysine, and so forth.
  • the basic nitrogen-containing groups may be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl; and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides and others.
  • lower alkyl halides such as methyl, ethyl, propyl, and butyl chloride, bromides and iodides
  • dialkyl sulfates like dimethyl, diethyl, dibutyl
  • diamyl sulfates long chain halides
  • the compounds of the present invention may be employed in solid or liquid form including, for example, amorphous powder or crystalline form, in solution or in suspension. They may be administered in numerous different ways, such as orally, parenterally (intravenously or intramuscularly), topically, transdermally or by inhalation.
  • the choice of carrier and the content of active compound in the carrier are generally determined in accordance with the solubility and chemical properties of the desired product, the particular mode of administration and well established pharmaceutical practice.
  • the carrier may be either solid or liquid.
  • liquid carriers examples include syrup, peanut oil, olive oil, water and the like.
  • emulsions, suspensions or solutions of the compounds according to the invention in vegetable oil for example sesame oil, groundnut oil or olive oil, or aqueous-organic solutions such as water and propylene glycol
  • injectable organic esters such as ethyl oleate, as well as sterile aqueous solutions of the pharmaceutically acceptable salts
  • injectable forms must be fluid to the extent they can be easily syringed, and proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
  • Prolonged absorption of the injectable compositions can be brought about by use of agents delaying absorption, for example, aluminum monostearate and gelatin.
  • the active compound may be orally administered with an ingestible solid carrier.
  • Compounds of the invention maybe enclosed in hard or soft shell gelatin capsules, or compressed into tablets, or incorporated directly with the food of the diet, or may be used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like.
  • oral solid dosage forms include tablets, capsules, troches, lozenges and the like.
  • oral liquid dosage forms include solutions, suspensions, syrups, emulsions, soft gelatin capsules and the like.
  • Carriers for oral use may include time delay materials known in the art, such as glyceryl monostearate or glyceryl distearate alone or with a wax.
  • time delay materials such as glyceryl monostearate or glyceryl distearate alone or with a wax.
  • lactose and a liquid carrier such as high molecular weight polyethylene glycols.
  • compositions and dosage forms prepared in accordance with the present invention optionally also may contain lactose, sodium citrate, calcium carbonate, dicalcium phosphate and disintegrating agents such as starch, alginic acids and certain complex silica gels combined with lubricants such as magnesium stearate, sodium lauryl sulfate and talc may be used for preparing tablets, troches, pills, capsules and the like.
  • Solutions of the active compound as a free base or pharmacologically acceptable salt can be prepared in water suitably mixed with a surfactant such as hydroxypropyl-cellulose. Dispersions also can be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils.
  • aqueous solutions also including solutions of the salts in pure distilled water, may be used for intravenous administration with the proviso that their pH is suitably adjusted, that they are judiciously buffered and rendered isotonic with a sufficient quantity of glucose or sodium chloride and that they are sterilized by heating, irradiation, microfiltration, and/or by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like.
  • various antibacterial and antifungal agents for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like.
  • injectable dosage forms include sterile injectable liquids, e.g., solutions, emulsions and suspensions.
  • Sterile injectable solutions are prepared by incorporating the active compound in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization.
  • dispersions are prepared by incorporating the various sterilized active ingredient into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above, hi the case of sterile powders for the preparation of sterile injectable solutions, methods of preparation may include vacuum drying and a freeze-dry technique that yields a powder of the active ingredient plus any additional desired ingredient from previously sterile-filtered solution thereof.
  • injectable solids examples include powders that are reconstituted, dissolved or suspended in a liquid prior to injection, hi injectable compositions, the carrier typically includes sterile water, saline or another injectable liquid, e.g., peanut oil for intramuscular injections. Also, various buffering agents, preservatives and the like can be included within the compositions of the present invention.
  • Solid dosage forms include dosage forms for rectal administration, which include suppositories formulated in accordance with known methods and containing at least one compound of the present invention.
  • solid carriers include lactose, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like.
  • Topical administration, in the form of gels (water or alcohol based), creams or ointments, for example, containing compounds of the invention maybe used.
  • Topical applications may be formulated in carriers such as hydrophobic or hydrophilic bases to form ointments, creams, lotions, in aqueous, oleaginous or alcoholic liquids to form paints or in dry diluents to form powders.
  • Such topical formulations can be used for example, to treat ocular diseases as well as inflammatory diseases such as rheumatoid arthritis, psoriasis, contact dermatitis, delayed hypersensitivity reactions and the like.
  • Compounds of the invention also may be incorporated in a gel or matrix base for application in a patch, which would allow a controlled release of compound through fransdermal barrier.
  • compounds of the invention may be dissolved or suspended in a suitable carrier for use in a nebulizer or a suspension or solution aerosol, or may be absorbed or adsorbed onto a suitable solid carrier for use in a dry powder inhaler.
  • Compositions according to the invention also may be formulated in a manner that resists rapid clearance from the vascular (arterial or venous) wall by convection and/or diffusion, thereby increasing the residence time of the compound at the desired site of action.
  • a periadventitial depot comprising a compound according to the invention may be used for sustained release.
  • One such useful depot for administering a compound according to the invention may be a copolymer matrix, such as ethylene- vinyl acetate, or a polyvinyl alcohol gel surrounded by a Silastic shell.
  • a compound according to the invention may be delivered locally from a silicone polymer implanted in the adventitia.
  • microparticles may be made from any of a variety of synthetic polymers, such as polylactide, or natural substances, including proteins or polysaccharides. Such microparticles enable strategic manipulation of variables including total dose of drug and kinetics of its release. Microparticles can be injected efficiently into the arterial or venous wall through a porous balloon catheter or a balloon over stent, and are retained in the vascular wall and the periadventitial tissue for at least about two weeks. Formulations and methodologies for local, intravascular site-specific delivery of therapeutic agents are discussed in Reissen et al. (J. Am. Coll. Cardiol. 1994; 23:
  • a channeled balloon catheter (such as “channelled balloon angioplasty catheter", Mansfield Medical, Boston Scientific Corp., Watertown, Mass.) may be used.
  • This catheter includes a conventional balloon covered with a layer of 24 perforated channels that are perfused via an independent lumen through an additional infusion orifice.
  • Various types of balloon catheters such as double balloon, porous balloon, microporous balloon, channel balloon, balloon over stent and hydrogel catheters, all of which maybe used to practice the invention, are disclosed in Reissen et al. (1994).
  • Another embodiment of the invention provides a compound according to the invention to be administered by means of perfusion balloons.
  • perfusion balloons which make it possible to maintain a blood flow and thus to decrease the risks of ischaemia of the myocardium, on inflation of the balloon, also enable the compound to be delivered locally at normal pressure for a relatively long time, more than twenty minutes, which may be necessary for its optimal action.
  • a composition according to the invention also may comprise a hydrogel which is prepared from any biocompatible or non-cytotoxic (homo or hetero) polymer, such as a hydrophilic polyacrylic acid polymer that can act as a drug absorbing sponge.
  • a biocompatible or non-cytotoxic (homo or hetero) polymer such as a hydrophilic polyacrylic acid polymer that can act as a drug absorbing sponge.
  • Such polymers have been described, for example, in application WO 93/08845. Certain of them, such as, in particular, those obtained from ethylene and/or propylene oxide are commercially available.
  • Another aspect of the present invention relates to a pharmaceutical composition including a compound according to the invention and poloxamer, such as Poloxamer 407, which is a non-toxic, biocompatible polyol, commercially available (e.g., from BASF, Parsippany, N.J.).
  • a poloxamer impregnated with a compound according to the invention may be deposited for example, directly on the surface of the tissue to be treated, for example during a surgical intervention.
  • Poloxamer possesses essentially the same advantages as hydrogel while having a lower viscosity.
  • the use of a channel balloon catheter with a poloxamer impregnated with a compound according to the invention may be advantageous in that it may keep the balloon inflated for a longer period of time, while retaining the properties of facilitated sliding, and of site-specificity of the poloxamer.
  • the composition also may be administered to a patient via a stent device.
  • the composition is a polymeric material in which the compound of the invention is incorporated, which composition is applied to at least one surface of the stent device.
  • Polymeric materials suitable for incorporating the compound of the invention include polymers having relatively low processing temperatures such as polycaprolactone, poly(ethylene-co-vinyl acetate) or poly(vinyl acetate or silicone gum rubber and polymers having similar relatively low processing temperatures.
  • suitable polymers include non-degradable polymers capable of carrying and delivering therapeutic drugs such as latexes, urethanes, polysiloxanes, styrene-ethylene/butylene-styrene block copolymers (SEBS) and biodegradable, bioabsorbable polymers capable of carrying and delivering therapeutic drugs, such as poly-DL-lactic acid (DL-PLA), and poly-L-lactic acid (L-PLA), polyorthoesters, polyiminocarbonates, aliphatic polycarbonates, and polyphosphazenes.
  • DL-PLA poly-DL-lactic acid
  • L-PLA poly-L-lactic acid
  • polyorthoesters polyiminocarbonates
  • aliphatic polycarbonates aliphatic polycarbonates
  • polyphosphazenes polyphosphazenes.
  • the compounds of the present invention also may be formulated for use in conjunction with other therapeutically active compounds or in connection with the application of therapeutic techniques to address pharmacological conditions, which may be ameliorated through the application of a compound according to the present invention.
  • the percentage of active ingredient in the compositions of the invention maybe varied.
  • Several unit dosage forms may be administered at about the same time.
  • a suitable dose employed may be determined by a physician or qualified medical professional, and depends upon various factors including the desired therapeutic effect, the nature of the illness being treated, the route of administration, the duration of the treatment, and the condition of the patient, such as age, weight, general state of health and other characteristics, which can influence the efficacy of the compound according to the invention.
  • doses are generally from about 0.001 to about 50, preferably about 0.001 to about 5, mg/kg body weight per day by inhalation; from about 0.01 to about 100, preferably 0.1 to 70, more preferably 0.5 to 10, mg/kg body weight per day by oral administration; from about 0.1 to about 150 mg applied externally; and from about 0.001 to about 10, preferably 0.01 to 10, mg/kg body weight per day by intravenous or
  • the compounds of the present invention inhibit or regulate phosphorylation events.
  • Tyrosine kinase inhibition may be determined by measuring the autophosphorylation level of recombinant kinase receptor, and/or phosphorylation of natural or synthetic substrates. Phosphorylation can be detected, for example, using an antibody specific for phosphotyrosine in an ELISA assay or on a western blot. Some assays for tyrosine kinase activity are described in Panek et al., J. Pharmacol. Exp. Thera., 283: 1433-44 (1997) and Batley et al., Life Sci., 62: 143-50 (1998).
  • IHC immunohistochemisfry
  • FISH fluorescence in situ hybridization
  • competitive radioligand binding assays solid matrix blotting techniques, such as Northern and Southern blots, reverse franscriptase polymerase chain reaction (RT-PCR) and ELISA.
  • RT-PCR reverse franscriptase polymerase chain reaction
  • VEGF receptor tyrosine kinase inhibition can be observed by mitogenic assays using HUVEC cells (ATCC) stimulated with VEGF in the presence and absence of inhibitor.
  • HUVEC cells ATCC
  • Another method involves testing for inhibition of growth of VEGF-expressing tumor cells, using for example, human tumor cells injected into a mouse. (See, U.S. Patent No. 6,365,157 to Rockwell et al.)
  • VEGF receptor tyrosine kinases especially KDR
  • freating or preventing VEGF receptor kinase-dependent diseases and conditions in mammals using the VEGF receptor kinase inhibitors of Formula I.
  • the VEGF receptor is usually bound to a cell, such as an endothelial or tumor cell. Alternatively, the VEGF receptor may be free from the cell.
  • an effective anti- angiogenic amount of one or more compounds of Formula (I), or pro-drug thereof is administered to a mammal in need of such freatment.
  • the diseases which may be freated or prevented by the present methods include, for example, those in which pathogenic angiogenesis or tumor growth is stimulated through a VEGF/VEGFR paracrine and/or autocrine loop.
  • pathogenic angiogenesis or tumor growth is stimulated through a VEGF/VEGFR paracrine and/or autocrine loop.
  • paracrine VEGFR stimulation of vascular endothelium is associated with angiogenic diseases and vascularization of tumors.
  • VEGF receptors are also found on tumor cells, indicating the presence of an autocrine and/or paracrine loop in these cells.
  • the method is also useful for neutralizing VEGF receptors on such cells, thereby inhibiting autocrine and/or paracrine stimulation and inhibiting tumor growth.
  • the compounds and compositions according to the invention may be administered as frequently as necessary as determined by a skilled practitioner in order to obtain the desired therapeutic effect. Some patients may respond rapidly to a higher or lower dose and may find much weaker maintenance doses adequate. For other patients, it may be necessary to have long-term treatments at the rate of 1 to 4 doses per day, in accordance with the physiological requirements of each particular patient. Generally, the active product may be administered orally 1 to 4 times per day. For other patients, it may be necessary to prescribe not more than one or two doses per day.
  • Tumors and neoplasms include, for example, malignant tumors and neoplasms, such as blastomas, carcinomas or sarcomas, and highly vascular tumors and neoplasms.
  • Cancers that may be treated by the methods of the present invention include, for example, cancers of the brain, genitourinary tract, lymphatic system, stomach, renal, colon, larynx, lung and bone.
  • Non-limiting examples further include epidermoid tumors, squamous tumors, such as head and neck tumors, colorectal tumors, prostate tumors, breast tumors, lung tumors, including lung adenocarcinoma and small cell and non-small cell lung tumors, pancreatic tumors, thyroid tumors, ovarian tumors, and liver tumors.
  • the method is also useful for freatment of vascularized skin cancers, including squamous cell carcinoma, basal cell carcinoma, and skin cancers that can be freated by suppressing the growth of malignant keratinocytes, such as human malignant keratinocytes.
  • cancers that can be treated include Kaposi's sarcoma, CNS neoplasms (neuroblastomas, capillary hemangioblastomas, meningiomas and cerebral metastases), melanoma, gastrointestinal and renal carcinomas and sarcomas, rhabdomyosarcoma, glioblastoma, including glioblastoma multiforme, histiocytic lymphoma, and leiomyosarcoma.
  • Kaposi's sarcoma CNS neoplasms (neuroblastomas, capillary hemangioblastomas, meningiomas and cerebral metastases), melanoma, gastrointestinal and renal carcinomas and sarcomas, rhabdomyosarcoma, glioblastoma, including glioblastoma multiforme, histiocytic lymphoma, and leiomyosarcoma.
  • the freatment method of this invention includes freatment or prevention of non- neoplastic angiogenic dependent diseases like inflammatory diseases and other diseases characterized by paracrine stimulation through VEGF receptors.
  • non-neoplastic angiogenic diseases include diseases characterized by retinal vascularization, such as neovascular glaucoma, proliferative retinopathy, including diabetic retinopathy, retinopathy of prematurity (retrolental fibroplastic), macular degeneration, and corneal graft rejection.
  • inflammatory diseases that may be freated include, but are not limited to, atherosclerosis, rheumatoid arthritis (RA), insulin-dependent diabetes mellitus, multiple sclerosis, myasthenia gravis, Chron's disease, autoimmune nephritis, primary biliary cirrhosis, psoriasis, acute pancreatitis, allograph rejection, allergic inflammation, contact dermatitis and delayed hypersensitivity reactions, inflammatory-bowel disease, septic shock, osteoporosis, osteoarthritis, and cognition defects induced by neuronal inflammation.
  • the compounds of this invention are not the first 1,2,4-triazoles found to have anti-inflammatory properties.
  • 1,2,4-triazole compounds having certain acetamidyl substituents on N-4 are useful as anti-inflammatory agents.
  • Other non-limiting examples of angiogenic diseases are hemangiomas, angiofibromas, Osier- Weber syndrome, restinosis, and fungal, parasitic and viral infections, including cytomegaloviral infections.
  • the freatment method of the present invention also includes treatment of tumors that express VEGF receptors (e.g. KDR), for example through inhibition of an autocrine VEGF/VEGFR loop, wherein one or more of the Formula I compounds are administered in an amount effective to reduce tumor growth or size.
  • VEGF receptors e.g. KDR
  • the method can be used to treat a solid or liquid tumor that is not vascularized, or is not yet substantially vascularized.
  • Examples of solid tumors which may be accordingly treated include breast carcinoma, lung carcinoma, colorectal carcinoma, pancreatic carcinoma, glioma and lymphoma.
  • Examples of liquid tumors include leukemia, multiple myeloma and lymphoma.
  • leukemias include acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), erythrocytic leukemia or monocytic leukemia.
  • Some examples of lymphomas include Hodgkin's and non-Hodgkin's lymphoma.
  • an effective anti-angiogenic amount of one or more of the Formula (I) compounds, including salts and solvates is administered to a mammal in need.
  • administering means delivering the compounds of the present invention to a mammal by any method that may achieve the result sought. They may be administered, for example, orally, parenterally (intravenously or intramuscularly), topically, transdermally or by inhalation.
  • mammal as used herein is intended to include, but is not limited to, humans, laboratory animals, domestic pets and farm animals.
  • Effective anti-angiogenic amount means an amount of compound of the present invention that when administered to a mammal influences the progression of an angiogenic dependent disease.
  • the influence is mediated through a slowing or arrest of pathogenic neovascularization around diseased cells. Accordingly, the influence may be a prevention or arrest of neovascularization that leads to the death of diseased cells and eradication of the disease from the body.
  • the influence will be therapeutically beneficial even when not so far-reaching.
  • influencing the progression of the angiogenic disease includes causing the progression of the disease to be slowed by partial or complete restriction of the blood supply to diseased cells, resulting in an increase in life expectancy of the mammal afflicted with the disease.
  • reaction mixture was diluted with ethyl acetate (50 mL), washed with aqueous sodium bicarbonate (30 mL) and brine (2x30 mL). The organic layer was separated and dried over anhydrous sodium sulfate. The dried solution was filtered and evaporated to give a solid. This solid was washed with warm methanol to get a white solid (1.1 g, 81.5% yield).
  • N-(3,5-Dimethoxyphenyl)-N'-(4-fluorobenzoyl)thiourea (1.5 g, 4.4 mmol) was heated to reflux with 5% aqueous NaOH (10 mL) for 15 min.
  • the cooled reaction mixture was freated with concenfrated HCl until acidic to precipitate both 4-fluorobenzoic acid and N-(3,5-dimethoxyphenyl)thiourea.
  • the mixture was then made basic (pH 9) with concentrated NH 4 OH to dissolve the 4-fluorobenzoic acid.
  • the product was filtered and recrystallized from 95% ethyl alcohol to give the pure product, N-(3,5- dimethoxyphenyl)thiourea .
  • 1,2,4-triazoles of the present invention can be prepared by procedures analogous to those of Examples 7-9.
  • 2-Aminobenzonitrile hydrochloride 50 g, 0.324 mol was suspended in anhydrous methanol in a 2 L three necked flask.
  • One mole equivalent of sodium methoxide (17.5 g, 0.324 mol) was added portionwise to the mixture (during the addition the temperature rose to 35°C).
  • the reaction mixture was then stirred for 30 minutes at room temperature and a second equivalent of sodium methoxide (17.5 g, 0.324 mol) was added portionwise.
  • hydroxylamine hydrochloride (22.5 g, 0.324 mol) was added and the mixture heated under reflux for 20 hours.
  • HTRF Homogeneous Time-Resolved Fluorescence Assay for VEGFR-2 (KDR) Kinase Inhibition
  • VEGFR tyrosine kinase inhibition is determined by measuring the phosphorylation level of poly-Glu-Ala-Tyr-biotin (pGAT-biotin) peptide in a Homogeneous Time- Resolved Fluorescence (HTRF) assay.
  • pGAT-biotin poly-Glu-Ala-Tyr-biotin
  • HTRF Homogeneous Time- Resolved Fluorescence
  • reaction buffer 25 mM Hepes pH 7.5, 5 mM MgC12, 5 mM MnC12, 2 mM DTT, 1 mg/ml BSA
  • reaction buffer 25 mM Hepes pH 7.5, 5 mM MgC12, 5 mM MnC12, 2 mM DTT, 1 mg/ml BSA
  • kinase reaction is initiated by the addition of 10 ⁇ l of 10 ⁇ M ATP in reaction buffer, after which the plate is incubated at room temperature for 45 min.
  • the reaction is stopped by the addition of 50 ⁇ l of KF buffer (50 mM Hepes pH 7.5, 0.5 M KF,
  • Example 20 Cell-based assay for VEGFR-2 (KDR) Kinase Inhibition Representative compounds of the invention were tested using the ELISA Cell-based assay for KDR inhibition. The results are reported in Table 6.
  • DNA for transfection was diluted to a final concentration of 5 ⁇ g/ml DNA in 1XBBS, 125 mM CaCl 2 and incubated at room temperature for 30 min. 293 cells were seeded in 15 cm tissue culture plates using 2 xlO 7 cells per plate and incubated for 4 hrs, followed by dropwise addition of 3 ml of DNA solution. The plates were incubated overnight.
  • the cells were trypsinized, collected by centrifugation, resuspended (4 x 10 5 cell/ml), divided into wells of 48 well tissue culture plates (1 ml/well) and incubated overnight.
  • Compounds of the invention were added to individual wells to a final concentration of 10-30 ⁇ M and incubated for 2 hours.
  • 10 mM stock solution were diluted 1/300-1/1000, yielding a final DMSO concentration of
  • ELISA for Detection of Tyrosine-phosphorylated Chimeric Receptor 96 well ELISA plates were coated using 100 ⁇ l/well of 10 ⁇ g/ml ⁇ FGFRl, and incubated overnight at 4°C. ⁇ FGFRl is prepared in a buffer made with 16 ml 0.2M Na 2 CO 3 and 34 ml 0.2M NaHCO 3 and the pH adjusted to 9.6. Concurrent with lysis of the transfected cells, ⁇ FGFRl coated ELISA plates are washed three times with PBS+0.1% Tween-20, blocked by addition of 200 ⁇ l/well of 3% BSA in PBS and incubated for lh. Blocking solution is removed from the wells. 80 ⁇ l of lysate is then transferred to the coated and blocked wells and incubated for lh at 4°C. The plates are washed three times with PBS+0.1% Tween-20.
  • the methods of the present invention are not limited to treating only the exemplified diseases and conditions, but rather any disease or condition that may be treated by regulation of kinases. Additionally, the methods of synthesis of the present invention are not limited to the methods exemplified in the example. The methods of the present invention include methods of making any of the compounds set forth in the present invention that those skilled would be able to make in view of the present disclosure, and are not limited to the exemplified method. For example, methods encompassed by the present invention may involve the use of a different starting material depending on the desired final compound, different amounts of various ingredients, or substitution of different ingredients such as other reactants or catalysts that would be suitable depending on the starting material and result to be achieved.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compounds that inhibit angiogenesis and are useful in the treatment of angiogenic dependent diseases like cancer are disclosed as well as pharmaceutical compositions that contain such compounds, methods of treating angiogenic dependent diseases and conditions in mammals using such compounds and methods of producing the compounds and compositions.

Description

A TI-A GIOGENIC COMPOUNDS AND THEIR USE IN CANCER TREATMENT
This application claims priority to U.S. Proviosnal Application No. 60/432,007, filed
December 10, 2002 and to U.S. Patent Application No.(awaited), filed December 4, 2003.
FIELD OF THE INVENTION
The present invention relates to novel five-membered ring heterocycles that inhibit the tyrosine kinase activity of VEGF receptors and are useful in the treatment of cancers, processes for making the heterocycles, pharmaceutical compositions and dosage forms that contain them, methods of treating angiogenic dependent diseases in mammals using them, and methods of manufacturing the compositions and dosage forms.
BACKGROUND OF THE INVENTION
Angiogenesis is the process by which new blood vessels develop in an organism. During angiogenesis, capillary endothelial cells proliferate and migrate f om pre-existing blood vessels into other tissues where they assemble into tubular structures and join to form tubular assemblies and closed-circuit vascular systems. These vascular systems undergo maturation to form new capillary vessels connected to the vascular network.
Angiogenesis is important to normal physiological processes like embryonic development, follicular growth, and wound healing. Angiogenesis also is necessary to the progression of some pathological conditions like neoplastic diseases (cancers) and non-neoplastic diseases that involve abnormal neovascularization like some inflammatory diseases and vascular proliferative diseases like atherosclerosis, restenosis and neovascular glaucoma (Folkman, J. and Klagsbrun, M. Støeflee 235:442-447 (1987)). In neoplastic diseases, the vascularization provides nourishment to the neoplasm and enables the migration of tumor cells through the vasculature. Inflammatory diseases whose progression is accompanied by blood vessel proliferation include rheumatoid arthritis, psoriasis, diabetic retinopathy and age-related macular degeneration. These and other pathological conditions that are aggravated by persistent or uncontrolled angiogenesis are known as angiogenic dependent diseases.
One means of influencing the progression of angiogenic dependent diseases is to restrict the blood supply to diseased cells. Occlusion of the blood vessels that supply diseased cells by invasive procedures requires that the site(s) of the diseased cells be identified. Invasive procedures are generally limited to treatment at a single site, or a small number of sites. Direct mechanical restriction of blood supply often is ineffective at killing the diseased cells because collateral blood vessels develop, often quite rapidly, restoring the blood supply to the diseased cells. Other approaches to restricting blood supply to tumor cells have focused on the modulation of factors that are involved in the regulation of angiogenesis at the cellular level. See e.g. U.S. Patent No. 6,365,157. Angiogenesis, like many other biological mechanisms requiring regulation of cellular proliferation, is dependent on the phosphorylation of proteins by protein tyrosine kinases. Overexpression or aberrations in the pathways coupled to these kinases can produce pathological outcomes (like uncontrolled angiogenesis and tumor growth). Inhibitors, modulators or regulators of kinase activity have the potential to be therapeutically relevant agents in the treatment of tumor growth and other angiogenic dependent diseases.
Vascular endothelial growth factor ("VEGF") has been implicated in the regulation of angiogenesis in vivo (Klagsbrun, M. and D'Amore, P. (1991) Annual Rev. Physiol. 53:
217-239). VEGF is a homodimeric glycoprotein consisting of two 23 kD subunits. Four different monomeric isoforms of VEGF resulting from alternative splicing of mRNA have been identified. These include two membrane bound forms (VEGF206 and VEGFlg9) and two soluble forms (VEGF165 and VEGF121). VEGF165 is the most abundant isoform in all human tissues except placenta.
VEGF is a potent endothelial-cell specific mitogen (ED50 2-10 pM), specifically promoting proliferation of endothelial cells. VEGF is expressed in embryonic tissues (Breier et al., Development (Camb.) 114:521 (1992)), macrophages, and proliferating epidermal keratinocytes during wound healing (Brown et al., J. Exp. Med., 176:1375 (1992)), and may be responsible for tissue edema associated with inflammation (Ferrara et al, Endocr. Rev. 13:18 (1992)). In situ hybridization studies have demonstrated high levels of VEGF expression in a number of human tumor lines including glioblastoma multiforme, hemangioblastoma, other central nervous system neoplasms and ALDS-associated Kaposi's sarcoma (Plate, K. et al. (1992) Nature 359: 845-848; Plate, K. et al. (1993) Cancer Res. 53: 5822-5827; Berkman, R. et al. (1993) J Clin. Invest. 91:
153-159; Nakamura, S. et al. (1992) AIDS Weekly, 13 (1)). A high level of VEGF expression also has been found in atherosclerotic lesions, plaques and inflammatory cells. VEGF mediates its biological effect through high affinity VEGF receptors which are selectively expressed on endothelial cells during, for example, embryogenesis (Millauer, B., et al. (1993). Cell 72: 835-846) and tumor formation. These receptors comprise a tyrosine kinase cytosolic domain that initiates the signaling pathway involved , in cell growth.
VEGF receptors are class HI receptor-type tyrosine kinases characterized by having several, typically 5 or 7, immunoglobulin-like loops in their amino-terminal extracellular receptor ligand-binding domains (Kaipainen et al, J. Exp. Med., 178:2077-88 (1993)).
The other two regions include a transmembrane region and a carboxy-terminal intracellular catalytic domain interrupted by an insertion of hydrophilic interkinase sequences of variable lengths, called the kinase insert domain (Terman et al., Oncogene, 6:1677-83 (1991)). VEGF receptors include fms-Vke tyrosine kinase receptor (flt-1), or VEGFR-1, sequenced by Shibuya et al., Oncogene, 5:519-24 (1990), kinase insert domain-containing receptor/fetal liver kinase (KDR/flk-1), or VEGFR-2, described in WO 92/14248, filed February 20, 1992, and Terman et al., Oncogene, 6:1677-83 (1991) and sequenced by Matthews et al., Proc. Natl. Acad. Sci. USA, 88:9026-30 (1991), although other receptors can also bind VEGF. Another tyrosine kinase receptor, VEGFR-3 (flt-4), binds the VEGF homologues VEGF-C and VEGF-D and is important in the development of lymphatic vessels.
It is generally believed that KDR/VEGFR-2 is the main VEGF signal transducer that results in endothelial cell proliferation, migration, differentiation, tube formation, increase of vascular permeability, and maintenance of vascular integrity. VEGFR-1 possesses a much weaker kinase activity, and is unable to generate a mitogenic response when stimulated by VEGF, although it binds to VEGF with an affinity that is approximately 10-fold higher than KDR. VEGFR-1 has also been implicated in VEGF and placenta growth factor (P1GF) induced migration of monocytes and macrophages and production of tissue factor. When VEGF is expressed by a tumor mass, endothelial cells adjacent to the
VEGF+ tumor cells will up-regulate expression of VEGF receptor molecules, e.g., VEGFR-1 and VEGFR-2. High levels of VEGFR-2 are expressed by endothelial cells that infiltrate gliomas (Plate, K. et al., (1992) Nature 359: 845-848), and are specifically upregulated by VEGF produced by human glioblastomas (Plate, K. et al. (1993) Cancer Res. 53: 5822-5827). The finding of high levels of VEGR-2 expression in glioblastoma associated endothelial cells (GAEC) suggests that receptor activity is induced during tumor formation, since VEGFR-2 transcripts are barely detectable in normal brain endothelial cells, indicating generation of a paracrine VEGF/VEGFR loop. This upregulation is confined to the vascular endothelial cells in close proximity to the tumor. Blocking VEGF activity with neutralizing anti-VEGF monoclonal antibodies (mAbs) results in inhibition of the growth of human tumor xenografts in nude mice (Kim, K. et al. (1993) Nature 362: 841-844), suggesting a direct role for VEGF in tumor-related angiogenesis.
Accordingly, VEGFR antagonists have been developed to treat vascularized tumors and other angiogenic associated diseases. These have included neutralizing antibodies that block signaling by VEGF receptors expressed on vascular endothelial cells to reduce tumor growth by blocking angiogenesis through an endothelial-dependent paracrine loop. See, e.g., U.S. Patent No. 6,365,157 and International Publications Nos. WO 00/44777, WO 01/54723, WO 01/74296, WO 01/90192, "Bispecific Antibodies That Bind to VEGF Receptors" (Zhu, International PCT application filed June 26, 2002), and "Method of Treating Atherosclerosis and Other Inflammatory Diseases" (Carmeliet et al.; International
PCT application filed Jun. 20, 2002).
VEGF receptors also have been found on some non-endothelial cells, such as tumor cells producing VEGF, wherein an endothelial-independent autocrine loop is generated to support tumor growth. It has been demonstrated that a VEGF/human VEGFR-2 autocrine loop mediates leukemic cell survival and migration in vivo. Dias et al., "Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration," J. Clin. Invest. 106:511-521 (2000); Witte et al., "Treatment of non-solid mammalian tumors with vascular endothelial growth factor receptor antagonists;" and International Publication No. WO 01/74296. Similarly, VEGF production and VEGFR expression also have been reported for some solid tumor cell lines in vitro. (See Tohoku, Sato, J. Exp. Med., 185(3):
173-84 (1998); Nippon, Sanka Fujinka Gakkai Zasshi,:47(2): 133-40 (1995); and Ferrer, FA, Urology, 54(3):567-72 (1999)). It has further been demonstrated that VEGFR-1 Mabs inhibit an autocrine VEGFR/human VEGFR-1 loop in breast carcinoma cells. Wu, et al., "Monoclonal antibodys against VEGFR1 inhibits fltl -positive DU4475 human breast tumor growth by a dual mechanism involving anti-angiogenic and tumor cell growth inhibitory activities," AACR_NCI_EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 29-November 2, 2001, Abstract #7; and Carmeliet et al. (International PCT application filed June 20, 2002).
In view of the foregoing, it will be appreciated that inhibitors of VEGF receptor tyrosine kinase activity can interrupt the paracrine and/or autocrine VEGF/ VEGFR loop.
Such inhibitors hold the potential to disrupt pathological angiogenisis and influence the progression of angiogenic dependent diseases.
Accordingly, there is a need for inhibitors of VEGF receptor tyrosine kinase activity. However, the road from the discovery that a compound is an inhibitor of VEGF receptor tyrosine kinases to the development of effective therapeutic agents against pathogenic vascularization is uncertain. Many factors impinge upon the outcome whether a compound shown to be effective in in vitro experiments will be an effective therapeutic agent against cancer. Such factors include side effects caused by administration of the compound in dosages necessary for anti-angiogenic effectiveness, the cost of producing or obtaining the compound, the method by which the compound must be administered and many others.
It would be highly desirable to have available new candidate therapeutic compounds with VEGF receptor tyrosine kinase activity, that are storage stable and preparable by multi-step chemical synthesis from commercially available or readily accessible starting materials. SUMMARY OF THE INVENTION
Accordingly, it is an object of the present invention to provide active agents capable of inhibiting the tyrosine kinase activity of vascular endothelial cells, in particular vascular endothelial cells adjacent to cells affected by a disease that needs neo vascularization in order to advance to a life threatening stage. It is a further object of the invention to provide agents that are useful for the treatment of cancer. Novel small molecules have been discovered which have an inhibitory effect on the tyrosine kinase activity of VEGFR-2 receptors and utility in cancer treatment. These compounds share a 1,3-disubstituted five-membered heterocyclic ring scaffold represented by Formula (I):
Figure imgf000007_0001
wherein :
Xj and X2 are atoms or radicals independently selected from the group consisting of oxygen, sulfur, nitrogen, radicals of formula C-R3 and radicals of formula N-R3, with the proviso that at least one of Xj and X2 is oxygen, sulfur, nitrogen or a diradical of formula N-R3, wherein:
R3 is an atom or radical selected from the group consisting of: 1) hydrogen, 2) halogen,
3) alkyl, optionally substituted with one or more substituents selected
Figure imgf000007_0002
4) alkenyl, optionally substituted with one or more substituents selected from R4; 5) alkynyl, optionally substituted with one or more substituents selected from R4; wherein R4 is an atom or radical selected from the group consisting of: a) halogen; b) alkyl, which may be optionally substituted with one or more halogen, hydroxy or lower alkoxy; c) alkenyl, which may be optionally substituted with one or more halogen, hydroxy or lower alkoxy; d) nitro; e) cyano; f) oxo; g) vinyl; h) styryl; i) a group of formula -C(O)R5, -CO2R5, -OR5, -SR5, -SOR5, -
SO2R5, -NRjRg, -NCO2R5, or -OCO2R5 where R5 and R6 are atoms or radicals independently selected from the group consisting of hydrogen, lower alkyl, aralkyl, aryl and heteroaryl; X3 is selected from the group consisting of oxygen, sulfur, nitrogen and diradicals of formula N-R3,
Yj and Y2 are atoms independently selected from the group consisting of nitrogen and carbon,
Rj is a radical selected from the group consisting of:
Figure imgf000008_0001
wherein Wj is nitrogen or C-R^,,, W2 is nitrogen or C-R^, W3 is nitrogen or C-Rw3, W4 is nitrogen or C-R^, W5 is nitrogen or C-R^, W6 is nitrogen or
Figure imgf000009_0001
and W9 is nitrogen or C-R^ , each R^, Rw2, Rw3, Rw4, Rw5, R^, R^, R^ and R^ being an atom or radical independently selected from the group consisting of: 1) hydrogen, 2) halogen,
3) nitro,
4) cyano,
5) alkyl, optionally substituted with one or more substituents selected from R4, 6) alkenyl, optionally substituted with one or more substituents selected from R4,
7) alkynyl, optionally substituted with one or more substituents selected from R4,
8) aralkyl, optionally substituted with one or more substituents selected from R4,
9) phenyl, optionally substituted with 1 to 5 substituents selected from R4,
10) a group of the formula -CO2R5, -COR5, -OR5, -SR5, -SOR5, -SO2R6, -NR5R6, 11) pyridyl, optionally substituted with 1 to 4 substituents selected from
R ,
12) pyrazinyl, optionally substituted with 1 to 3 substituents selected from R4,
13) pyrimidinyl, optionally substituted with 1 to 3 substituents selected from R4,
14) indazolyl, optionally substituted with 1 to 5 substituents selected
Figure imgf000009_0002
15) tetrazolyl, and
14) heterocyclic radicals of formulae: (R4)a (R4)b (R4)b
Figure imgf000010_0001
wherein X4 is O, S, or N-R4, a is 0 to 3, b is 0 to 2, c is 0 or l, or together, one or more of the combinations R^ and R^, Rw2 and Rw3, Rw3 and R^, R,v5 and Rw6, Rw6 and Rw7, R^ and R^, and Rw8 and R^ form a fused 5- or 6- membered carbocyclic ring or heterocyclic ring having one or two heteroatoms selected from nitrogen, oxygen and sulfur, Z is selected from the group consisting of oxygen, sulfur, -S(O)-, -S(O)2-, -
CR5R6-, -CR5R6O-, CR5R6NR3- and -NR3- R2 is a radical of formula -OR7a, -SR7a, -S(O)R7a,
Figure imgf000010_0002
-CR5R6-OR7a wherein R7a is a radical selected from the group consisting of: 1) -CH2-R8,
2) -CH2CH2-R8,
3) -CH2CH2CH2-R8, and
4) -R83 wherein R8 is a cyclic radical selected from the group consisting of: a) aromatic carbocyclic radicals, optionally substituted with 1 to 5 substituents wherein the substituents are selected from
R4 or two adjacent substituents can form a 5, 6 or 7 membered fused carbocyclic or heterocyclic ring optionally substituted with one or more substituents selected from R4, and b) aromatic and non-aromatic heterocyclicyl radicals, optionally substituted with 1 to 5 substituents wherein the substituents are either selected from R4 or two adjacent substituents can form a 5, 6 or 7 membered fused carbocyclic or heterocyclic ring optionally substituted with one or more substituents selected from R4, or R2 is a radical selected from the group consisting of -CR5R6NR7aR7b, and -N ^R,,, and: R7a and R^ are both hydrogen,
R7a and R^ together form a 6 membered ring heterocycle, optionally substituted with one or more substituents selected from the group R4, or R-Tb is hydrogen or a radical selected from R4 and R7a is a radical selected from the group consisting of: 1) -CH2-R8,
2) -CH2CH2-R8,
3) -CH2CH2CH2-R8, and
4) -R* wherein R8 is a cyclic radical selected from the group consisting of: a) aromatic carbocyclic radicals, optionally substituted with 1 to 5 substituents wherein the substituents are selected from R4 or two adjacent substituents can form a 5, 6 or 7 membered fused carbocyclic or heterocyclic ring optionally substituted with one or more substituents selected from R4, and b) aromatic and non-aromatic heterocyclicyl radicals, optionally substituted with 1 to 5 substituents wherein the substituents are either selected from R4 or two adjacent substituents can form a 5, 6 or 7 membered fused carbocyclic or heterocyclic ring optionally substituted with one or more substituents selected from R4. Processes for preparing the active agents are also provided. The active agents may be incorporated into pharmaceutical compositions and dosage forms in accordance with further teachings of this disclosure. The active agents, compositions and dosage forms may be used independently or together to treat angiogenic dependent diseases according to the method aspect of the invention.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
Definitions
Unless otherwise indicated, chemical terms used in this disclosure have the meaning attributed to them by those skilled in the art of medicinal and organic chemistry and biological terms have the meaning attributed to them by those skilled in the art of molecular and cell biology. The following express definitions are consonant with those understandings.
A "hydrocarbyl" radical means a fragment of a molecule that contains carbon and hydrogen. As used in this disclosure, the term is intended to include fragments that contain, in addition to carbon and hydrogen, any number of heteroatoms. Heteroatoms may be pendant, such as the carbonyl oxygen of acetone or the fluorine atoms of 2,2- difluoropropane. Heteroatoms also may be incorporated into a hydrocarbyl fragment, such as the nitrogen of N,N-dimethylaminomethyl, the oxygen atom of diethyl ether or a polyethyleneglycol fragment. The term "alkyl" as used herein refers to a saturated hydrocarbyl radical that may be unsubstituted or substituted with one or more substituents. The alkyl radical may be straight, branched or cyclic. The term "lower alkyl" is reserved for alkyl radicals containing from 1 to 6 carbon atoms. Linear and branched lower alkyl substituents include methyl, ethyl, propyl, isopropyl, butyl and t-butyl, and the like. Cyclic lower alkyl radicals include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
The term "alkenyl" as used herein refers to a straight, branched or cyclic non- aromatic hydrocarbyl radical containing at least one carbon to carbon double bond. The term "lower alkenyl" as used herein is reserved for an alkenyl radical containing from 2 to 6 carbon atoms. Lower alkenyl groups include ethenyl, propenyl, butenyl cyclohexenyl, and the like.
The term "alkynyl" as used herein refers to a straight, branched or cyclic hydrocarbyl radical containing at least one carbon to carbon triple bond. The term "lower alkynyl" as used herein is reserved for an alkynyl radical containing from 2 to 6 carbon atoms. Lower alkynyl groups include ethynyl, propynyl and butynyl, and the like. Alkyl, alkenyl and alkyl radicals typically have between 1 and 40 carbon atoms. The term "aryl" as used herein refers to carbocyclic and heterocyclic radicals that are "aromatic," i.e. they possess cyclic π electron systems that have a stabilizing electromc character called resonance stabilization. Fieser & Fieser, Organic Chemistry 525-526 (3rd ed. 1956), Streitweiser, A.; Heathcock, CH. Introduction to organic Chemistry 643 (2nd ed. 1981 ). Aryl radicals can be distinguished by those skilled in the art from other radicals having cyclic π electron systems by applying the Huckel rule which states that resonance stabilization will occur when the number of electrons that are delocalized in the π electron system is 4n+2 where n is an integer. Aryl radicals include unsubstituted or substituted 6-membered aromatic rings, such as, phenyl, substituted phenyl and like, as well bicyclic rings, such as naphthyl, and polycyclic rings, such as anthracenyl, and heterocyclic radicals, such as pyridinyl as well as, imidazolyl, oxazolyl, thiazolyl, indazolyl and the like (wherein the Huckel rule is satisfied by the contribution by a heteroatom of a pair of electrons to the aromatic stabilization).
The terms "heterocycle," "heteroaryl" and "heterocyclic" mean a stable 5- to 6-membered mono- or 7- to 10-membered fused bicyclic ring system, any ring of which may be saturated or unsaturated, aromatic or non-aromatic, provided that from one to three ring atoms are selected from the heteroatoms N, O and S while the other ring atoms are carbon. The nitrogen and sulfur heteroatoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized. The term "heterocycles" includes the abovementioned heteroaryls, as well as reduced (e.g. dihydro and tetrahydro) analogs thereof. Heterocycles include any bicyclic group in which any of the above-defined rings is fused to a benzene ring. The heterocyclic ring may be attached at any heteroatom or carbon atom, which results in the creation of a stable structure. Examples of such heterocyclic components include piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolodinyl, 2-oxoazepinyl, azepinyl, pyrrolyl, 4-piperidonyl, pyrrolidinyl, pyrazolyl, pyrazolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, oxazolidinyl, isoxazolyl, isoxazolidinyl, mo holinyl, thiazolyl, thiazolidinyl, isothiazolyl, - quinuclidinyl, isothiazolidinyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl, thiadiazoyl, benzopyranyl, benzothiazolyl, benzoxazolyl, furyl, tefrahydrofuryl, tefrahydropyranyl, thiophenyl, imidazopyridinyl, tetrazolyl, triazinyl, thienyl, benzothienyl, thiamorpholinyl sulfoxide, thiamorpholinyl sulfone, and oxadiazolyl.
The term "alkoxy" refers to a radical containing a straight, branched or cyclic hydrocarbyl radical attached via an oxygen atom. Substituents on the hydrocarbyl group may include for example, a phenyl ring, in which the alkoxy may be for example, a benzyloxy group. Examples of alkoxy groups are methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, tertiary butoxy, pentoxy, isopentoxy, hexoxy, isohexoxy allyloxy, propargyloxy, vinyloxy, and the like.
The term "aralkyl" as used herein contemplates a lower alkyl group which has as a substituent an aryl group.
The term "halo" or "halogen" as used herein is intended to include the halogen atoms fluorine, chlorine, bromine and iodine.
The chemical nomenclature used in this disclosure follows the system for naming compounds of the International Union of Pure and Applied Chemistry (IUPAC). The IUPAC system assigns a number to every atom in a compound. This disclosure also uses relative numbering where it is the clearest way to describe the invention to those skilled in the art. The absolute numbering assigned by the IUPAC system is to be distinguished from relative numbering commonly used to express bonding relationships between functional groups. Thus, it will be appreciated that the phenyl groups of 3,5-diphenyl-l,2,4-triazole are in a 1,3 relationship to each other because they are separated by three atoms including those to which they are attached. Whether atom numbering is absolute or relative will be clear to one skilled in the art from the context in which it is used.
When one or more chiral centers are present in the compounds of the present invention, the individual isomers and mixtures thereof (e.g., racemates, etc.) are intended to be encompassed by the formulae depicted herein.
1.3-Disubstituted Five-membered Ring Heterocyclic VEGF Tyrosine Kinase Inhibitors
The present invention provides novel compounds that inhibit tyrosine kinase activity of vascular endothelial growth factor receptors. The present invention is not intended to be limited to any particular mechanism of VEGF receptor kinase inhibition. The compounds of the present invention are certain appropriately 1,3-disubstituted five- membered ring heterocycles that are encompassed by Formula (I).
Figure imgf000016_0001
wherein :
X, and X2 are atoms or radicals independently selected from the group consisting of oxygen, sulfur, nitrogen, radicals of formula C-R3 and radicals of formula N-R3, with the proviso that at least one of Xj and X2 is oxygen, sulfur, nitrogen or a diradical of formula N-R3, wherein:
R3 is an atom or radical selected from the group consisting of:
1) hydrogen,
2) halogen,
3) alkyl, optionally substituted with one or more substituents selected from R4;
4) alkenyl, optionally substituted with one or more substituents selected from R4;
5) alkynyl, optionally substituted with one or more substituents selected from R4; wherein R4 is an atom or radical selected from the group consisting of: a) halogen; b) alkyl, which may be optionally substituted with one or more halogen, hydroxy or lower alkoxy; c) alkenyl, which may be optionally substituted with one or more halogen, hydroxy or lower alkoxy; d) nitro; e) cyano; f) oxo; g) vinyl; h) styryl; i) a group of formula -C(O)R5, -CO2R5, -OR5, -SR5, -SOR5, -
SO2R5, -NR5R6, -NCO2R5, or -OCO2R5 where R5 and R6 are atoms or radicals independently selected from the group consisting of hydrogen, lower alkyl, aralkyl, aryl and heteroaryl;
X3 is selected from the group consisting of oxygen, sulfur, nitrogen and diradicals of formula N-R3,
Yj and Y2 are atoms independently selected from the group consisting of nifrogen and carbon, Rλ is a radical selected from the group consisting of:
Figure imgf000017_0001
wherein Wj is nitrogen or C-R^, W2 is nifrogen or C-R^, W3 is nitrogen or C-R^, W4 is nifrogen or C-R^, W5 is nifrogen or C-R^, W6 is nitrogen or C-Rw6, W7 is nitrogen or C-R^, W1 is nitrogen or C-R^ and W9 is nitrogen or C-R^ , each R^, R^, R^, R^, Rw5, Rw6, R^, R^ and Rw9 being an atom or radical independently selected from the group consisting of:
1) hydrogen,
2) halogen, 3) nitro,
4) cyano, 5) alkyl, optionally substituted with one or more substituents selected from R4, 6) alkenyl, optionally substituted with one or more substituents selected from R4, 7) alkynyl, optionally substituted with one or more substituents selected from R4,
8) aralkyl, optionally substituted with one or more substituents selected from R4,
9) phenyl, optionally substituted with 1 to 5 substituents selected from R4,
10) a group of the formula -CO2R5, -COR5, -OR5, -SR5, -SOR5, -SO2R6, -NR5R6,
11) pyridyl, optionally substituted with 1 to 4 substituents selected from R4, 12) pyrazinyl, optionally substituted with 1 to 3 substituents selected from R4,
13) pyrimidinyl, optionally substituted with 1 to 3 substituents selected
Figure imgf000018_0001
14) indazolyl, optionally substituted with 1 to 5 substituents selected from R4,
Figure imgf000018_0002
15) tetrazolyl, and
14) heterocyclic radicals of formulae:
Figure imgf000018_0003
wherein X4 is O, S, or N-R4, a is 0 to 3, b is 0 to 2, c is 0 or 1, or together, one or more of the combinations R^ and Rw2, R^ and Rw3, Rw3 and R^, Rw5 and Rw6, Rw6 and R^, R^ and ^, and Rw8 and R^ form a fused 5- or 6- membered carbocyclic ring or heterocyclic ring having one or two heteroatoms selected from nitrogen, oxygen and sulfur, Z is selected from the group consisting of oxygen, sulfur, -S(O)-, -S(O)2-, - CR5R6-, -CR5R6O-, CR5R6NR3- and -NR3- R2 is a radical of formula -OR7a, -SR7a, -S(O)R7a, -CR5R6R7a, -CR5R6-OR7a wherein R7a is a radical selected from the group consisting of:
1) -CH2-R85
2) -CH2CH2-R8,
3) -CH2CH2CH2-R8, and
Figure imgf000019_0001
wherein R8 is a cyclic radical selected from the group consisting of: a) aromatic carbocyclic radicals, optionally substituted with 1 to 5 substituents wherein the substituents are selected from R4 or two adjacent substituents can form a 5, 6 or 7 membered fused carbocyclic or heterocyclic ring optionally substituted with one or more substituents selected from R4, and b) aromatic and non-aromatic heterocyclicyl radicals, optionally substituted with 1 to 5 substituents wherein the substituents are either selected from R4 or two adjacent substituents can form a 5, 6 or 7 membered fused carbocyclic or heterocyclic ring optionally substituted with one or more substituents selected from R4, or R2 is a radical selected from the group consisting of -CR5R6-NR7aR7b, and -NR^R^ and:
R7a and R^ are both hydrogen,
R7a and R^ together form a 6 membered ring heterocycle, optionally substituted with one or more substituents selected from the group R4, or R-Tb is hydrogen or a radical selected from R4 and R7a is a radical selected from the group consisting of: 1) -CH2-R8,
2) -CH2CH2-R8,
3) -CH2CH2CH2-R8, and
4) -R8, wherein R8 is a cyclic radical selected from the group consisting of: a) aromatic carbocyclic radicals, optionally substituted with 1 to 5 substituents wherein the substituents are selected from R4 or two adjacent substituents can form a 5, 6 or 7 membered fused carbocyclic or heterocyclic ring optionally substituted with one or more substituents selected from R4, and b) aromatic and non-aromatic heterocyclicyl radicals, optionally substituted with 1 to 5 substituents wherein the substituents are either selected from R4 or two adjacent substituents can form a 5, 6 or 7 membered fused carbocyclic or heterocyclic ring optionally substituted with one or more substituents selected from R4. Generally, substituent R2 is preferably a radical of formula -NH-R8, -NHCH2-R8, - NHCH2CH2-R8 or -NHCH2CH2CH2-R8, wherein R8 is an optionally substituted phenyl radical, optionally substituted bicyclic aromatic carbocyclic radical, optionally substituted polycyclic aromatic carbocyclic radical, optionally substituted monocyclic aromatic heterocyclic radical, optionally substituted bicyclic aromatic heterocyclic radical or optionally substituted polycyclic aromatic heterocyclic radical. Preferred R8 substituents are phenyl, optionally substituted with 1 to 5 substituents selected from R4; pyridinyl, optionally substituted with 1 to 4 substituents selected from R4; pyrazinyl, optionally substituted with 1 to 3 substituents selected from R4; pyrimidinyl, optionally substituted with 1 to 3 substituents selected from R4; indazolyl, optionally substituted with 1 to 5 subsitutents selected from R4; tetrazolyl;or an aromatic heterocyclic radical of formula:
Figure imgf000021_0001
wherein X, R4 and a-c are as previously defined. An especially preferred Z substituent is NH.
Compounds of Formula (I) were previously unknown in any state of purity and are not a known component of any naturally occurring composition. Thus, the present invention is directed to these compounds in all states of purity. The compounds of this invention exist in different physical states as well, such as dissolved states and condensed states. Condensed states include salts and solvates of the compound (particular salts suitable for pharmaceutical use are described below). The present invention also relates to "prodrugs" of compounds of Formula (1). A "pro-drug" is a compound that is administered to a patient and is converted within the patient's body into a second compound that exerts a therapeutic effect. The present invention encompasses pro-drugs that are transformed in vivo to yield the Formula (I) compound or a protein conjugate of it. Pro-drugs are thoroughly discussed in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems Vol. 14 of the A. C. S. Symposium Series, and in Edward B. Roche, ed.,
Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987.
The VEGF receptor antagonists of the invention are readily prepared by general methodologies described in compendia and freatises on heterocycles and organic synthesis methods. In particular, there may be mentioned Comprehensive Heterocyclic Chemistry
(Alan Katritzky and Charles Rees eds., Pergamon Press: Oxford 1984); Heterocyclic Compounds (John Wiley & Sons: New York 1981) and Methoden der Organishchen Chemie (Houben-Weyl: Stuttgart 1974). Any heterocyclic ring systems encompassed by Formula (I) that are inaccessible because they are unstable can be readily determined by those skilled in the art by consulting standard reference works in the field such as those referenced immediately above. 1.2.4-Triazole VEGF Tyrosine Kinase Inhibitors
One preferred class of 1,3-disubstituted (relative numbering) five-membered ring heterocycles of Formula (I) are 3,5-disubstiruted-l,2,4-triazoles. Triazoles are 5- membered ring heterocycles containing three nitrogen atoms. Triazoles exist in two distinct classes-l,2,3-triazoles and l,2,4-triazoles~differentiated by the positions of the nitrogen atoms in the aromatic ring. Both classes have aromatic character. 1,2,3- Triazoles characteristically have a annular nifrogen atom bonded to two other annular nifrogen atoms. The 1,2,4-triazoles characteristically have only one direct bond between annular nitrogen atoms. The triazoles that have been discovered to have VEGF receptor kinase inhibitory activity are 1,2,4-triazoles. Accordingly, one preferred class of 1,2,4- triazoles of the present invention are those that are encompassed by Formula (la):
Figure imgf000022_0001
wherein Rl5 R2, R3, W,, W2, W3 and W4 are as previously defined with respect to Formula
(I). i preferred 1,2,4-triazoles of the present invention, R3 is hydrogen. In yet more preferred 1,2,4-triazoles of the present invention, R2 is -NH-R7a, R3 is hydrogen, W2 is C-
Rw2, W3, W4, W5 and W9 are CH, W7 is C-R^ and W8 is C-R^. Accordingly, more preferred 1,2,4-triazoles of the present invention are those encompassed by Formula (la'):
Figure imgf000023_0001
wherein W]5 W6, R^, R^, Rw8 and R7a are as previously defined with respect to Formula
(I)-
In a second preferred group of 1,2,4-triazoles of the present invention, the triazole ring and one of the aryl rings are connected through a linking group Z. In addition, R2 is a radical of formula -NR^R^. Accordingly, this second preferred class of 1,2,4-frazoles is encompassed by Formula (la"):
Figure imgf000023_0002
wherein W]3 R^-R^, R7a, ^ and Z are as previously defined with respect to Formula (I). Yet more preferred 1,2,4-triazoles of Formula (la") are those wherein Z is -NH-, -CH2O-, or -CH2-.
1,2,4-Triazoles whose annular nitrogens are unsubstituted as they are in Formulae (la') and (la") are likely to exist as a rapidly equilibrating mixture of three isomers, a phenomenon called protofropy. In fact, it has been stated that the parent compound 1,2,4- triazole is best represented as a proton associated with a resonance stabilized triazole anion. Ainsworth et al. J. Med. Pharm. Chem. 1962, 5, 383. Representations of the three isomers, or tautomers, may be generated by attaching the hydrogen atom whose point of attachment is unspecified to each of the annular nitrogen atoms and adjusting the positions of the two double bonds to obtain proper valency. In the general case, these tautomers are not separable at ambient temperature. All three interconverting tautomers are intended to be covered by Formulae (I), (la') and (la"), it being understood by those skilled in the art that, when protofropy occurs, one tautomer does not exist free of the other tautomers under conditions in which the compounds of the present invention will be used, e.g. in a pharmaceutical composition or the bloodstream of a mammal.
1,2,4-Triazoles are readily prepared by methods described in Comprehensive Heterocyclic Chemistry Part 4a (Alan Katritzky and Charles Rees eds., Pergamon Press: Oxford 1984); Heterocyclic Compounds Vol. 37 (John Wiley & Sons: New York 1981) stndMethoden der Organishchen Chemie (Houben-Weyl: Stuttgart 1974).
1,2,4-Triazoles can be prepared from acyclic starting materials by reacting a substituted or unsubstituted hydrazine with certain compounds containing a (-C(=O)-NH-) or -C(=NH)-NH- fragment. Methodologies for making 1,2,4-triazoles from acyclic starting materials include (1) condensation of a hydrazine (R-NHNH2) with an imide (R'-C(O)NHC(O)-R"), known as the Einhorn-Brunner reaction. Einhorn et al. Liebigs
Ann. Chem. 1905, 343, 229; Briinner £er. Dtsch Chem. Ges. 1914, 472671; Brunner /?. Chem. 1915, 3(5, 509. Additional methodologies include (2) condensation of a hydrazide (a.k.a. acylhydrazine) (R-C(O)NHNH2) with a primary amide (R'C(O)NH2), known as the Pellizzari reaction (3) condensation of an amidrazone (RC(=NH)NR'-NH2) with a carboxylic acid (R"COOH) and (4) cyclization of an acylamidrazone (RC(O)-NR'-
N=C(R")NH2).
Conversion of these compounds to 1,2,4-triazoles is generally performed in a polar organic solvent, like a lower alcohol or THF, under neutral or mildly basic conditions at a concentration of about lmM to about 2 M. Depending upon the choice of solvent, concenfration and nature of the particular starting materials, the reaction may proceed at reduced, ambient or elevated temperatures. Generally, reaction conditions of about IM in refluxing anhydrous ethanol may be tried as a starting point for optimization of any particular ring closing reaction. Ethanol may be replaced with a high boiling solvent if the reaction does not proceed at a practicable rate. The Pellizzari reaction suffers in comparison to some of the other methods because high reaction temperatures are frequently required.
In a preferred process, the 1,2,4-triazoles of this invention are prepared by contacting a hydrazide of Formula (II)
Figure imgf000025_0001
or salt thereof, with an amidine of Formula (IH)
Figure imgf000025_0002
or salt thereof under conditions effective to condense the hydrazide group of (II) and amidine group of (in) into a 1,2,4-triazole ring. The ring closure is effected under basic conditions which can be established using a strong base, with alkali metal hydroxides and alkoxides being preferred. Other bases that may suitable include sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, trialkylamines, such as trimethylamine and triethylamine, dialkylanilines, such as N,N-diethylaniline, pyridines, such as 2,4,6-trimethylpyridine, pyridine, and dimethylaminopyridine, DBU, or DABCO, The molar amount of the base to be used is 1 to 20, preferably 1 to 5, times the amount of limiting reagent. Compounds (TJ) and (III) can be contacted in a melt (if at least one is a liquid at the reaction temperature) or in an inert diluent. Diluents include water and organic compounds that are liquid at ambient temperature like certain lower alcohols, such as methanol, ethanol, 1-propanol, 2-propanol, 1-butanol, 2-butanol and zjo-butanol; aliphatic and aromatic hydrocarbons, such as hexane, pefroleum ether, benzene, toluene, and xylene; halogenated hydrocarbons, such as dichloromethane, chloroform and Freons; ethers, such as diethyl ether, methyl t-butyl ether, 1,2-dimethoxyethane, dioxane and tetrahydrofuran;
N,N-dialkyl amides, such as dimethylformamide and dimethylacetamide; ketones, such as acetone and methyl ethyl ketone; nitriles, such as acetonitrile and acrylonitrile; and sulfoxides, such as dimethylsulfoxide. Preferably, compounds (H) and (III) are contacted in a lower alcohol diluent, with a preferred lower alcohol being ethanol. Conveniently, the ring closure is conducted in a lower alcohol using an alkali metal salt of the corresponding alkoxide anion or different alkoxide anion as base. Although any concenfration that allows the ring closure to go substantially to completion is suitable, a concentration of from about 100 mM to about 2 M, more particularly about 1 M, is recommended. If the reaction does not go to completion in a practicable period of time at the boiling temperature of the alcohol in the recommended concentration ranges then the reaction mixture can be concentrated and the residue taken up in a higher boiling solvent, like chlorobenzene.
Alternatively, it may be desirable for functional group compatibility to prepare a hydrazide of Formula (IV)
Figure imgf000026_0001
or salt thereof, and an amidine of Formula (V)
Figure imgf000026_0002
or salt thereof and react them under generally the same conditions used when reacting (H) and (m). The hydrazides and amidines, in turn, may be prepared conventionally by known synthetic pathways. Scheme I depicts a process whereby commercially available and readily accessible nitriles may be converted into an amidine (HI) salt that can be used in the making of the 1,2,4-triazoles of this invention. In an anhydrous lower alcohol solvent (e.g. ethanol) an appropriately substituted nitrile undergoes addition by a molecule of solvent when treated with anhydrous hydrochloric acid to form an imidate. The imidate may be conveniently isolated as an acid addition salt with the acid catalyst. The imidate salt may be carried forward in the next step of the process. Treatment of the imidate or imidate salt with ammonia transforms the imidate group into an amidine group.
Scheme I
NH NH aN II ll
R^ rT Rf "OEt - HX NH3 Rf NH2 • HX
HOEt
(HT)
Ort o-alkylamino substituted benzoic acid hydrazides can be prepared by condensation of an ester of anthranilic acid and a lower alcohol with an aldehyde followed by reduction of the so-formed imine. The resulting ort/zo-methylamino substituted benzoic acid is then contacted with hydrazine to yield hydrazide (H), as shown in Scheme H
Scheme H
Figure imgf000027_0001
(II)
To form the intermediate imine, the aldehyde and anthranilic acid lower alcohol ester are contacted under mildly acidic conditions. Preferred acid catalysts are acetic acid, methanesulfonic acid, trifluoroacetic acid, pivalic acid, hydrochloric acid, hydrobromic acid, with the most preferred acid being acetic acid. After formation of the imine, optionally with isolation, the imine group is reduced with a suitable reducing agent. Suitable reducing agents include sodium cyanoborohydride, sodium borohydride, lithium aluminum hydride, DIBAL, diborane and the like and catalytic reducing agents such as Raney nickel, and palladium on carbon. The most preferred reducing agent is sodium cyanoborohydride. Additional reducing agents that are known to reduce imines to amines can be found in Larock R.C. Comprehensive Organic Transformations 2nd ed. (Wiley-
VCH: New York 1999). The addition-elimination and reduction can both be performed in lower alcohols, as wells as ethers and halogenated organic solvents that will solubilize the reactants and reagents that are adapted for use in homogenous liquid phase reactions. Hydrazide (II) may be prepared by reacting the carboxylic acid group of the reduced product with a hydrazine. Unsubstituted hydrazine is conveniently available as a solid hydrate (Aid. Cat. Nos. 22,581-9 and 20,794-2) and in solutions in THF and water (Aid. Cat. Nos. 43,363-2 and 30,940-0). Substituted hydrazines may be readily prepared from NH2NH2 by methods well known to those skilled in the art.
Alternatively, it maybe possible with some starting materials to prepare the 1,2,4- triazole in a reasonable yield in a one pot process by heating an appropriately substituted nitrile with a benzene hydrazide. See, Weidinger, H.; Kranz, J. Berichte 1963, 96, 1064. However, its lack of general applicability makes it a less preferred process.
Generally, the ring-forming condensation proceeds cleanly and in good yield without protection when ortAo-secondary amines are present on (V). However, compounds (II)-(V) may bear functionality that inhibits one or more reactions used in making the compounds of the present invention. Compounds (II)-(V) may be derivatized to a form that modifies interfering chemical functionality using well established techniques of functional group protection. For instance, if necessary, hydroxy groups, carboxylic acids, and primary and secondary amine groups on substituents R^ may be protected as desired as silyl ethers, esters, carbamates, carbonates and the like using techniques well known to the skilled artisan. The selection, application and removal of protective groups are the subjects of many reference works such as Green & Wuts, Protective Groups in Organic Synthesis (John Wiley & Sons: New York 1999) and McOmie, Protective Groups in Organic Chemistry (Plenum Press: London 1973). The use of protection strategies to make compounds of other heterocyclic classes discussed below also may be advantageous.
1.3.4-Oxadiazole VEGF Tyrosine Kinase Inhibitors
A second preferred class of 1,3-disubstituted five-membered ring heterocycles of Formula (I) is 2,5-disubstituted oxadiazoles. Oxadiazoles are 5-membered ring heterocycles containing two double bonds, one oxygen atom and two nitrogen atoms. Oxadiazoles are potentially capable of existing in three distinct classes, 1,2,3-, 1,2,4-, 1,3,4- and 1,2,5-oxadiazoles. However, few unfused 1,2,3-oxadiazoles are stable. Especially preferred oxadiazoles of the present invention are 1,3,4-triazoles. Accordingly, one preferred class of 1 ,3-disubstituted five-membered ring heterocycles of the present invention are those that are encompassed by Formula (lb)
Figure imgf000029_0001
wherein Rl5 R2, W1? W2, W3 and W4 are as previously defined with respect to Formula (I). In yet more preferred 1,3,4-oxadiazoles of the present invention, Rj is a substituted or unsubstituted aniline group (-NH-Aryl) and R2 is a radical of formula -NR^ ^. Accordingly, yet more preferred 1,3,4-oxadiazoles of the present invention are those that are encompassed by Formula (lb')
Figure imgf000030_0001
Yet more preferably, Wj is nitrogen and W2, W3 and W4 are each CH.
Methods of preparing 1,3,4-oxadiazoles are described in Comprehensive Heterocyclic Chemistry Part 6, pp. 440-445 (Alan Katritzky and Charles Rees eds.,
Pergamon Press: Oxford 1984); Heterocyclic Compounds "Five- And Six-Membered Compounds with Nitrogen And Oxygen" (Richard H. Wiley ed., John Wiley & Sons: New York 1962), Katritzky, A.R.; Pozharskii, A.F. Handbook of Heterocyclic Chemistry 2nd edition pp. 591-596 (Pergamon: NY 2000); Gilchrist, T.L. Heterocyclic Chemistry 3rd edition, p. 336 (Longman Publ.: Singapore 1997); Joule, J.A. et al. Heterocyclic
Chemistry 3rd edition p.445 (Chapman & Hall: London 1995). These methods include cyclization-dehydration of diacylhydrazines (RC(O)-NHNH-C(O)-R). Each of the treatises referenced in this paragraph is hereby incorporated by reference in its entirety and, in particular, for the discussion of methods of preparing 1,3,4-oxadiazoles contained on the cited pages.
In accordance with a particularly preferred process for preparing 1,3,4-oxadiazoles of Formula (lb'), a hydrazide of Formula (II) (wherein R2=NR7aR7b), previously defined, is contacted with an isothiocyanate of Formula (VI):
Figure imgf000030_0002
to give an intermediate of Formula (VH).
Figure imgf000031_0001
This addition reaction is generally performed in an organic solvent, like dichloromethane, under neutral conditions and at ambient or elevated temperature at a concenfration of about ImM to about 2 M. The intermediate is then cyclized by treating it with a coupling agent like dicyclohexylcarbodiimide.
Isothiocyanate starting materials of Formula (VI) are either commercially available or can be conveniently prepared using well-establish techniques of functional group interconversion starting from the corresponding unsubstituted benzene derivative by electrophilic aromatic substituted with, e.g., ammonium thiocyanate; the corresponding nitro derivative by reaction with carbon disulfide; or the corresponding trialkylsilylamine, or amide by treatment with carbon disulfide and many other techniques described in Comprehensive Organic Functional Group Transformations Vol. 5 pp. 1021-1045 (Katritzky, A.R. et al. editors, Elsevier Science Ltd: Oxford 1995) which is hereby incorporated by reference in its entirety and, in particular, for its description of methods of making isothiocyanates contained in the cited pages of the reference.
Oxazole VEGF Tyrosine Kinase Inhibitors
A third preferred class of 1,3-disubstituted five-membered ring heterocycles of Formula (I) are oxazoles. Oxazoles contain two double bonds, one oxygen atom and one nitrogen atom that is not adjacent to the oxygen atom in the five-membered heterocyclic ring. One preferred class of 1,3-disubstituted oxazoles are 2,5-disubstituted oxazoles (absolute numbering) encompassed by Formula (lc):
Figure imgf000032_0001
wherein either Xj is nitrogen and X2 is C-R3 or Xj is C-R3 and X2 is nifrogen, and Rl5 R2, Wlt W2, W3 and W4 are as previously defined with respect to Formula (I). hi preferred 2,5-disubstituted oxazoles of the present invention, Rj is optionally substituted phenyl, Wl5 W2, W3 and W4 are each CH and R2 is -NH-R7a. Especially preferred 2,5-disubstituted oxazoles are those encompassed by Formula (lc'):
Figure imgf000032_0002
wherein Rw5, Rvι6 and Rw7 are as previously defined with respect to Formula (I) and X, and
X2 are as previously defined with respect to Formula (lc).
Methods of preparing oxazoles are described in Comprehensive Heterocyclic Chemistry Part 6, pp. 216-223 (Alan Katritzky and Charles Rees eds., Pergamon Press:
Oxford 1984); Heterocyclic Compounds "Oxazoles Part A" Vol. 60 pp. 4-127 (David C.
Palmer ed., John Wiley & Sons: New York 2003), Katritzky, A.R.; Pozharskϋ, A.F.
Handbook of Heterocyclic Chemistry 2nd edition pp. 591-596 (Pergamon: NY 2000);
Gilchrist, T.L. Heterocyclic Chemistry 3rd edition, pp. 320-322 (Longman Publ.: Singapore 1997); Joule, J.A. et al. Heterocyclic Chemistry 3rd edition pp.386-392 (Chapman & Hall: London 1995). These methods include cyclization-dehydration of α- acylaminocarbonyl compounds (R'C(O)C(R")-NH-C(O)-R'") known as the Robinson- Gabriel synthesis and the condensation of aldehyde cyanohydrins and aromatic aldehydes in dry ether in the presence of dry hydrochloric acid known as the Fischer Oxazole synthesis. R. H. Wiley, Chem. Rev. 1945 37, 410; J. W. Cornforth, R. H. Cornforth, J. Chem. Soc. 1949, 1028; J. W. Cornforth, Heterocyclic Compounds 1957, 5, 309; T. Onaka, Tetrahedron Letters 1971, 4391. Each of the freatises and articles referenced in this paragraph is hereby incorporated by reference in its entirety and, in particular, for the discussion of methods of preparing oxazoles contained on the cited pages.
Imidazole VEGF Tyrosine Kinase Inhibitors
A fourth preferred class of 1,3-disubstituted five-membered ring heterocycles of Formula (I) are 2,4-disubstituted imidazoles. Imidazoles contain two double bonds and two non-adjacent nifrogen atoms. in the five-membered heterocyclic ring. Accordingly, one preferred class of 2,4-disubstituted imidazoles of the present invention are those that are encompassed by Formula (Id):
Figure imgf000033_0001
wherein either X, is nitrogen and X2 is -CR3 or Xt is -CR3 and X2 is nitrogen and R„ R2,
Wl9 W2, W3 and W4 are as defined with respect to Formula (I). In preferred 2,4- disubstituted imidazoles of the present invention, X! is CR3 (more preferably CH or CH3), and X2 is nifrogen, Rj is optionally substituted phenyl, R2 is -NH2, and Wl5 W2, W3 and W4 are each CH. Yet more preferred imidazoles of the present invention are those encompassed by Formula (Id').
Figure imgf000034_0001
Methods of preparing imidazoles are described in Comprehensive Heterocyclic Chemistry Part 5, pp. 457-496 (Alan Katritzky and Charles Rees eds., Pergamon Press: Oxford 1984); Heterocyclic Compounds "Imidazole And Derivatives Part I" pp.33-43 (Klaus Hofinann ed., Interscience Publishers: New York 1953); Gilchrist, T.L. Heterocyclic Chemistry 3rd edition, pp. 299-300 (Longman Publ.: Singapore 1997); Joule, J.A. et al. Heterocyclic Chemistry 3rd edition pp. 384-387 (Chapman & Hall: London 1995). Each of the treatises referenced in this paragraph is hereby incorporated by reference in its entirety and, in particular, for the discussion of methods of preparing imidazoles contained on the cited pages.
In a preferred process, the imidazoles of this invention are prepared by contacting an amidine of Formula (V) with an -halo carboxyl compound of Formula (VIII) :
Figure imgf000034_0002
wherein substituent "hal" is bromine or iodine, or by contacting an amidine of Formula (HI) with an α-halo ketone of Formula (IX):
Figure imgf000034_0003
When R2 is NH2, R2 is an interfering functionality. We overcame this problem by using a 2-nitro analog of the (2-aminoaryl) α-halo ketone (DC) (NO2 in place of R2) and then reducing the nitro group with palladium-on-carbon. Accordingly, imidazoles of Formula (Id') may be prepared by a variation of the reaction expressed in Scheme HI.
Scheme UJ
Figure imgf000035_0001
The cyclization reaction is generally performed in a polar aprotic solvent like DMF or THF, under basic conditions at a concentration of about ImM to about 2 M. If the starting halide is a bromide, it can be activated by addition of sodium iodide to the reaction mixture. In addition, the reaction mixture may be refluxed to accelerate the reaction. After the cyclization, the nitro group is reduced using conditions well known in the art for reducing aryl nitro groups to amines. Such conditions are summarized and citations to primary references are given in Larock, R.C. Comprehensive Organic Transformations 2nd ed. pp. 823-827 (Wiley- VCH: New York 1999), which pages and the primary references to which they refer are hereby incorporated by reference for their teachings how to reduce nitroarenes to aminoarenes.
Specific representative compounds of the present invention are set forth in Tables 1, 2, 3 and 4, below
Table 1
Figure imgf000036_0001
CH CH H OC 3HH,2C6HH5, H
Figure imgf000036_0002
Figure imgf000036_0003
Cmpd. No. W, Wfi ^v2 Rw7 R*
Figure imgf000037_0001
15 CH CH H H (CH2)3N(CH3)2
16 CH CH H (CH2)3N(CH3)2 H
Figure imgf000037_0002
Figure imgf000037_0003
Cmpd. No. W, Wfi Rw2 R- 7 Rφ? R*
Figure imgf000038_0001
Cmpd. No. Wi Wfi R 7 RwS R 2.a_
Figure imgf000039_0001
Figure imgf000039_0002
45 N CH H H CF, H2 H2
H2
Figure imgf000039_0003
Cmpd. No. W, WΛ Rw2 Rw? Rws R 2.a_
48 N N H H H H2
H2
Figure imgf000040_0001
Figure imgf000040_0002
Cmpd. No. W, WΛ Rwa Rw7 is R*
Figure imgf000041_0001
Cmpd. No. W, Wfi Rw2 RwS R 2.a_
Figure imgf000042_0001
Table 2
Compound No. X, X,
76 N N
77 N C
78 C N Table 3
Figure imgf000043_0001
Cmpd. No. W, X3 Rw5 Rw( w7 Rγv8 Rw9 R,. T,
Figure imgf000044_0001
89 N NH NH H H N(CH3)2 H H H
Figure imgf000044_0002
Figure imgf000044_0003
94 N NH NH H -0-CH,-0- H H H
Figure imgf000044_0004
Figure imgf000044_0005
96 N NH NH H OCH3 H H H H2 H2 H
H2
Figure imgf000044_0006
Figure imgf000045_0001
Cmpd. No. , X3 t w6 wi w9 R7, R •7b
Figure imgf000046_0001
102 N NH NH H -0-CH,-0- H H H
103 N O NH H -0-CH,CH,-0- H H H
104 N O NH H -0-CH,CH,-0- H H H
105 N O NH H -0-CH,CH,-0- H H H
106 N O NH H -0-CH,CH,-0- H H H
107 N O NH H -0-CH,CH,-0- H H H
Figure imgf000046_0002
Cmpd. No. , X3 R- 5 : Rwl Rw9 R7, R7,
108 N O NH H -0-CH,CH,-0- H H H
Figure imgf000047_0001
Figure imgf000047_0002
110 N O NH H -0-CH,CH,-0- H H H
Figure imgf000047_0003
111 N O NH H -0-CH2CH2-0- H H H2 H
N
HN-^
Figure imgf000047_0004
Figure imgf000048_0001
125 N O NH H OCH 3, O uωCHl3, H H H
Figure imgf000048_0002
Figure imgf000048_0003
Cmpd. No. W, X3 Rγv5 Rw6 RΪV w8 9 R7, Rτι
Figure imgf000049_0001
135 N O NH H -CH, 2CωHι 2,CωHι,2"- H H H
Figure imgf000049_0002
Figure imgf000049_0003
Figure imgf000050_0001
148 N O NH H -0-CH2-0- H H H H2
Figure imgf000050_0002
Cmpd. No. W, X3 Rγv5 Rw6 Rw8 R7 Rn
Figure imgf000051_0001
Figure imgf000052_0001
Cmpd. No. W, X3 V: Rw6 lv7 RwS Rw9 R7, RT,
Figure imgf000053_0001
Figure imgf000054_0001
Figure imgf000055_0001
Cmpd. No. W, X3 Rw5 w6 Rw7 RwS Rw9 R7, Rτι
Figure imgf000056_0001
208 N NH NH H -0-CH2-0- H H -CH2CH2N(CH3)CH2CH2-
209 N NH CH2 H OCH3 H H H -CH2CH2N(CH3)CH2CH2-
210 N O NH H -0-CH2CH2-0- H H -CH2CH2N(CH3)CH2CH2-
211 CH O NH H OCH3 H H H H H
212 CH NH NH OCH3 OCH3 H H H H H
213 CH NH NH H H N(CH,), H H H H
Table 4
Figure imgf000056_0002
Cmpd. No. X! , Rw5 Rw7 R ■7a R7i
214 N N H OCH, H -CH2CH2N(CH3)CH2CH2-
215 N N H CF, H -CH2CH2N(CH3)CH2CH2
216 N N H -0-CH,-0- -CH2CH2N(CH3)CH2CH2.
217 CH CH H CF, H H H Cmpd. No. X! W, R-W5 Rw6 w7 RT, R71
218 N CH H OCF, H H H
219 N CH Cl H H H H
220 N CH H OCH, H H H
221 N CH H H Br H H
222 N CH H Br H H H
223 C-CH, CH H C CFF3, H H H H
224 N CH H H H O OCCFF3, H H
225 N CH H HH CCFF33 H H
226 N CH 13 H CF^ H H
Pharmaceutical Compositions and Dosage Forms Useful in The Treatment Of Angiogenic
Dependent Diseases
Other aspects of the present invention are pharmaceutical compositions and dosage forms containing at least one compound of Formula (I) or a pharmaceutically acceptable salt, hydrate or pro-drug thereof, in combination with a pharmaceutically acceptable carrier.
As used herein, the terms "pharmaceutically acceptable salts" and "hydrates" refer to those salts and hydrated forms of the compound that would favorably affect the physical or pharmacokinetic properties of the compound, such as solubility, palatability, absorption, distribution, metabolism and excretion. Other factors, more practical in nature, which those skilled in the art may take into account in the selection include the cost of the raw materials, ease of crystallization, yield, stability, solubility, hygroscopicity and flowability of the resulting bulk drug. When a compound of the present invention is present as a salt or hydrate that is not pharmaceutically acceptable, that compound can be converted in certain circumstances to a salt or hydrate form that is pharmaceutically acceptable in accordance with the present invention. When the compound is negatively charged, it is balanced by a counterion, such as, an alkali metal cation such as sodium or potassium. Other suitable counterions include calcium, magnesium, zinc, ammonium, or alkylammonium cations, such as teframethylammonium, tetrabutylammonium, choline, triethymydroammonium, meglumine, triethanol-hydroammoniiim, and the like. An appropriate number of counterions are associated with the molecule to maintain overall charge neutrality.
Likewise, when the compound is positively charged, e.g., protonated, an appropriate number of negatively charged counterions are present to maintain overall charge neutrality. These pharmaceutically acceptable salts are within the scope of the present invention.
Pharmaceutically acceptable salts of bases may be prepared by the addition of an appropriate acid. Thus, the compounds of the present invention can be used in the form of salts derived from inorganic or organic acids. Examples include acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxy-ethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, pamoate, pectinate, persulfate, 3-phenylpropionate, pivalate, propionate, succinate, tartrate and undecanoate.
If the compound has an acidic proton, a salt may be formed by the addition of base to form a pharmaceutically acceptable base addition salt. Base salts include ammonium salts, alkali metal salts such as sodium and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases such as dicyclohexylamine salts, N-methyl-D-glucamine, and salts with amino acids such as arginine, lysine, and so forth.
The basic nitrogen-containing groups may be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl; and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides and others.
The compounds of the present invention may be employed in solid or liquid form including, for example, amorphous powder or crystalline form, in solution or in suspension. They may be administered in numerous different ways, such as orally, parenterally (intravenously or intramuscularly), topically, transdermally or by inhalation. The choice of carrier and the content of active compound in the carrier are generally determined in accordance with the solubility and chemical properties of the desired product, the particular mode of administration and well established pharmaceutical practice. The carrier may be either solid or liquid.
Examples of liquid carriers include syrup, peanut oil, olive oil, water and the like. For parenteral administration, emulsions, suspensions or solutions of the compounds according to the invention in vegetable oil, for example sesame oil, groundnut oil or olive oil, or aqueous-organic solutions such as water and propylene glycol, injectable organic esters such as ethyl oleate, as well as sterile aqueous solutions of the pharmaceutically acceptable salts, are used. Injectable forms must be fluid to the extent they can be easily syringed, and proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prolonged absorption of the injectable compositions can be brought about by use of agents delaying absorption, for example, aluminum monostearate and gelatin.
The active compound may be orally administered with an ingestible solid carrier. Compounds of the invention maybe enclosed in hard or soft shell gelatin capsules, or compressed into tablets, or incorporated directly with the food of the diet, or may be used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Examples of oral solid dosage forms include tablets, capsules, troches, lozenges and the like. Examples of oral liquid dosage forms include solutions, suspensions, syrups, emulsions, soft gelatin capsules and the like. Carriers for oral use (solid or liquid) may include time delay materials known in the art, such as glyceryl monostearate or glyceryl distearate alone or with a wax. To prepare a capsule, it may be advantageous to use lactose and a liquid carrier, such as high molecular weight polyethylene glycols.
Compositions and dosage forms prepared in accordance with the present invention optionally also may contain lactose, sodium citrate, calcium carbonate, dicalcium phosphate and disintegrating agents such as starch, alginic acids and certain complex silica gels combined with lubricants such as magnesium stearate, sodium lauryl sulfate and talc may be used for preparing tablets, troches, pills, capsules and the like.
Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets, pills, or capsules may be coated with shellac, sugar or both. When aqueous suspensions are used they may contain emulsifying agents or agents which facilitate suspension. Diluents such as sucrose, ethanol, polyols such as polyethylene glycol, propylene glycol and glycerol, and chloroform or mixtures thereof also may be used, hi addition, the active compound may be incorporated into sustained-release preparations and formulations. The solutions of the salts of the products according to the invention are especially useful for administration by intramuscular or subcutaneous injection. Solutions of the active compound as a free base or pharmacologically acceptable salt can be prepared in water suitably mixed with a surfactant such as hydroxypropyl-cellulose. Dispersions also can be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. The aqueous solutions, also including solutions of the salts in pure distilled water, may be used for intravenous administration with the proviso that their pH is suitably adjusted, that they are judiciously buffered and rendered isotonic with a sufficient quantity of glucose or sodium chloride and that they are sterilized by heating, irradiation, microfiltration, and/or by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like.
Examples of injectable dosage forms include sterile injectable liquids, e.g., solutions, emulsions and suspensions. Sterile injectable solutions are prepared by incorporating the active compound in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredient into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above, hi the case of sterile powders for the preparation of sterile injectable solutions, methods of preparation may include vacuum drying and a freeze-dry technique that yields a powder of the active ingredient plus any additional desired ingredient from previously sterile-filtered solution thereof.
Examples of injectable solids include powders that are reconstituted, dissolved or suspended in a liquid prior to injection, hi injectable compositions, the carrier typically includes sterile water, saline or another injectable liquid, e.g., peanut oil for intramuscular injections. Also, various buffering agents, preservatives and the like can be included within the compositions of the present invention.
Solid dosage forms include dosage forms for rectal administration, which include suppositories formulated in accordance with known methods and containing at least one compound of the present invention. Examples of solid carriers include lactose, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like. Topical administration, in the form of gels (water or alcohol based), creams or ointments, for example, containing compounds of the invention maybe used. Topical applications may be formulated in carriers such as hydrophobic or hydrophilic bases to form ointments, creams, lotions, in aqueous, oleaginous or alcoholic liquids to form paints or in dry diluents to form powders. Such topical formulations can be used for example, to treat ocular diseases as well as inflammatory diseases such as rheumatoid arthritis, psoriasis, contact dermatitis, delayed hypersensitivity reactions and the like.
Compounds of the invention also may be incorporated in a gel or matrix base for application in a patch, which would allow a controlled release of compound through fransdermal barrier. For administration by inhalation, compounds of the invention may be dissolved or suspended in a suitable carrier for use in a nebulizer or a suspension or solution aerosol, or may be absorbed or adsorbed onto a suitable solid carrier for use in a dry powder inhaler. Compositions according to the invention also may be formulated in a manner that resists rapid clearance from the vascular (arterial or venous) wall by convection and/or diffusion, thereby increasing the residence time of the compound at the desired site of action. A periadventitial depot comprising a compound according to the invention may be used for sustained release. One such useful depot for administering a compound according to the invention may be a copolymer matrix, such as ethylene- vinyl acetate, or a polyvinyl alcohol gel surrounded by a Silastic shell. Alternatively, a compound according to the invention may be delivered locally from a silicone polymer implanted in the adventitia.
An alternative approach for minimizing washout of a compound according to the invention during percutaneous, transvascular delivery comprises the use of nondiffusible, drug-eluting microparticles. The microparticles may be made from any of a variety of synthetic polymers, such as polylactide, or natural substances, including proteins or polysaccharides. Such microparticles enable strategic manipulation of variables including total dose of drug and kinetics of its release. Microparticles can be injected efficiently into the arterial or venous wall through a porous balloon catheter or a balloon over stent, and are retained in the vascular wall and the periadventitial tissue for at least about two weeks. Formulations and methodologies for local, intravascular site-specific delivery of therapeutic agents are discussed in Reissen et al. (J. Am. Coll. Cardiol. 1994; 23:
1234-1244). A channeled balloon catheter (such as "channelled balloon angioplasty catheter", Mansfield Medical, Boston Scientific Corp., Watertown, Mass.) may be used. This catheter includes a conventional balloon covered with a layer of 24 perforated channels that are perfused via an independent lumen through an additional infusion orifice. Various types of balloon catheters, such as double balloon, porous balloon, microporous balloon, channel balloon, balloon over stent and hydrogel catheters, all of which maybe used to practice the invention, are disclosed in Reissen et al. (1994).
Another embodiment of the invention provides a compound according to the invention to be administered by means of perfusion balloons. These perfusion balloons, which make it possible to maintain a blood flow and thus to decrease the risks of ischaemia of the myocardium, on inflation of the balloon, also enable the compound to be delivered locally at normal pressure for a relatively long time, more than twenty minutes, which may be necessary for its optimal action.
A composition according to the invention also may comprise a hydrogel which is prepared from any biocompatible or non-cytotoxic (homo or hetero) polymer, such as a hydrophilic polyacrylic acid polymer that can act as a drug absorbing sponge. Such polymers have been described, for example, in application WO 93/08845. Certain of them, such as, in particular, those obtained from ethylene and/or propylene oxide are commercially available. Another aspect of the present invention relates to a pharmaceutical composition including a compound according to the invention and poloxamer, such as Poloxamer 407, which is a non-toxic, biocompatible polyol, commercially available (e.g., from BASF, Parsippany, N.J.). A poloxamer impregnated with a compound according to the invention may be deposited for example, directly on the surface of the tissue to be treated, for example during a surgical intervention. Poloxamer possesses essentially the same advantages as hydrogel while having a lower viscosity. The use of a channel balloon catheter with a poloxamer impregnated with a compound according to the invention may be advantageous in that it may keep the balloon inflated for a longer period of time, while retaining the properties of facilitated sliding, and of site-specificity of the poloxamer. The composition also may be administered to a patient via a stent device. In this embodiment, the composition is a polymeric material in which the compound of the invention is incorporated, which composition is applied to at least one surface of the stent device.
Polymeric materials suitable for incorporating the compound of the invention include polymers having relatively low processing temperatures such as polycaprolactone, poly(ethylene-co-vinyl acetate) or poly(vinyl acetate or silicone gum rubber and polymers having similar relatively low processing temperatures. Other suitable polymers include non-degradable polymers capable of carrying and delivering therapeutic drugs such as latexes, urethanes, polysiloxanes, styrene-ethylene/butylene-styrene block copolymers (SEBS) and biodegradable, bioabsorbable polymers capable of carrying and delivering therapeutic drugs, such as poly-DL-lactic acid (DL-PLA), and poly-L-lactic acid (L-PLA), polyorthoesters, polyiminocarbonates, aliphatic polycarbonates, and polyphosphazenes.
The compounds of the present invention also may be formulated for use in conjunction with other therapeutically active compounds or in connection with the application of therapeutic techniques to address pharmacological conditions, which may be ameliorated through the application of a compound according to the present invention. The percentage of active ingredient in the compositions of the invention maybe varied. Several unit dosage forms may be administered at about the same time. A suitable dose employed may be determined by a physician or qualified medical professional, and depends upon various factors including the desired therapeutic effect, the nature of the illness being treated, the route of administration, the duration of the treatment, and the condition of the patient, such as age, weight, general state of health and other characteristics, which can influence the efficacy of the compound according to the invention. In adults, doses are generally from about 0.001 to about 50, preferably about 0.001 to about 5, mg/kg body weight per day by inhalation; from about 0.01 to about 100, preferably 0.1 to 70, more preferably 0.5 to 10, mg/kg body weight per day by oral administration; from about 0.1 to about 150 mg applied externally; and from about 0.001 to about 10, preferably 0.01 to 10, mg/kg body weight per day by intravenous or
Method of the Invention.
The compounds of the present invention inhibit or regulate phosphorylation events. Tyrosine kinase inhibition may be determined by measuring the autophosphorylation level of recombinant kinase receptor, and/or phosphorylation of natural or synthetic substrates. Phosphorylation can be detected, for example, using an antibody specific for phosphotyrosine in an ELISA assay or on a western blot. Some assays for tyrosine kinase activity are described in Panek et al., J. Pharmacol. Exp. Thera., 283: 1433-44 (1997) and Batley et al., Life Sci., 62: 143-50 (1998). Detailed descriptions of conventional assays, such as those employed in phosphorylation assays, can be obtained from numerous publications, including Sambrook, J. et al, Molecular Cloning: A Laboratory Manual, 2nd ed. (Cold Spring Harbor Laboratory Press 198(. All references mentioned herein are incorporated in their entirety. hi addition, methods of detecting expression of proteins whose expression is regulated by tyrosine kinase activity can be used. These methods include immunohistochemisfry (IHC) for detection of protein expression, fluorescence in situ hybridization (FISH) for detection of gene amplification, competitive radioligand binding assays, solid matrix blotting techniques, such as Northern and Southern blots, reverse franscriptase polymerase chain reaction (RT-PCR) and ELISA. See, e.g., Grandis et al., Cancer, 78:1284-1292. (1996); Shimizu et al., Japan J. Cancer Res., 85:567-571 (1994); Sauter et al., Am. J. Path., 148:1047-1053 (1996); Collins, Glia, 15:289-296 (1995); Radinsky et al., Clin. Cancer Res., 1:19-31 (1995); Petrides et al., Cancer Res.,
50:3934-3939 (1990); Hoffmann et al, Anticancer Res., 17:4419-4426 (1997); Wikstrand et al., Cancer Res., 55:3140-3148 (1995).
In vivo assays also can be utilized. For example, VEGF receptor tyrosine kinase inhibition can be observed by mitogenic assays using HUVEC cells (ATCC) stimulated with VEGF in the presence and absence of inhibitor. Another method involves testing for inhibition of growth of VEGF-expressing tumor cells, using for example, human tumor cells injected into a mouse. (See, U.S. Patent No. 6,365,157 to Rockwell et al.)
Also included within the scope of the present invention are methods of inhibiting VEGF receptor tyrosine kinases, especially KDR, and/or freating or preventing VEGF receptor kinase-dependent diseases and conditions in mammals using the VEGF receptor kinase inhibitors of Formula I. The VEGF receptor is usually bound to a cell, such as an endothelial or tumor cell. Alternatively, the VEGF receptor may be free from the cell. According to the treatment method of the present invention, an effective anti- angiogenic amount of one or more compounds of Formula (I), or pro-drug thereof, is administered to a mammal in need of such freatment. The diseases which may be freated or prevented by the present methods include, for example, those in which pathogenic angiogenesis or tumor growth is stimulated through a VEGF/VEGFR paracrine and/or autocrine loop. For example, paracrine VEGFR stimulation of vascular endothelium is associated with angiogenic diseases and vascularization of tumors. VEGF receptors are also found on tumor cells, indicating the presence of an autocrine and/or paracrine loop in these cells. Thus, the method is also useful for neutralizing VEGF receptors on such cells, thereby inhibiting autocrine and/or paracrine stimulation and inhibiting tumor growth.
The compounds and compositions according to the invention may be administered as frequently as necessary as determined by a skilled practitioner in order to obtain the desired therapeutic effect. Some patients may respond rapidly to a higher or lower dose and may find much weaker maintenance doses adequate. For other patients, it may be necessary to have long-term treatments at the rate of 1 to 4 doses per day, in accordance with the physiological requirements of each particular patient. Generally, the active product may be administered orally 1 to 4 times per day. For other patients, it may be necessary to prescribe not more than one or two doses per day.
Thus, the method is effective for treating subjects with tumors and neoplasms, particularly where disease development involves angiogenesis. Tumors and neoplasms include, for example, malignant tumors and neoplasms, such as blastomas, carcinomas or sarcomas, and highly vascular tumors and neoplasms. Cancers that may be treated by the methods of the present invention include, for example, cancers of the brain, genitourinary tract, lymphatic system, stomach, renal, colon, larynx, lung and bone. Non-limiting examples further include epidermoid tumors, squamous tumors, such as head and neck tumors, colorectal tumors, prostate tumors, breast tumors, lung tumors, including lung adenocarcinoma and small cell and non-small cell lung tumors, pancreatic tumors, thyroid tumors, ovarian tumors, and liver tumors. The method is also useful for freatment of vascularized skin cancers, including squamous cell carcinoma, basal cell carcinoma, and skin cancers that can be freated by suppressing the growth of malignant keratinocytes, such as human malignant keratinocytes. Other cancers that can be treated include Kaposi's sarcoma, CNS neoplasms (neuroblastomas, capillary hemangioblastomas, meningiomas and cerebral metastases), melanoma, gastrointestinal and renal carcinomas and sarcomas, rhabdomyosarcoma, glioblastoma, including glioblastoma multiforme, histiocytic lymphoma, and leiomyosarcoma.
The freatment method of this invention includes freatment or prevention of non- neoplastic angiogenic dependent diseases like inflammatory diseases and other diseases characterized by paracrine stimulation through VEGF receptors. Examples of non-neoplastic angiogenic diseases include diseases characterized by retinal vascularization, such as neovascular glaucoma, proliferative retinopathy, including diabetic retinopathy, retinopathy of prematurity (retrolental fibroplastic), macular degeneration, and corneal graft rejection. Examples of inflammatory diseases that may be freated include, but are not limited to, atherosclerosis, rheumatoid arthritis (RA), insulin-dependent diabetes mellitus, multiple sclerosis, myasthenia gravis, Chron's disease, autoimmune nephritis, primary biliary cirrhosis, psoriasis, acute pancreatitis, allograph rejection, allergic inflammation, contact dermatitis and delayed hypersensitivity reactions, inflammatory-bowel disease, septic shock, osteoporosis, osteoarthritis, and cognition defects induced by neuronal inflammation. The compounds of this invention are not the first 1,2,4-triazoles found to have anti-inflammatory properties. In U.S. Patent No. 4,020,064, it is reported that 1,2,4-triazole compounds having certain acetamidyl substituents on N-4 are useful as anti-inflammatory agents. Other non-limiting examples of angiogenic diseases are hemangiomas, angiofibromas, Osier- Weber syndrome, restinosis, and fungal, parasitic and viral infections, including cytomegaloviral infections.
The freatment method of the present invention also includes treatment of tumors that express VEGF receptors (e.g. KDR), for example through inhibition of an autocrine VEGF/VEGFR loop, wherein one or more of the Formula I compounds are administered in an amount effective to reduce tumor growth or size. The method can be used to treat a solid or liquid tumor that is not vascularized, or is not yet substantially vascularized.
Examples of solid tumors which may be accordingly treated include breast carcinoma, lung carcinoma, colorectal carcinoma, pancreatic carcinoma, glioma and lymphoma. Examples of liquid tumors include leukemia, multiple myeloma and lymphoma. Some examples of leukemias include acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), erythrocytic leukemia or monocytic leukemia. Some examples of lymphomas include Hodgkin's and non-Hodgkin's lymphoma.
Moreover, included within the scope of the present invention is use of the present inventive compounds in vivo and in vitro for investigative, diagnostic, or prophylactic methods, which are well known in the art.
In the methods of the present invention, an effective anti-angiogenic amount of one or more of the Formula (I) compounds, including salts and solvates, is administered to a mammal in need. The term "administering" as used herein means delivering the compounds of the present invention to a mammal by any method that may achieve the result sought. They may be administered, for example, orally, parenterally (intravenously or intramuscularly), topically, transdermally or by inhalation. The term "mammal" as used herein is intended to include, but is not limited to, humans, laboratory animals, domestic pets and farm animals. "Effective anti-angiogenic amount" means an amount of compound of the present invention that when administered to a mammal influences the progression of an angiogenic dependent disease. The influence is mediated through a slowing or arrest of pathogenic neovascularization around diseased cells. Accordingly, the influence may be a prevention or arrest of neovascularization that leads to the death of diseased cells and eradication of the disease from the body. However, the influence will be therapeutically beneficial even when not so far-reaching. Thus, as the term is used in this disclosure, "influencing the progression of the angiogenic disease" includes causing the progression of the disease to be slowed by partial or complete restriction of the blood supply to diseased cells, resulting in an increase in life expectancy of the mammal afflicted with the disease.
Having thus described the present invention with reference to certain preferred embodiments, the invention will now be further illustrated by the following non-limiting examples.
EXAMPLES
Example 1 Preparation of Ethyl Benzimidate Hydrochloride (A)
Figure imgf000068_0001
Dry HCl (g) was bubbled through a solution of benzonitrile in absolute ethanol for 4 h. A white precipitate formed and was collected by filtration, washed with absolute ethanol and dried under high vacuum to give the title compound in nearly quantitative yield. Example 2 Preparation of Benzamidine Hydrochloride (B)
Figure imgf000069_0001
A slight molar excess of dry ammonia gas was bubbled through a solution of ethyl benzimidate hydrochloride in absolute ethanol. The mixture was stirred at room temperature for 3 h. Ammonium chloride produced from the excess ammonia was removed by filtration and the filtrate was collected and concentrated. The residue was recrystallized from ethanol, filtered and dried under high vacuum to give the title compound in nearly quantitative yield.
Example 3 Preparation of Ethyl 2- (4-Pyridinyl)methylamino]benzoate (C)
Figure imgf000069_0002
A mixture of methyl anthranilate (7.5 g) and 4-pyridinylcarboxaldehyde (8.6 g) in MeOH (300 mL) and acetic acid (3 mL) was stirred at room temperature for 12 h. Sodium cyanoborohydride (NaBH3CN) (6.9 g) was added to the reaction mixture and the resulting solution was stirred at r.t. for 12 h. The reaction mixture was then concentrated and the residue was dissolved in ethyl acetate and washed with saturated NaHCO3 and brine. The organic layer was dried with MgSO4, filtered, concentrated and purified by flash chromatography over SiO2 (1:1 ethyl acetate/hexane) to give the title compound (10.2 g, 50%). Example 4 Preparation of 2-[(4-Pyridinyl)methylamino']benzoic Acid Hydrazide (D
Figure imgf000070_0001
A mixture of Ethyl 2-[(4-pyridinyl)methylamino]benzoate (10 g) in hydrazine (50 ml) was refluxed. After 2 h the excess hydrazine was removed and the remaining mixture was dissolved in dichloromethane, washed with brine and dried with MgSO4 and concentrated. The crude residue was purified by flash chromatography to give the title compound as a white solid (9.2 g, 97%).
Example 5 Preparation of 2-[2-f4-Pyridinyl methylaminolphenyl-4-phenyl-1.2.4-triazole (i)
Figure imgf000070_0002
A solution of sodium methylate (0.32 g, 6 mmol) in anhydrous ethanol (6 ml) was added to a solution of the benzamidine hydrochloride B prepared in Example 2 (0.7 g, 4.5 mmol) in anhydrous ethanol (7 ml) at room temperature. The milky slurry was stirred at room temperature for 45 min. and filtered. 2-[(4-Pyridinyl)methylamino]benzoic acid hydrazide D prepared in Example 4 (0.73 g, 3 mmol) was then added to the ethanol filtrate and the resulting yellow solution was refluxed for 2 hours. The ethanol was evaporated off and the residue was re-dissolved in chlorobenzene, the resulting solution was refluxed overnight. The mixture was cooled to room temperature and evaporated under vacuum. The solid residue was washed with water and recrystallized from ethanol to give the title compound (0.9 g, 91%) as a white solid. Its structure was confirmed by NMR and elemental analysis. Η NMR (300 MHz, OMSO-d6) δ (ppm) 14.8 (br. s, IH), 8.7 (m, 3H), 8.2 (m, 3H), 7.5 (m, 5H), 7.3 (t, IH), 6.7 (m, 2H), 4.6 (d, 2H); 13C NMR (75 MHz, DMSO- d6) δ (ppm) 150.1, 149.4, 146.4, 131.2, 130.0, 129.2, 128.0, 126.4, 122.6, 115.0, 111.8,
45.7; MS 328.2 (M+H+); Formula C20H17N5 + 0.25H2O, Calculated C 72.39, Found C 72.82, Calculated H 5.32, FoundH 5.22, Calculated N 21.09, Found N 21.07.
Other 1,2,4-triazoles of this invention can be made by procedures analogous to those of Examples 1-5.
Example 6 Preparation of Compound ( 14)
Figure imgf000071_0001
To a solution of 2-(3,5-dimethoxyphenylamino)nicotinic acid hydrazide(1.0g, 3.48 mmol) in dichloromethane (20 mL) was added 4-trifluoromethoxy phenyl isothiocyanate (0.64 mL, 3.83 mmol). The reaction mixture was refluxed for 2 hours under argon. The reaction mixture was allowed to cool and a solid precipitated from the solution, filtered, the solid was washed with ether to provide a yellow solid 1.489 g. Yield: 93%. !H NMR (DMSO-^) δ 10.95 (s, IH), 10.71 (s, IH), 9.93-9.96 (m, 2H), 8.45-8.48 (m, IH), 8.25- 8.28 (m, IH), 7.60-7.66 (m, 2H), 7.35-7.42 (m, 2H), 6.90-7.05 (m, 3H), 6.20 (s, IH), 3.80 (s, 6H). MS m/z: 508. To this yellow solid (1.45 g, 2.86 mmol) in toluene (20 mL) was added 1,3- dicyclohexylcarbodiimide (0.885 g, 4.3 mmol). Then, the reaction mixture was refluxed for 5 hours. The reaction mixture was diluted with ethyl acetate (50 mL), washed with aqueous sodium bicarbonate (30 mL) and brine (2x30 mL). The organic layer was separated and dried over anhydrous sodium sulfate. The dried solution was filtered and evaporated to give a solid. This solid was washed with warm methanol to get a white solid (1.1 g, 81.5% yield). Η NMR DMSO-d6) δ 11.10 (s, IH), 10.06 (s, IH), 8.42-8.44 (m, IH), 8.06-8.09 (m, 1 H), 7.76-7.80 (m, 2H), 7.43-7.46 (d, 2H), 7.04-7.08 (m, 3H), 6.25- 6.26 (t, IH), 3.81 (t, 6H). Ms m/z: 474.
Other 1,3,4-oxadiazoles of this invention can be made by procedures analogous to those of Example 6
Example 7 Preparation of 2-f3.5-dimethoxyphenylamino nicotinic acid hydrazide (E)
Figure imgf000072_0001
2-Chloropyridine-3 -carboxylic acid (25 g) was refluxed in 200 mL of benzene and 150 mL of SOC12. The solution was concentrated and chased with toluene. The residue obtained was refluxed in 100 mL of ethanol for 20 minutes. The solvents were removed under vacuum to give the pure product, 2-chloro-nicotinic acid ethyl ester. Light yellow oil; yield 72%; Η NMR (CDC13) δ 1.42 (t, J = 6.6 Hz, 3H), 4.43(q, J = 6.8Hz, 2H), 7.37 (br s, IH), 8.18 (d, J = 6.6Hz, IH), 8.54 (s, IH); 13C NMR δ 13.8, 61.8, 122.0, 126.9, 140.0, 149.5, 151.4, 164.2 _ 2-Chloro-nicotinic acid ethyl ester (2 mmol, 0.343g) and 3,5-dimethoxyaniline
(2mmol, 0.306g) were dissolved in ethylene glycol (lOmL) and heated to 160 °C with stirring. The reaction mixture was maintained at this temperature for 6h. HCl gas evolved during the course of the reaction. On cooling, the reaction mixture was poured into water (10 mL) and extracted with ether (4 x 100 mL). The ethereal layer was dried over MgSO4, evaporated and the residue was distilled at 162-165 °C/0.5 mm Hg. The product,2-(3,5- dimethoxyphenylamino)nicotinic acid ethyl ester, was used in the next step without further purification. Yellow oil, yield 63%; Η NMR (CDC13) δ 1.24 (t, J= 7.1 Hz, 3H), 3.78 (s, 6H), 4.11 (t, J= 7.1 Hz, 2H), 6.17 (s, IH), 6.68 (t, J= 6.0 Hz, IH), 6.97 (s, 2H), 8.20 (d, J = 7.7 Hz, IH), 8.36 (s, IH), 10.24 (s, IH); ,3C NMR δ 20.7, 55.0, 60.1, 94.8, 98.7, 103.2, 107.1, 113.1, 139.9, 141.2, 152.7, 155.8, 160.7, 167.2, 170.9. 2-(3,5-Dimethoxyphenylamino)nicotinic acid ethyl ester (1.94 mmol, 560mg) and
85% hydrazine hydrate (1.18 mL) and 2-propanol (2 mL) were refluxed for 3 h. On cooling, the red solution deposited a yellow solid that was filtered off and washed with a little 2-propanol. Compound E appeared as a yellow solid, 84% yield: *H NMR (DMSO- d6) δ 1.22 (br s, 2H), 4.00 (s, 6H), 6.18 (t, J= 2.2 Hz, IH), 6.66-6.70 (m, IH), 6.94 (s, 2H), 7.64 (dd, J= 1.8 Hz, 7.7 Hz, IH), 7.70 (br s, IH), 8.33 (dd, J= 1.5 Hz, 4.8 Hz), 10.1
(br s, IH); 13C NMR δ 55.3, 94.8, 98.7, 100.2, 103.4, 100.4, 109.5, 113.1, 135.1, 141.5, 151.8, 160.9, 169.1.
Example 8 S.S-Dimethoxyphenvπ-^-Methylisothiourea Hvdroiodide (F)
Figure imgf000073_0001
4-Fluorobenzoyl chloride (1.03 g, 6.5 mmol) was added dropwise to a vigorously stirred hot solution of anhydrous ammonium thiocyanate (0.61 g, 7.8 mmol) in dry acetone (20 mL). The reaction mixture was refluxed for 5 min. Then, a solution of 3,5- dimethoxyaniline (1.0 g, 6.5 mmol) in dry acetone (10 mL) was added dropwise. The reaction mixture was heated for 1 h. The solvent was evaporated and water (50 mL) was added to the residue. The precipitate was collected and recrystallized from ethyl alcohol to give the product, N-(3,5-dimethoxyphenyl)-N'-(4-fluorobenzoyl)thiourea. White needles (ethanol), Yield 69%; Η NMR (DMSO) δ 3.76 (s, 6H), 6.43 (br s, IH), 6.99 (br s, 2H), 7.35-7.41 (m, 2H), 8.04-8.09 (m, 2H), 11.62 (s, IH) ; 13C NMR (DMSO) δ . Anal. Calcd for C16H15FN2O3S: C, 57.47; H, 4.52; N, 8.38. Found: C, 57.49; H, 4.43; N, 8.26.
N-(3,5-Dimethoxyphenyl)-N'-(4-fluorobenzoyl)thiourea (1.5 g, 4.4 mmol) was heated to reflux with 5% aqueous NaOH (10 mL) for 15 min. The cooled reaction mixture was freated with concenfrated HCl until acidic to precipitate both 4-fluorobenzoic acid and N-(3,5-dimethoxyphenyl)thiourea. The mixture was then made basic (pH 9) with concentrated NH4OH to dissolve the 4-fluorobenzoic acid. The product was filtered and recrystallized from 95% ethyl alcohol to give the pure product, N-(3,5- dimethoxyphenyl)thiourea . White prisms, yield 75%; Η NMR (DMSO) δ 3.72 (s, 6H), 6.27 (br s, IH), 6.62 (br s, 2H), 7.53 (br s, 2H), 9.66 (s, IH); 13C NMR (DMSO) δ 55.2, 96.4, 100.8, 140.6, 160.4, 180.7. Anal. Calcd for C9H12N2O2S: C, 50.92; H, 5.70; N,
13.20. Found: C, 50.88; H, 5.66; N, 12.96.
A solution of N-(3,5-dimethoxyphenyl)thiourea (0.53 g, 2.5 mmol) in freshly distilled dry methanol (10 mL) was treated with CH3I (0.36 g, 2.5 mmol). The solution was refluxed for 2h, cooled, and evaporated to dryness under vacuum. The crystalline product was washed with several portion of ethyl ether and dried to give pure Compound F which appeared as white microcrystals; yield 92%; JH NMR (DMSO) δ 2.70 (s, 3H), 3.78 (s, 6H), 6.53-6.56 (m, 3H), 9.30 (br s, 2H); 13C NMR (DMSO) δ 55.6, 100.1, 103.7, 136.5, 161.1, 169.1.
Example 9
Preparation of 3.5-Dimethoxyphenyl -(3-["5- 3.5-dimethoxy-phenylamino -2H-
|"1.2.41triazol-3-yl]-ρyridin-2-yll amine (154)
Figure imgf000075_0001
A solution of 2-(3,5-dimethoxyphenylamino)nicotinic acid hydrazide (E) (lmmol) and- (3,5-dimethoxyphenyl)-S-methylisothiourea hydroiodide (F) (lmmol) in 1 mL of pyridine were refluxed for 6 h. The cooled mixture was poured into crushed ice and extracted with ether. The solvent was removed and the crude product was recrystallized from ethyl acetate (and two drops of ethanol) to give the pure product. Brown solid; yield 25%; Η NMR (OMSO-d6, 100 °C) δ 3.75 (s, 3H), 3.76 (s, 3H), 6.11 (br s, IH), 6.18 (t, J= 2.2 Hz, IH), 6.81 (d, J= 2.2 Hz, 2H), 6.89-6.93 (m, IH), 7.07 (d, J= 1.8 Hz, 2H), 8.28-8.29 (m, 2H), 9.22 (br s, IH), 10.7 (br s, IH).
Other 1,2,4-triazoles of the present invention can be prepared by procedures analogous to those of Examples 7-9.
Example 10 Preparation of 3-(Trifluoromethyl)phenacyl Bromide (G)
Figure imgf000076_0001
A solution of 3-(trifluoromethyl)acetophenone (25 g, 0.133 mol) in diethyl ether (20 ml) was cooled to 0°C. Aluminium chloride (0.15 g) was added in one portion, with stirring, followed by dropwise addition of bromine (6.85 ml, 0.133 mol), and the reaction mixture was allowed to reach room temperature overnight. Solvent was removed under vacuum and the crude product purified by distillation (94-97°C, 1mm Hg). The title compound was obtained as a colorless liquid (20.2g, 57%).
Example 11
Preparation of 2-Nitrobenzamidine hydrochloride (H)
Figure imgf000076_0002
A solution of 2-nitrobenzonitrile (12.3 g, 0.083 mol) in THF (60 ml) was added dropwise with stirring to a cooled (0°C) solution of LiHMDS (IM in THF; 99.6 ml, 0.0996 mol) in ether (60 ml) and the reaction mixture allowed to warm to room temperature overnight. The reaction was quenched at 0°C with ethereal HCl (-150 ml). A brown semi- solid formed and the solvent was decanted off. The crude product was triturated with ether
(~200 ml) and collected by filtration. After washing with ether (~1L) the title compound was obtained as a tan solid (~20 g, >100%, i.e. inorganic salts present). Example 12 Preparation of 2-[5-(3-trifluoromethylphenyl -lH-imidazol-2-yl]nitrobenzene (I)
Figure imgf000077_0001
A mixture of compound H (13.78 g, 68.4 mmol), DMF (300 ml), compound G (18.27 g, 68.4 mmol), sodium iodide (~1 g) and triethylamine (19 ml, 136.8 mmol) was heated at 120°C for 48 hrs. Solvent was removed under vacuum and the residue dissolved in ethyl acetate (150 ml) and washed with water (3 x 200 ml) and then brine (200 ml), dried (MgSO4) and the solvent removed under vacuum. The crude product obtained was purified by 'dry flash' chromatography [Methanol/dichloromethane (1:99) - (3:97)]. Solvent was removed under vacuum and the residue dissolved in ethanol (~100 ml) and heated with activated charcoal for a few minutes then filtered through Celite. Solvent was removed under vacuum and the residue was purified by 'flash' chromatography [Methanol/ dichloromethane (1 :99) - (3 :97)] . The title compound was obtained as an orange/yellow glassy solid (7 g, 25% over 2 steps).
Example 13 Preparation of 2-|"5-(3-trifluoromethylphenyl -lH-imidazol-2-yl]aniline (217)
Figure imgf000078_0001
A mixture of compound H (6.25 g, 0.0188 mol), ethanol (350 ml) and palladium on carbon (5% wt) (1.25 g) was stirred under an atmosphere of hydrogen at room temperature overnight. The catalyst was filtered off through Celite and washed with ethanol (200 ml). Solvent was removed under vacuum to give an orange solid. This was washed with dichloromethane/petrol [200 ml, (1:1)] and the solid that remained was collected by filtration. The title compound (1.1 g, 20%) was obtained as an off-white solid after recrystallisation from dichloromethane/pefrol/methanol. MS m/z: 304 (M+H+)
Other imidazoles of the present invention can be prepared by procedures analogous to those of Examples 10-13.
Example 14
Preparation of 2-Aminobenzamidoxime (J)
Figure imgf000078_0002
2-Aminobenzonitrile hydrochloride (50 g, 0.324 mol) was suspended in anhydrous methanol in a 2 L three necked flask. One mole equivalent of sodium methoxide (17.5 g, 0.324 mol) was added portionwise to the mixture (during the addition the temperature rose to 35°C). The reaction mixture was then stirred for 30 minutes at room temperature and a second equivalent of sodium methoxide (17.5 g, 0.324 mol) was added portionwise. After stirring for 30 minutes at room temperature, hydroxylamine hydrochloride (22.5 g, 0.324 mol) was added and the mixture heated under reflux for 20 hours. The mixture was concenfrated and the residue partitioned between EtOAc (500 ml) and 2N sodium hydroxide (500 ml). The basic phase was separated and extracted with EtOAc (4 x 500 ml). The combined organic extract was washed with brine (4 x 500 ml) and dried over magnesium sulphate. After filtration and evaporation, a brown oil was obtained. Dry flash chromatography on silica gel [dichloromethane/ethanol (95:5)] followed by precipitation from dichloromethane/petroleum ether afforded the 2-aminobenzamidoxime (J) as a pale brown solid (31 g, 63%).
Example 15
Preparation of 2-Aminobenzamidine Dihydrochloride (K)
Figure imgf000079_0001
Following generally the method described in J. Med. Chem. 2003, 46, 913-916, a suspension of 2-aminobenzamidoxime (J) (31 g, 0.205 mol) and wet Raney nickel (50% slurry in water) (ca. 15 g) in EtOH (350 ml) was stirred under 3 atmospheres of hydrogen at 60°C for 16 hours. The catalyst was removed by filtration through a pad of celite and the cake was washed with EtOH (300 ml). The solvent was evaporated to give a brown oil, 2- aminobenzamidine (250 MHz !H NMR in CDC13 consistent with structure). This material was dissolved in ethanol (200 ml) and 2N HCl in ether (230 ml, 0.46 mol) was added dropwise (during the addition the temperature rose to 35°C). The resulting precipitate was collected by filfration and dried under vacuum to give 2-aminobenzamidine dihydrochloride (K) as an off-white powder (37 g, 87%). Example 16 General Procedure for Preparing 2-(5-Aryl-7H-[1.2.41-triazol-3-yl anilines ("218-222. 224-
226)
Figure imgf000080_0001
In a dry 100 ml three necked flask, 2-aminobenzamidine dihydrochloride (K) (12.0-16.9 mmol) was suspended in dry EtOH (18-20 ml) under nitrogen. A freshly prepared solution of sodium methoxide (2.3 eq.) in EtOH (30-35 ml) was added to the reaction mixture. The brown slurry was stirred at room temperature for 1 hour and filtered. To the ethanol filtrate was added the appropriate arylcarboxyhc acid hydrazide (1 eq.) and the reaction mixture heated under reflux for 3-6 hours. The solvent was evaporated under vacuum and the brown residue was dissolved in chlorobenzene (35-45 ml). The flask was equipped with a Dean-stark trap and the reaction mixture was heated under reflux overnight. After cooling to room temperature, the solvent was evaporated under vacuum. The brown residue was purified by dry flash chromatography on silica gel
[dichloromethane/methanol (99:1) - (95:5)], followed by trituration from dichloromethane/pefroleum ether and recrystalhsation from the appropriate solvent to give the corresponding triazole.
Although most of the arylcarboxyhc acid hydrazides used to prepare compounds 218-222 and 224-226 are commercially available, the 3-trifluoromethoxy-benzene-l- carbohydrazide was prepared in our laboratory. It was prepared as follows. 3- (Trifluoromethoxy)-methylbenzoate (5.0g, 22.7 mmol) was dissolved in dry MeOH (20mL) under nifrogen. Hydrazine monohydrate (2.27g, 45.4 mmol, 2 eq.) was added dropwise and the mixture was heated under reflux for 3 hours. The reaction mixture was then concenfrated under vacuum to give a solid. Water was removed by azeofroping with
EtOH (x2), to leave an off-white solid (5.4 g, quantitative). Example 17 Preparation of 2-(2-Nifroberιzyl)-4- 3-trifluoromethylbenzyD-5-methylimidazole (L
Figure imgf000081_0001
l-(3-Trifluoromethyl(benzyl))-l,2-propandione (4.80 g, 22.2 mmol) was dissolved in acetic acid (250mL) under nitrogen. 2-Nitrobenzaldehyde (3.69 g, 24.4 mmol, 1.1 eq.) and ammonium acetate (34.21 g, 444 mmol, 20 eq.) were added and the resulting mixture was heated at 100°C overnight. TLC analysis (EtOAc/t-Hexane, 3:7) showed no starting material remained so the resulting solution was concentrated to approx. 50mL and the remaining acetic acid was neutralized with NaHCO3 (solid and saturated solution). Ethyl acetate (300mL) was added and the phases separated. The aqueous layer was back- extracted with EtOAc (2x 250mL). The combined organic layers were washed with brine (250mL), dried (MgSO4) and concentrated under vacuum to give a dark oil. Flash column chromatography [Acetone/z-Hexane (2:8)] provided the nifro-imidazole L as a dark orange oil (4.8g, 62%).
Example 18 Preparation of 2-(4-methyl-5 -(3 -trifluoromethylphenyl - 1 H-imidazol-2-yl aniline (223)
Figure imgf000081_0002
2-(2-Nitrobenzyl)-4(3-trifluoromethylbenzyl)-5-methylimidazole (M) (2.5 g, 7.2 mmol) was dissolved in EtOH (60mL) and water (lOniL). Iron powder (3.63 g, 9 eq.) and ammonium chloride (0.77 g, 14.4 mmol, 2 eq.) were added and the resulting suspension was heated under reflux for 3 hours. More ammonium chloride (0.77 g, 2 eq.) was added and the heating was continued overnight. The reaction mixture was then concentrated and the residue partitioned between dichloromethane (75mL) and saturated NaHCO3 (aq.) (50mL). The aqueous layer was back-extracted with dichloromethane (2x 50mL). The combined organic layers were washed with water (75mL), dried (MgSO4), filtered and concenfrated under vacuum to give an orange solid. This material was recrystallised twice [dichloromethane/z'-Hexane (1:1)] to give compound 223 as a pale orange crystalline solid (1.25g, 55%). MS m z: 318 (M+H+)
Analytical Data for Selected Compounds
2- 2-("4-Pyridinyl methylaminolphenyl-4-r3-bromophenylV1.2.4-triazole ('2): 'H NMR (300 MHz, DMSO-cQ δ (ppm) 14.8 (br. s, IH), 8.7 (m, 3H), 8 (m, 9H), 6.7 (q, 2H), 4.7 (d, 2H); 13C NMR (75 MHz, DMSO- 6) δ (ppm) 150.1, 149.3, 146.4, 131.8, 131.4, 128.6, 127.6, 125.3, 122.5, 116.0, 112.0, 45.8; MS 406.1 (M+); Formula C20H16BrN5, Calculated C 59.13, H 3.97, N 17.23; Found C 58.95, H 3.94, N 17.11.
2-[2-(4-Pyridinyl methylamino]phenyl-4-r4-trifluoromethylphenyl)-1.2,4-triazole r3 : *H NMR (300 MHz, OMSO-d6) δ (ppm) 14.8 (br. s, IH), 8.8 (br. s, 2H), 8.6 (d, 2H), 8.3 (d, 2H), 7.9 (m, 3H), 7.4 (d, 2H), 7.2 (t, IH), 6.7 (m, 2H), 4.6 (d, 2H); 13C NMR (75 MHz, DMSO-rf6) δ (ppm) 150.1, 149.4, 146.5, 131.9, 127.8, 127.0, 126.2, 122.7, 122.5, 116.0,
112.0, 45.7; MS 396.2 (M+H+); Formula C21H16F3N5, Calculated C 63.79, H 4.08, N 17.7; Found C 63.85, H 4.18, N 17.57.
2-[2-r4-Pyridinyl methylamino]phenyl-4-r3-chlorophenyl -1.2.4-triazole (4 : Η NMR (300 MHz, DMSO- 6) δ (ppm) 14.8 (br. s, IH), 8.8 (m, 3H), 8.0 (m, 3H), 7.4 (m, 6H), 6.8
(q, 2H), 4.5 (d, 2H); 13C NMR (75 MHz, DMSO- 6) δ (ppm) 150.1, 149.3, 146.4, 134.0,
132.9, 131.2, 129.5, 127.8, 125.9, 124.9, 122.5, 116.0, 111.9, 45.8; MS 362.2 (M+H1");
Formula C20H16C1N5, Calculated C 66.39, H 4.46, N 19.35; Found C 66.32, H 4.48, N
19.31. 2-[2-('4-Pyridinvnmethylaminolphenyl-4-r4-biphenyl)- 1.2.4-triazole (5) : !H NMR (300 MHz, OMSO-d6) δ (ppm) 14.8 (br. s, IH), 8.8 (br. s, IH), 8.6 (m, IH), 8.3 (m, 3H), 7.9 (m, 6H), 7.3 (m, 6H), 6.7 (m, 2H), 4.6 (d, 2H); 13C NMR (75 MHz, OMSO-d6) δ (ppm) 160.2, 155.5, 150.1, 149.4, 146.4, 141.1, 139.9, 133.5, 131.8, 130.6, 129.4, 128.7, 128.4, 127.4, 122.5, 116.0, 112.1, 109.2, 45.7; MS 404.2 (M+H+); Formula C26H21N5 + 0.25H2O:
Calculated C 76.55, H 5.31, N 17.15; Found C 76.67, H 5.20, N 16.25.
2-[2-(4-Pyridinyl methylamino]phenyl-4-(3-benzoxyphenyl)-1.2.4-triazole (6): 'H NMR (300 MHz, DMSO- 6) δ (ppm) 14.6 (br. s, IH), 8 (m, 17H), 6.7 (m, 2H), 5.3 (s, 2H), 4.6 (d, 2H); 13C NMR (75 MHz, DMSO- 6) δ (ppm) 159.0, 150.1, 149.4, 146.4, 137.3, 130.3,
128.8, 128.2, 128.1, 127.6, 122.5, 118.9, 116.0, 112.5, 112.1, 69.7, 45.7; MS 434.2 (M+H+); Formula C27H23N5O: Calculated C 74.81, H 5.35, N 16.15; Found C 74.79, H 5.20, N 15.88.
2-[2-(4-Pyridinyl methylamino]phenyl-4-(4-benzoxyphenyl - 1.2.4-triazole (7) : 'HNMR
(300 MHz, DMSO- 6) δ (ppm) 14.6 (br. s, IH), 8 (m, 17H), 6.6 (m, 2H), 5.3 (s, 2H), 4.6 (d, 2H); 13C NMR (75 MHz, DMSO-tf6) δ (ppm) 159.9, 149.6, 149.0, 145.9, 136.7, 128.4, 127.8, 127.7, 115.5, 115.2, 115.0, 111.5, 111.0, 69.3, 45.3; MS 434.2 (M+H+); Formula C27H23N5O: Calculated C 74.81, H 5.35, N 16.15; Found C 74.78, H 5.34, N 16.12.
2-[2-(4-Pyridinyl methylamino-5-chloro]phenyl-4-(3-trifluoromethylphenyl -1.2.4-triazole (8): Η NMR (300 MHz, OMSO-d6) δ (ppm) 14.8 (br. s, IH), 8 (m, 17H), 6.7 (d, IH), 4.7 (d, 2H); 13C NMR (75 MHz, DMSO- 6) δ (ppm) 150.1, 148.8, 145.2, 130.9, 130.6, 130.4, 130.3, 129.9, 129.5, 127.2, 126.6, 126.2, 122.5, 122.4, 119.6, 113.7, 45.8; MS 430.1 (M+H+); Formula C21H15ClF3N5O, Calculated C 58.68, H 5.52, N 16.29; Found C 58.38, H
5.61, N 16.06.
2-[3-[2-(4-Pyridinyl)methylamino]pyridinyl]-4-r3-trifluoromethylphenyl -l,2.4-triazole (9): Η NMR (300 MHz, OMSO-d6) δ (ppm) 14.6 (br. s, IH), 8.4 (m, 7H), 7.8 (m, 2H), 7.2 (d, 2H), 6.7 (m, 2H), 4.6 (d, 2H); 13C NMR (75 MHz, DMSO- 6) δ (ppm) 153.6, 148.6, 148.5, 134.2, 129.2, 129.0, 128.9, 128.5, 128.1, 125.2, 124.8, 121.2, 121.0, 110.9, 42.3; MS 397.3 (M+H+); Formula C20H15F3N6: Calculated C 60.61, H 3.81, N 21.19; Found C 60.57, H 3.87, N 21.12.
2-[2-(4-Pyridinyl)methylamino]phenyl-4-(3-phenoxyphenyl -1.2.4-triazole (10 : 'H NMR (300 MHz, OMSO-d6) δ (ppm) 14.6 (br. s, IH), 8 (m, 16H), 6.6 (m, 2H), 4.6 (d, 2H); 13C NMR (75 MHz, DMSO- 6) δ (ppm) 157.7, 156.9, 150.0, 149.2, 146.4, 131.0, 130.5, 124.2, 122.4, 121.4, 119.4, 116.0, 111.8, 45.6; MS 420.2 (M+H ); Formula C26H21N5O: Calculated C 74.44, H 5.05, N 16.704; Found C 74.25, H 4.92, N 16.54.
2- r4-Pyridinyl methylamino]phenyl-4-(4-phenoxyphenyl -1.2.4-triazole (ll : Η NMR (300 MHz, DMSO-GQ δ (ppm) 14.6 (br. s, IH), 8 (m, 16H), 6.6 (m, 2H), 4.6 (d, 2H); 13C NMR (75 MHz, DMSO- 6) δ (ppm) 158.4, 156.4, 150.1, 149.4, 145.4, 130.5, 128.7, 128.4, 127.6, 126.6, 124.3, 122.6, 119.5, 115.9, 111.8, 45.7; MS 420.2 (M+H+); Formula C26H21N5O: Calculated C 74.44, H 5.05, N 16.70; Found C 74.22, H 4.94, N 16.45.
2- (4-Pyridinyl methylamino]phenyl-4-(4-ethvnylphenylV1.2.4-triazole (12): 'H NMR (300 MHz, DMSO- 6) δ (ppm) 14.6 (br. s, IH), 8 (m, 12H), 6.6 (m, 2H), 4.7 (d, 2H), 4.4 (s, IH); 13C NMR (75 MHz, DMSO- 6) δ (ppm) 150.1, 149.3, 146.4, 132.6, 131.5, 127.9, 126.5, 122.7, 122.5, 116.0, 111.9, 88.6, 82.5, 55.4, 45.7; MS 352.2 (M+H+); Formula
C22H17N5 + 0.25H2O: Calculated C 74.25, H 4.96, N 19.67. Found C 74.23, H 5.09, N 19.14.
2-[(4-Pyridinyl)methylamino1phenyl-4-(,3-biphenyl -1.2.4-triazole (13): *H NMR (300 MHz, DMSO-tf6) δ (ppm) 14.6 (br. s, IH), 8 (m, 16H), 6.6 (m, 2H), 4.6 (d, 2H); 13C
NMR (75 MHz, ΩMSO-d6) δ (ppm) 149.1, 148.3, 145.3, 140.2, 139.0, 130.1, 129.3, 128.9, 128.4, 127.3, 127.1, 127.0, 126.1, 124.6, 123.5, 121.5, 114.1, 110.8, 110.4, 45.7; MS 404.2 (M+H4); Formula C26H21N5: Calculated C 77.40, H 5.25, N 17.36. Found C 77.07, H 5.34, N 17.24. 2-[(4-PyridinvDmethylaminolphenyl-4-[3-(2-phenylethenyl phenyl]-1.2.4-triazole (14 : !H NMR (300 MHz, DMSO- 6) δ (ppm) 14.6 (br. s, IH), 8 (m, 18H), 6.6 (m, 2H), 4.6 (d, 2H); 13C NMR (75 MHz, OMSO-d6) δ (ppm) 150.1, 149.3, 146.4, 138.0, 137.8, 133.7, 130.6, 129.7, 129.1, 128.7, 128.2, 127.4, 127.0, 126.9, 124.7, 122.6, 116.0, 111.9, 45.8; MS 430.2 (M+H+); Formula C26H21N5O: Calculated C 78.30, H 5.40, N 16.31. Found C
78.30, H 5.40, N 16.16.
2-[(4-Pyridinyl methylamino]phenyl-4-[3-[(NN-dimethylaminomethyl)phenyl -l,2,4- triazole (15): Η ΝMR (300 MHz, CDC13) δ (ppm) 8.6 (m, 3H), 8.0 (d, IH), 7.9 (m, 3H), 7.4 (m, 3H), 7.3 (m, 3H), 6.8 (t, IH), 6.6 (d, IH), 4.6 (s, 2H), 2.7 (t, 2H), 2.4 (m, 2H), 2.3
(s, 6H), 1.9 (m, IH); 13C MR (75 MHz, CDC13) δ (ppm) 157.7, 157.2, 148.5, 148.3, 145.0, 141.2, 129.6, 128.5, 128.3, 127.5, 126.7, 125.1, 122.9, 121.2, 115.0, 110.6, 110.1, 57.8, 45.3, 43.9, 32.2, 27.5; MS 413.3 (M+H+); C25H28N6: Calculated: C, 69,75 %; H, 6.56 %; N, 19.51 %; Found: C, 69.33 %; H, 6.69 %; N, 19.41 %.
2-[(4-Pyridinyl methylamino]phenyl-4-[4-[(N.N-dimethylaminopropyl)phenyl -1.2,4- triazole (16): Η ΝMR (300 MHz, CDC13) δ (ppm) 8.6 (m, 3H), 7.9 (m, 3H), 7.4 (d, 2H), 7.2 (m, 4H), 6.8 (t, IH), 6.6 (d, IH), 4.6 (s, 2H), 2.7 (t, 2H), 2.4 (m, 2H), 2.3 (s, 6H), 1.9 (m, IH); 13C ΝMR (75 MHz, CDC13) δ (ppm) 158.7, 158.1, 149.5, 149.3, 146.0, 143.4, 130.5, 128.5, 127.7, 127.1, 126.3, 122.2, 116.0, 111.6, 111.1, 58.8, 46.2, 45.0, 33.2, 28.5;
MS 413.3 (M+H4); Formula C25H28N6: Calculated: C 69.75 %, H 6.56 %, N 19.51 %; Found: C 69.86 %, H 6.52 %, N, 19.39 %.
2- [2-(4-Pyridinyl methylamino]phenyl-4-(3 -trifluoromethylphenylV 1 ,2.4-triazole (18): !H NMR (300 MHz, DMSO- 6) δ (ppm) 14.6 (br. s, IH), 8 (m, 13H), 4.6 (d, 2H); MS 396.2
(M+H÷).
Compound (19): Η NMR (DMSO-d6) δ (ppm) 8.89 (s, IH), 8.15-8.35 (m, 4H), 7.98-8.02 (m, 2H), 7.00 (s, IH), 7.10 (s, 2H), 6.68-6.78 (m, IH), 6.00 (s, 2H), 4.67-4.69 (d, 2H), 3.28 (s, 3H); MS m/z: 450 (M+H") Compound (20): Η NMR (DMSO-eQ δ (ppm) 14.44 (s, IH), 8.16 -8.45 (m, 2H), 7.65- 7.75 (m, 2H), 6.68-7.15 (m, 5H), 6.06 (s, 2H), 4.65-4,67 (d, 2H), 3.83-3.90 (d, 6H); MS m/z: 432 (M+H+)
Compound (21): Η NMR (OMSO-d6) δ (ppm) 14.72 (s, IH), 8.18-8.50 (m, 3H), 7.44-7.65
(m, 3H), 7.08 (s, IH), 6.72-6.77 (m, IH), 6.60-6.61 (d, 2H), 6.41-6.42 (d, IH), 4.70-4.71 (d, 2H), 3.71-3.81 (m, 9H); MS m/z: 418 (M+H+)
Compound (22): IH NMR (DMSO-d6) δ (ppm) 14.21 (s, IH), 8.52-8.56 (m, 2H), 7.98- 8.02 (m, IH), 7.55-7.64(m, 2H), 7.34-7.38 (m, 2H), 7.22-7.26 (m, IH), 7.06-7.10 (m, IH),
4.62-4.64 (d, 2H), 3.72-3.88 (m, 6H); MS m/z: 388 (M+H+)
Compound (23): 1H NMR (DMSO-^) δ (ppm) 8.55-8.61 (m, 3H), 7.90-7.98 (m, IH), 7.55-7.64 (m, 2H), 7.35-7.40 (m, 2H), 7.16-7.24 (m, IH), 6,64-6.72 (m, 2H), 6.10 (s, 2H), 4.60-4.62 (d, 2H); MS m/z: 372 (M+H+)
Compound (24): Η NMR (DMSO-c δ (ppm) 14.63 (s, IH), 8,53-8.59 (m, 3H), 8.08-8.24 (m, 2H), 7.91-7.94 (m, IH), 7.54-7.60 (m, IH), 7.40-7.42 (m, 2H), 6.65-6.75 (m, 2H), 4.63-4.65 (d, 2H); MS m z: 380 (M+H+)
Compound (25): Η NMR (DMSO-^) δ (ppm) 14.60 (s, IH), 8.61-8.72 (m, 3H), 7.90-8.04 (m, 3H), 7.20-7.71 (m, 5H), 6.62-6.84 (m, 2H), 4.64-4.68 (m, 2H); MS m/z: 346 (M+lT)
Compound (26): !H NMR (DMSO-d6) δ (ppm) 14.71(s, IH), 8.55-8.68 (m, 3H), 8.30-8.38 (m, 2H), 7.83-7.94 (m, 3H), 7.40-7.44 (m, 2H), 7.14-7.26 (m, IH), 6.63-6.78 (m, 2H),
4.64-4.66 (d, 2H); MS m z: 396 (M+H+)
Compound (27): Η NMR (DMSOO 10.59 (s, IH), 8.50-8.53 (m, 2H), 7.97-8.00 (m, IH), 7.62-7.64 (m, IH), 7.24-7.36 (m, 3H), 6.88-6.89 (d, 2H), 6.67-6.68 (m, 2H), 6.20 (s, IH), 4.66-4.68 (d, 2H), 3.76 (s, 6H); MS m z 404 (M+H+) Compound (28): Η NMR (DMSO-d6) δ (ppm) 8.68-8.74 (m, IH), 8.50-8.56 (m, 2H), 8.30-8.35 (m, 2H), 8.04-8.08 (m, 2H), 7.91-7.96 (m, IH), 7.41-7.43 (m, 2H), 7.20-7.28 (m, IH), 6.62-6.71 (m, 2H), 4.60-4.62 (d, 2H), 3.28 (s, 3H); MS m/z: 406 (M+H4)
Compound (29): Η NMR (DMSO- 5) δ (ppm) 12.84(s, IH), 9.33 (s, IH), 8.82-8.86 (m,
IH), 8.40-8.44 (m, IH), 7.98-8.08 (s, IH), 7.30-7.82 (m, 6H), 6.92-6.99 (m, IH), 6.74-6.78 (m, IH), 4.37-4.39(d, 2H); MS m/z: 318 (M+H )
Compound (30): 'H NMR (DMSO- 6) δ (ppm) 8.48-8.52 (m, 2H), 7.40-8.02 (m, 7H), 6.70-6.94 (m, 2H), 4.35-4.42 (d, 2H); MS m/z: 385 (M+H+)
Compound (31): Η NMR (methanol-^) δ (ppm) 8.18-8.22 (m, IH), 7.85-7.97 (m, 3H), 6.90-7.00 (m, 2H), 6.54-6.60 (m, IH), 3.75-3.78 (m, 3H), 3.30-3.50 (m, 6H), 2.20-2.25 (m, 2H), 1.85-1.90 (m, 4H); MS m/z: 393 (M+H4)
Compound (32): Η NMR (OMSO-d6) δ (ppm) 12.69 (s, IH), 7.96-7.98 (m, 2H), 7.82-7.89 9m, IH), 7.67 (s, IH), 7.40-7.48 (m, 2H), 7.25-7.30 (m, IH), 7.02-7.10 (m, 2H), 6.86-6.89 (m, IH), 6.60-6.68 (m, IH), 4.26-4.27 (d, 2H), 3.78 (s, 3H); MS m z: 347 (M+H+)
Compound (33): Η NMR (CDC13) δ (ppm) 8.45-8.52 (m, IH), 8.04-8.09 (m, 2H), 7.81-
7.98 (m, 4H), 6.22-6.27 (m, IH), 3.35-3.68 (m, 6H), 2.95 (s, 3H), 2.37-2.43 (m, 2H), 1.90- 2.02 (m, 4H); MS m/z: 441(M+H+)
Compound (34): ΗNMR(CDC13) δ (ppm) 8.40 (s, IH), 8.10-8.16 (m, IH), 8.03-8.06 (m, IH), 7.50-7.55 (m, 2H), 6.65-6.71 (m, IH), 6.40-6.48 (m, IH), 5.90-5.92 (m, 2H), 3.32-
3.58 (m, 6H), 2.27-2.35 (m, 2H), 1.84-1.92 (m, 4H); MS m/z: 407 (M+H+)
Compound (35): Η NMR(methanol-^) δ (ppm) 8.27-8.34 (m, 4H), 8.01-8.13 (m, 2H), 7.52-7.67 (m, IH), 3.30-3.49 (m, 6H), 2.20-2.28 (m, 6H), 2.17-2.26 (m, 2H), 1.78-1.93 (m, 4H); MS m/z: 431 (M+IF) Compound (36): MS m/z: 393 (M+H+)
Compound (37): Η NMR (DMSO-d6) δ (ppm) 10.11 (s, IH), 8.28-8.39 (m, 2H), 8.12 (s, IH), 7.87-7.91 (m, IH), 7.25-7.68 (m, 6H), 6.93-7.02 (m, 3H), 6.02 (s, 2H); MS m z: 437 (M+H+)
Compound (38): MS m z: 423 (M+H+)
Compound (39): MS m/z: 365 (M+H+)
Compound (40): Η NMR (DMSO-c δ (ppm) 14.38-14.39 (d, IH), 12.59 (s, IH), 7.65- 7.75 (m, 3H), 7.31-7.45 (m, 3H), 6.45-6.76 (m, 3H), 5.95 (s, 2H), 4.14 (s, 2H); MS m/z: 361 (M+H4)
Compound (41): Η NMR (OMSO-d6) δ (ppm) 9.04-9.08 (s, IH), 8.46-8.49 (m, IH), 8.14-
8.22 (m, 2H), 7.78-7.81 (m, IH), 7.34-7.40 (m, IH), 4.18 (m, IH), 2.32-2.36 (m, 6H), 2.16-2.22 (m, IH), 1.98-2.06 (m, 4H), 1.55-1.80 (m, 2H); MS m/z: 336 (M+H*)
Compound (42): MS m z: 407 (M+H+)
Compound (43): Η NMR(methanol-< δ (ppm) 9.21 (s, IH), 7.98-8.07 (m, 2H), 8.45-8.52 (m, 2H), 7.40-7.48 (m, IH), 6.63-6.72 (m, IH), 3.35-3.52 (m, 6H), 2,18-2.25 (m, 2H), 1.80-1.92 (m, 4H); MS m/z: 364 (M+H+)
Compound (44): Η NMR (methanol-^) δ (ppm) 8.15-8.22 (m, 3H), 7.96-7.99 (m, IH),
7.58-7.63 (m, 2H), 6.91-6.98 (m, IH), 4.08 (s, IH), 2.71-2.79 (m, 2H), 2.21-2.43 (m, 8H), 1.78-2.00 (m, 2H); MS m/z: 403(M+H+)
Compound (45): MS m z: 431 (M+H+) Compound (46 : Η NMR (OMSO-d6) δ (ppm) 14.84 (s, IH), 10.98 (s, IH), 8.30-8.62 (m, 3H), 8.07 (s, IH), 7.50-7.75 (m, 4H), 7.00-7.16 (m, 2H), 6.26 (s, 2H), 3.25 (s, 3H); MS m/z: 436 (M+H4)
Compound (47): Η NMR (DMSO-c δ (ppm) 15.20 (s, IH), 11.22 (s, IH), 8.42-8.58 (m,
5H), 8.10-8.14 (m, IH), 7.85-7.96 (m, 2H), 7.55-7.70 (m, 2H), 7.12-7.17 (m, IH), 3.24 (s, 3H); MS m/z: 460 (M+H+)
Compound (48): Η NMR (methanol-^) δ (ppm) 9.32 ( s, IH), 8.52-8.64 (m, 2H), 8.26- 8.29 (m, IH), 8.11-8.16 (m, IH), 7.59-7.66 (m, IH), 6.70-6.78 (m, IH), 3.68-3.76 (m, 2H),
2.90-3.00 (m, 6H), 1.92-2.08 (m, 6H); MS m/z: 350(M+H+)
Compound (49): Η NMR (OMSO-d6) δ (ppm) 8.35-8.50 (m, 3H), 8.11-8.15 (m, IH), 7.48-7.74 (m, 5H), 7.00-7.14 (m, 2H), 3.89 (s, 3H), 3.23 (s, 3H); MS m/z: 422 (M+H )
Compound (50): Η NMR (OMSO-d6) δ (ppm) 8.75 (s, IH), 8.27-8.30 (m, IH), 8.16-8.18 (m, IH), 7.46-7.64 (m, 2H), 7.41-7.43 (m, IH), 7.00-7.07 (m, 2H), 6.87-6.93 (m, 2H), 6.71-6.75 (m, IH), 6.00 (s, 2H), 4.65-4.67 (d, 2H), 3.81 (s, 3H); MS m/z: 402 (M+H )
Compound (51): Η NMR (DMSO-d6) δ (ppm) 8.68 (s, IH), 8.27 -8.29 (m, IH), 8.17-8.19
(m, IH), 7.17-7.18 (d, 2H), 7.00-7.01 (s, IH), 6.90-6.94 (m, 2H), 6.71-6.75 (m, IH), 6.55 (s, IH), 6.00 (s, 2H), 4.64-4.66 (d, 2H), 3.79 (s, 6H); MS m/z: 432 (M+H )
Compound (52): Η NMR (DMSO-^) δ (ppm) 8.87 (s, IH), 8.10-8.25 (m, 5H), 7.50-7.60 (m, IH), 6.70-6.95 (m, 4H), 6.00 (s, 2H), 4.68-4.71 (d, 2H); MS m/z: 424 (M+H+)
Compound (53): Η NMR (DMSO-^) δ (ppm) 14.80 (s, br, IH), 9.10 (s, br, IH), 8.31- 8.38 (m, 2H), 7.35-7.85 (m, 4H), 6.70-6,95 (m, 3H), 6.00 (s, 2H), 4.65-4.70 (d, 2H); MS m/z: 390 (M+H4) Compound (54): Η NMR (DMSO- 6) δ (ppm) 8.80 (s, IH), 8.15-8.38 (m, 4H), 7.70-7.85 (m, 2H), 7.00 (s, IH), 6.85-6.90 (m, 2H), 6.72-6.78 (m, IH), 6.00 (s, 2H), 4.65-4.67 (d, 2H); MS m/z: 440 (M+H )
Compound (55): Η NMR (DMSO-<Q 14.85 (s, br, IH), 8.80 (s, br, IH), 8.15-8.25 (m,
4H), 7.85-7.92 (m, 2H), 7.00 (s, IH), 7.11 (s, 2H), 6.68-6.72 (m, IH), 6.00 (s, 2H), 4.65- 4.68 (d, 2H); MS m/z: 440 (M+H )
Compound (56): Η NMR (DMSO- 6) δ (ppm) 14.71 (s, IH), 8.65 (s, IH), 8.48-8.59 (m, IH), 8.10-8.30 (m, 2H), 7.78-7.82 (m, IH), 7.50-7.65 (m, 2H), 7.30-7.45 (m, 2H), 7.02-
7.08 (m, IH), 6,70-6.80 (m, IH), 4.80-4.82 (m, 2H), 3.82 (s, 3H); MS m/z: 359 (M+H+)
Compound (57): Η NMR (DMSO- ) δl4.78 (s, br, IH), 8.85 (s, br, IH), 8.60 (s, IH), 8.50 (d, IH), 8.05-8.30 (m, 3H), 7.75-7.80 (m, IH), 7.50-7.60 (m, IH), 7.30-7.40(m, IH), 6.72-6.80 (m, IH), 4.75-4.82 (d, 2H); MS m/z: 381 (M+H4)
Compound (58): Η NMR (DMSO-^) δ (ppm) 14.76 (s, IH), 8,88 (s, IH), 8.65 (s, IH), 8.48 (s, IH), 8.19-8.26 (m, 3H), 7.72-7.94 (m, 3H), 7.50-7.55 (m, 2H), 6.75-6.80 (m, IH), 4.82-4.84 (d, 2H); MS m/z: 347 (M+H4)
Compound (59): Η NMR (DMSO-c δ (ppm) 14.90 (s, IH), 8.91 (s, IH), 8.68 (s, IH), 8.45-8.48 (d, IH), 8.15-8.30 (m, 4H), 7.72-7.95 (m, 3H), 7.35-7.40 (m, IH), 6.70-6.79 (m, IH), 4.80-4.85 (d, 2H); MS m z: 397 (M+H4)
Compound (60): Η NMR (DMSO-cQ δ (ppm) 14.72 (s, IH), 8.66 (s, IH), 8.47-8.48 (m,
IH), 8.17-8.31 (m, 2H), 7.81-7.83 (d, IH), 7.35-7.39 (m, IH), 7.20-7.21 (d, 2H), 6.63-6.78 (m, 2H), 4.80-4.82 (m, 2H), 3.80 (s, 6H); MS m/z: 389 (M+H4)
Compound (61): Η NMR (DMSO-c δ (ppm) 14.50 (s, IH), 8.65-8.66 (m, IH), 8.47-8.49 (m, IH), 8.16-8.18 (m, IH), 7.80-7.83 (m, IH), 7.61-7.65 (m, 2H), 7.35-7.40 (m, IH), 7.10-7.12 (d, IH), 6.73-6.77 (m, IH), 4.79-4.81 (d, 2H), 3.81-3.83 (d, 2H); MS m/z: 389 (M+H4)
Compound (62): Η NMR (OMSO-d6) δ (ppm) 14.90 (s, IH), 8.91 (s, IH), 8.66 (s, IH), 8.02-8.35 (m, 6H), 7.81-7.84 (m, IH), 7.32-7.39 (m IH), 6.75-6.80 (m, IH), 4.82-4.84 (d,
2H), 3.28-3.33 (d, 3H); MS m/z: 407 (M+H4)
Compound (63): Η NMR DMSO-d6) 14.50 (s, IH), 8.17-8.57 (m, 3H), 7.57-7.64 (m, 2H), 7.10 (s, IH), 6.41-6.61 (m, 4H), 4.74-4.75 (d, 2H), 3.75-3.87 (m, 12 H); MS m/z: 448 (M+H4)
Compound (64): Η NMR (DMSO-d6) 8.11-8.42 (m, 7H), 7.85-7.90 (m, IH), 6.55-6.60 (m, IH), 6.38-6.40 (m, IH), 4.78-4.81 (d, 2H), 3.72-3.74 (m, 9H); MS m/z: 466 (M+H4)
Compound (65): Η NMR (DMSO- 6) δ (ppm) 8.34-8.58 (m, 2H), 7.70-7.73 (m, 2H),
7.13-7.23 (m, IH), 6.85-7.10 (m, 4H), 6.19 (s, IH), 3.74-3.88 (m, 9H); MS m/z: 404 (M+H4)
Compound (66): Η NMR DMSO-d6) δ (ppm) 8.50-8.58 (m, 3H), 8.32-8.36 (m, IH), 8.24-8.27 (m IH), 7.78-7.96 (m, 2H), 6.79-6.84 (m, IH), 3.75-3.79 (m, 2H), 3.15-3.23 (m,
6H), 1.91-2.12 (m, 6H); MS m/z: 417(M+H4)
Compound (67): Η NMR DMSO-d6)δ 8.49 (m, IH), 8.29-8.33 (m, IH), 8.15-8.22 (m, IH), 7.81-7.88 (m, 2H), 7.45-7.55 (m, IH), 7.10-7.14 (m, IH), 6.72-6.78 (m, IH), 3.91 (s, 3H), 3.72-3.79 (m, 2H), 3.05-3.24 (m, 6H), 1.97-2.08 (m, 6H); MS m/z: 377(M+H4)
Compound (68): Η NMR (methanol-^) δ (ppm) 8.14-8.18 (m, IH), 7.95-7.97 (m, IH), 7.45-7.50 (m, IH), 7.51 (s, IH), 6.82-6.86 (m, IH), 6.55-6.59 (m, IH), 5.93 (s, 2H), 3.40- 3.54 (m, 2H), 2.52-2.68 (m, 6H), 1.68-1.95 (m, 6H); MS m/z: 39304+^) Compound (69): Η NMR (methanol-^) δ (ppm) 8.25-8.28 ( , IH), 8.05-8.08 (m,lH), 7.20-7.24 (m, 2H), 6.57-6.73 (m, 2H), 3.91 (s, 6H), 3.55-3.63 (m, 2H), 2.74-2.93 (m, 6H), 1.82-2.08 (m, 6H); m z: 409(M+H4)
Compound (70): Η NMR (methanol-^) δ (ppm) 8.44-8.48 (m, IH), 8.04-8.10 (m, IH),
7.63-7.69 (m, 2H), 7.45-7.52 (m, IH), 6.98-6.12 (m, 2H), 4.32 (s, IH), 3.88 (s, 3H), 2.82- 2.91 (m, 2H), 2.64-2.68 (m, 4H), 2.38-2.46 (m, 4H), 1.95-2.15 (m, 2H); MS m/z: 365(M+H4)
Compound (71): Η NMR (OMSO-d6) δ (ppm) 11.27 (s, IH), 8.50-8.54 (m, IH), 8.34-8.37
(m, 2H), 8.00-8.06 (m, IH), 7.78-7.87 (m, 2H), 7.42-7.60 (m, 3H), 7.38 (s, 2H), 6,99-7.13 (m, 2H), 3.89 (s, 3H); MS m/z: 423 (M+H4)
Compound (72): 'H NMR fDMSOO δ (ppm) 15.30 (s, IH), 11.18 (s, IH), 8.38-8.51 (m, 5H), 7.82-7.98 (m, 3H), 7.30-7.58 (m, 4H), 7.00-7.07 (m, IH); MS m/z: 461(M+H4)
Compound (73): Η NMR (DMSO-d6) δ (ppm) 9.35 (s, IH), 8.68-8.71 (m, IH), 8.40-8.47 (m, 2H), 8.30-8.33 (m, IH), 7.59-7.66 (m, IH), 7.11 (s, 2H), 6.93-6.99 9m, IH), 6.22 (s, IH), 3.79 (s, 6H); MS m z: 375(M+H4)
Compound (74): Η NMR (OMSO-d6) δ (ppm) 14.98 (s, br, IH), 11.92 (s, br, IH), 8.60 (s, IH), 8.10-8.24 (m, 2H), 7.45-7.58 (m, 3H), 7.08-7.13 (m, IH), 6.82-6.88 (m, IH), 6.65- 6.70 (m, IH), 5.93 (s, 2H), 3.84-3.88 (m, 2H), 2.85-2.91 (m, 2H); MS m/z: 376(M+H4)
Compound (75): Η NMR (DMSO-^) δ (ppm) 14.40 (s, br, IH), 1.57 (s, br, IH), 8.55 (s,
IH), 8.15-8.22 (m, 2H), 7.42-7.65 (m, 4H), 7.07-7.10 (m, IH), 6.66-6.68 (m, IH), 6.65- 6.74 (m, IH), 3.92 (s, 3H), 3.78-3.86 (m, IH), 2.85-2.92 (m, 2H); MS m z: 362(M+H4)
Compound (76): MS m z: 397 (M+H4) Compound (77): MS m/z: 396 (M+H4)
Compound (78): MS m/z: 396 (M+H4)
Compound (79): MS m/z: 433 (M+H4)
Compound (80): MS m/z: 388 (M+H4)
Compound (81): MS m/z: 388 (M+H4)
Compound (82): Η NMR (DMSO ) δ (ppm) 8.47-8.49 (m, 2H), 8.22-8.25 (m, IH), 7.95-7.98 (m, IH), 7.25-7.34 (m, 4H), 6.60-6.95 (m, 5H), 6.56-6.60 (d, 2H), 4.14-4.22 (d, 2H), 3.68-3.72 (m, 3H); MS m/z: 373 (M+H4)
Compound (83): MS m/z: 408 (M+H4)
Compound (84): MS m/z: 439 (M+H4)
Compound (85): MS m/z: 423 (M+H4)
Compound (86): MS m/z: 377 (M+H4)
Compound (87): Η NMR (DMSO-^) δ (ppm) 14.38 (s, IH), 10.79 (s, IH), 8.27-8.37 (m, 2H), 7.23-7.28 (m, IH), 6.82-7.00 (m, 6H), 6.14-6.16 (m, IH), 4.19 (s, IH), 3.70-3.74 (m, 9H); MS m/z: 418 (M+H4)
Compound (88): MS m/z: 410 (M+H4)
Compound (89): MS m/z: 404 (M+H4)
Compound (90): MS m z: 391 (M+H4) Compound (91 : MS m/z: 422 (M+H4)
Compound (92 : MS m/z: 377 (M+H4)
Compound (93 : MS m/z: 417 (M+H4)
Compound (94 : MS m/z: 408 (M+H4)
Compound (95 : MS m z: 394 (M+H4)
Compound (96 : MS m/z: 394 (M+H4)
Compound (97 : MS m/z: 437 (M+H4)
Compound (98 : MS m/z: 451 (M+H4)
Compound (99): MS m/z: 380 (M+H4)
Compound (100): Η NMR(CDC13) δ (ppm) 12,35 (s, IH), 8.02-8.20 (m, 3H), 7.10-7.18 (m, IH), 6.65-6.80 (m, 3H), 6.45-6.52 (m, IH), 4.07-4.08 (d 2H), 3.72 (s, 3H), 3.42-3.52
(m, 2H), 3.25-3.38 (m, 4H), 2.15-2.22 (m, 2H), 1.80-1.90 (m, 4H); MS m/z: 407(M+H4)
Compound (101): Η NMR(CDC13) δ (ppm) 7.70-7.75 (m, IH), 7.39 9s, 2H), 7.02-7.25 (m, 2H), 6.55-6.68 (m, 5H), 4.25 (s, 2H), 3.96 9s, 2H), 3.54 (s, 3H); MS m z: 361 (M+H4)
Compound (102): MS m/z: 431 (M+H4)
Compound (103): MS m/z: 466 (M+H4)
Compound (104): MS m/z: 467 (M+H4) Compound (105): MS m/z: 392 (M+H4)
Compound (106): MS m/z: 437 (M+H4)
Compound (107): MS m/z: 409 (M+H4)
Compound (108): MS m/z: 403 (M+H4)
Compound (109): MS m/z: 452 (M+H4)
Compound (110): MS m/z: 448 (M+H4)
Compound (111): MS m/z: 406 (M+H4)
Compound (112): MS m/z: 453 (M+H )
Compound (113): MS m/z: 488 (M+H4)
Compound (114): £ee Example 6
Compound (115): Η NMR (DMSO-d6) δ (ppm) 11.40 (s, IH), 10.0 (s, IH), 8.40-8.43 (m, IH), 8.01-8.04 (m, IH), 7.01-7.06 (m, 2H), 6.81-6.95 (m, 4H), 6.23-6.25 (t, IH), 3.80 (s, 6H); MS m/z: 426 (M+H4). Calculated for C21H17F2N5O3: 425.13
Compound (116): Η NMR (DMSO-d6) δ (ppm) 11.34 (s, IH), 10.02 (s, IH), 8.43-8.45
(m, IH), 8.06-8.16 (m, 2H), 7.87-7.90 (m, IH), 7.64-7.70 (t, IH), 7.43-7.46 (d, IH), 7.05- 7.10 (m, 3H), 6.25-6.27 (t, IH), 3.81 (s, 6H); MS m z: 458 (M+H4). Calculated for C22H18F3N5O3: 457.13 Compound (117): Η NMR (DMSO-c^) δ (ppm) 10.93 (s, IH), 10.07 (s, IH), 8.41-8.44 (m, IH), 8.04-8.08 (m, IH), 7.04-7.54 (m, 11H), 6.74-6.77 (m, IH), 6.24-6.26 (t, IH), 5.16 (s, 2H), 3.80-3.84 (d, 6H); MS m/z: 496 (M+H4). Calculated for C22H19F3N5O5: 495.19
Compound (118): Η NMR (DMSO-^) δ (ppm) 10.76 (s, IH), 10.07 (s, IH), 8.40-8.43
(m, IH), 8.02-8.05 (m, IH), 7.33-7.34 (d, IH), 6.94-7.11 (m, 5H), 6.24-6.26 (t, IH), 6.05 (s, 2H), 3.77-3.80 (d, 6H); MS m/z: 434 (M+H4). Calculated for C22H19N5O5: 433.14
Compound (119): Η NMR (OMSO-d6) δ (ppm) 10.68 (s, IH), 10.04 (s, IH), 8.40-8.42-t, IH), 8.03-8.06 (t, IH), 7.35-7.36 (d, IH), 7.00-7.19 (m, 5H), 6.25 (s, IH), 3.78-3.82 (m,
12H); MS m/z: 450 (M+H4). Calculated for C23H23N5O5: 449.17
Compound (120): Η NMR (DMSO-d6) δlθ.86 (s, IH), 10.05 (s, IH), 8..35-8.37 (m, IH), 8.00-8.02 (m, IH), 7.65-7.68 (d, 2H), 7,34-7.40 (t, 2H), 6.96-7.12 (m, 8H), 6.19-6.20 (t, IH), 3.72-3.76 (d, 6H); MS m/z: 482 (M+H4). Calculated for C27H21N5O4: 481.18
Compound (121): Η NMR (DMSO-d6) δll.05 (s, IH), 8.28-8.30 (s, IH), 8.11-8.16 (t, IH), 7.92-7.96 (m, IH), 7.73-7.76 (d, 2H), 7.17-7.29 (m, IH), 7.00 (s, IH), 6.91 (s, 2H), 6.80-6.84 (m, IH), 6.02 (s, 2H), 4.70-4.72 (d, 2H); MS m z: 471 (M+H4). Calculated for C27H17F3N4O4: 470.12
Compound (122): Η NMR (DMSO-d6) δ (ppm) 11.22 (s, IH), 8.28-8.31 (m, IH), 8.15 (s, 2H), 7.91-7.95 (m, IH), 7.81-7.84 (d, IH), 7.64-7.67 (t, IH), 7.40-7.42 (d, IH), 6.80-7.00 (m, 4H), 6.02 (s, 2H), 4.71-4.73 (d, 2H); MS m/z: 456 (M+H4). Calculated for C23H17F3N4O3: 455.12
Compound (123): Η NMR (DMSO-^) δ (ppm) 10.83 (s, IH), 8.27-8.30 (m, IH), 8.12- 8.16 (m, IH), 7.90-7.94 (m, IH), 7.17-7.52 (m, 9H), 7.00 (s, IH), 6.90 (d, 3H), 6.71-6.84 (m, 2H), 6.02 (s, IH), 5.14 (s, IH), 4.71-4.73 (d, 2H); MS m z: 494 (M+H4). Calculated for C29H24N4O4: 492.18 Compound (124): Η NMR (OMSO-d6) δ (ppm) 10.81 (s, IH), 8.27-8.29 (m, IH), 8.13- 8.17 (t, IH), 7.92-7.95 (m, IH), 7.66-7.69 (m, 2H), 7.38-7.43 (t, 2H), 6.79-7.16 (m, 9H), 6.02 (s, 2H), 4.70-4.72 (m, 2H); MS m/z: 480(M+H4). Calculated for C27H21N5O4: 479.16
Compound (125): Η NMR (DMSO-d6) δlθ.60 (s, IH), 8.26-8.29 (m, IH), 8.15-8.17 (t,
IH), 7.89-7.93 (m, IH), 7.38-7.39 (d, IH), 6.79-7.12 (m, 6H), 6.02 (s, 2H), 4.70-4.72 (d, 2H), 3.76-3.80 (d, 6H); MS m/z: 448(M+H4). Calculated for C23H21N5O5: 447.15
Compound (126): Η NMR (DMSO-d6) δ (ppm) 10.62 (s, IH), 8.23-8.25 (m, IH), 8.09 (t, IH), 7.84-7.88 (m, IH), 7.27-7.28 (d, IH), 6.75-7.03 (m, 6H), 5.99-6.00 9d, 2H), 4.66-4.68
(d, 2H); MS m/z: 432(M+H4). Calculated for C22H17N5O5: 431.12
Compound (127): Η NMR DMSO-d6) δ (ppm) 11.03 (s, IH), 8.24-8.26 ( , IH), 8.13- 8.17 (t, IH), 7.90-7.93 (m, IH), 7.70-7.73 (d, 2H), 7.78-7.40 (d, 2H), 6.78-6.82 (m, IH), 6.40-6.54 (d, 2H), 6.54-6.55 (d, IH), 6.40 (s, IH), 4.71-4.73 (d, 2H), 3.72 (s, 6H); MS m/z:
488(M+H4). Calculated for C23H20F3N5O4: 487.15
Compound (128): Η NMR (OMSO-d6) δll.20 (s, IH), 8.11-8.27 (m, 3H), 7.90-7.93 (m, IH), 7.79-7.82 (d, IH), 7.58-7.64 (t, IH), 7.37-7.39 (d, IH), 6.77-6.82 (m, IH), 6.40-6.54 (d, 2H), 6.39-6.40 (d, IH), 4.71-4.73 (d, 2H), 3.72 (s, 6H); MS m z: 472(M+H4).
Calculated for C23H20F3N5O3: 471.15
Compound (129): Η NMR (OMSO-d6) δ (ppm) 10.80 (s, IH), 8.14-8.25 (m, 2H), 7.90- 7.93 (m, IH), 7.62-7.90 (m, 2H), 6.77-7.40 (m, 7H), 6.54-6.55 (d, 2H), 6.39-6.40 (t, 2H),
3.71 (s, 6H); MS m/z: 496(M+H4). Calculated for C28H25F3N5O4: 495.19
Compound (130): Η NMR (OMSO-d6) δ (ppm) 10.80 (s, IH), 8.15-8.25 (m, 2H), 7.88- 7.91 (d, IH), 7.07-7.48 (m, 9H), 6.40-6.81 (m, 5H), 5.11 (s, 2H), 4.71-4.73 (d, 2H), 3.71 (s, 6H); MS m/z: 510(M+H4). Calculated for C29H27F3N5O4: 509.21 Compound (131): Η NMR DMSO-d6) δ (ppm) 10.64 (s, IH), 8.12-8.24 (m, 2H), 7.86- 7.89 (m, IH), 7.28-7.29 (d, IH), 6.76-7.04 (m, 3H), 6.54-6.55 (d, 2H), 6.39-6.41 (t, IH), 6.00 (s, 2H), 4.70-4.72 (d, 2H), 3.72 (s, 6H); MS m z: 448(M+H4). Calculated for
C23H21F3N5O5: 447.15
Compound (132): Η NMR DMSO-d6) δ (ppm) 10.57 (s, IH), 8.15-8.24 (m, 2H), 7.87- 7,90 (m, IH), 7.35-7,36 (m, IH), 7.06-7.10 (m, IH), 6.94-6.97 (d, IH), 6.76-6.81 (m, IH), 6.54-6.55 (d, 2H), 6.39-6.40 (t, IH), 4.71-4.73 (d, 2H), 3.72-3.77 (m, 12H); MS m/z: 464 (M+H4). Calculated for C24H25F3N5O5: 463.19
Compound (133): Η NMR (DMSO-cQ δ (ppm) 11.05 (s, IH), 8.14-8.26 (m, 2H), 7.89- 7.92 (d, IH), 7.37-7.57 (m, 3H), 7.07-7.10 (d, IH), 6.80-6.88 (m, 2H), 6.54 (s, 2H), 6.40 (s, IH), 3.72 (s, 6H); MS m z: 422 (M+H4). Calculated for C22H20FN5O3: 421.42
Compound (134): Η NMR (OMSO-d6) δ (ppm) 11.25 (s, IH), 8.13-8.27 (m, 2H), 7.72-
7.94 (m, 5H), 6.80-6.82 (m, IH), 6.54-6.55 (d, 2H), 6.40-6.41 (t, IH), 4.71-4.73 (d, 2H), 3.72 (s, 6H); MS m z: 472 (M+H4). Calculated for C23H20F3N5O3: 471.15
Compound (135): Η NMR (DMSO-^) δ (ppm) 10.62 (s, IH), 8.14-8.25 (m, 2H), 7.87- 7.90 (m, IH), 7.52 (s, IH), 7.06-7.35 (m, 3H), 6.76-6.80 (m, IH), 6.54-6.55 (d, 2H), 6.40
(s, IH), 4.70-4.72 (d, 2H), 3.72 (s, 6H), 2.78-2.88 (m, 4H), 1.96-2.06 (m, 2H); MS m/z: 444 (M+H4). Calculated for C25H25F3N5O3: 443.20
Compound (136): Η NMR (OMSO-d6) δ (ppm) 10.29 (s, IH), 8.23-8.25 (m, IH), 8.14- 8.18 (t, IH), 7.88-7.91 (m, IH), 7.07-7.33 (m, 3H), 6.77-6.81 (m, IH), 6.54-6.62 (m, 3H),
6.39 (s, IH), 4.71-4.73 (d, 2H), 3.71-3.76 (d, 9H) ; MS m/z: 420(M+H4). Calculated for C22H21N5O4: 419.16
Compound (137): Η NMR MSO-^) δ (ppm) 8.61 (s, IH), 8.45-8.46 (d, IH), 8.22-8.30 (m, 2H), 7.89-7.91 (m, IH), 7.76-7.79 (m, IH), 7.13-7.36 (m, 4H), 6.72-6.83 (m, IH), 6.59-6.61 (m, IH), 4.82-4.84 (d. 2H), 3.76 (s. 3H); MS m/z: 375(M+H4). Calculated for C20H18N6O2- 374.40
Compound (138): Η NMR (DMSO-cQ δ (ppm) 10.60 (s, IH), 8.10-8.15 (m, IH), 7.88- 7.92 (t, IH), 7.61-7.70 (m, IH), 6.41-7.14 (m, 8H), 5.85 (s, 2H), 4.49-4.51 (d, 2H), 3.62 (s,
3H); MS m/z: 418(M+H4). Calculated for C22H19N5O4: 417.14
Compound (139): Η NMR DMSO-d6) δ (ppm) 10.95 (s, IH), 9.94 (s, IH), 8.42-8.44 (m, IH), 8.06-8.11 (m, IH), 7.62-7.63 (d, IH), 6.91-7.14 (m, 5H), 6.31-6.33 (t, IH), 6.12 (s, 2H), 3.86 (s, 6H); MS m/z: 434 (M+H4). Calculated for C22H19N5O5: 433.14
Compound (140): Η NMR (T>MSO-d6) δ (ppm) 10.89 (s, IH), 10.20 (s, IH), 8.33-8.38 (m, IH), 8.01-8.04 (m, IH), 7.22-7.33 (m, 2H), 7.10-7.22 (m, IH), 7.01-7.09 (m, 3H), 6.62-6.69 (m, IH), 6.21-6.25 (m, IH), 3.78-3.87 (m, 9H); MS m/z: 420 (M+H4) Calculated for C22H21N5O4: 419.43
Compound (141): Η NMR (DMSO- d6) δ (ppm) 10.90 (s, IH), 9.91 (s, IH), 8.38-8.42 (m, IH), 7.98-8.02 (m, IH), 7.57-7.70 (m, IH), 6.94-7.38 (m, 6H), 6.66-6.70 (m, IH), 6.03 (s, 2H), 3.83 (s, 3H); MS m/z: 404 (M+H4). Calculated for C21H17N5O4: 403.13
Compound (142): Η NMR (DMSO-^ δ (ppm) 10.30 (s, IH), 8.23-8.25 (m, IH), 8.14- 8.18 ( t, IH), 7.07-7.33 (m, 3H), 6.62-6.81 (m, IH), 6.40-6.59 (m, 3H), 6.39-6.40 (t, IH), 4.71-4.73 (m, 2H), 3.67-3.76 (m, 9H); MS m/z: 434 (M+H4). Calculated for C23H23N5O4: 433.18
Compound (143): Η NMR (OMSO-d6) δ (ppm) 8.61 (s, IH), 8.45-8.46 (d, IH), 8.23-8.30 (m, 2H), 7.89-7.91 (m, IH), 7.76-7.79 (m, IH), 7.13-7.34 (m, 4H), 6.78-6.82 (m, IH), 6.59-6.61 (d, IH), 4.82-4.84 (d, 2H), 3.76 (s, 3H); MS m/z: 375 (M+H4). Calculated for
C20H18N6O2: 374.15 Compound (144): Η NMR (OMSO-d6) δ (ppm) 8.62 (s, IH), 8.42-8.45 (t, IH), 88.10- 8.23 (m, 2H), 7.76-7.79 (d, IH), 7.60-7.62 (m, IH), 7.23-7.37 (m, 2H), 6.78-6.87 (m, 3H), 6.12-6.18 (m, IH), 4.82-4.84 (d, 2H), 3.78 (s, 6H); MS m/z: 405 (M+H4). Calculated for C21H20N6O3: 404.16
Compound (145): Η NMR OMSO-d6) δ (ppm) 10.76 (s, IH), 8.22-8.25 (m, IH), 8.13- 8.17 (t, IH), 7.87-7.90 (m, IH), 7.06-7.09 (d, IH), 6.77-6.86 (m, 3H), 6.53-6.54 (d, 2H), 6.38-6.40 (t, IH), 6.19-6.21 (t, IH), 4.71-4.73 (d, 2H), 3.68-3.78 (m, 12H); MS m/z: 464 (M+H4). Calculated for C24H25N5O5: 463.19
Compound (146): Η NMR (OMSO-d6) δ (ppm) 10.60 (s, IH), 8.51-8.53 (d, 2H), 8.00- 8.01 (t, IH), 7.62-7.64 (d, IH), 7.24-7.37 9m, 3H), 6.88-6.89 (d, 2H), 6.68-6.78 (m, 2H), 6.20 (s, IH), 4.66-4.68 (d, 2H), 3.76 (s, 3H); MS m/z: 448 (M+H4). Calculated for C23H21N5O5: 447.15
Compound (147): Η NMR DMSO-d6) δ (ppm) 8.62 (s, IH), 8.46-8.47 9d, IH), 8.23-8.29 (m, 2H), 7.68-7.92 (m, 6H), 7.34-7.38 (t, IH), 6.78-6.82 (t, IH), 4.82-4.84 9d, 2H); MS m/z: 413 (M+H4). Calculated for C20H15F3N5O: 412.13
Compound (148): Η NMR (DMSO-^) δ (ppm) 10.69 (br, s, IH), 8.61-8.62 (d, IH), 8.45-
8.47 9m, IH), 8.21-8.28 (m, 2H), 7.86-7.89 (m, IH), 7.76-7.79 (d, IH), 7.31-7.38 (m, 2H), 7.02-7.06 (m, IH), 6.89-6.92 (m, IH), 6.77-6.81 (m, IH), 6.00 (s, 2H), 4.81-4.83 (d, 2H); MS m/z: 389 (M+H4). Calculated for C20H16N6O3 : 388.13
Compound (149): Η NMR (DMSO-d6) δ (ppm) 8.61 (s, IH), 8.45-8.47 (m, IH), 8.21-8.30
9m, 2H), 7.90-7.92 (m, IH), 7.76-7.79 (m, IH), 7.63-7.67 (m, 2H), 7.33-7.40 (m, 3H), 6.96-7.12 (m, 4H), 6.78-6.82 (m, IH), 4.81-4.83 (d, 2H); MS m/z: 437 (M+H4). Calculated for C25H20N6O2: 436.16 . „ Compound (150): Η NMR (DMSO-d6) δ (ppm) 8.62 (s, IH), 8.44-8.46 (m, IH), 8.21- 8.31 (m, 2H), 7.76-7.90 (m, 2H), 7.32-7.40 (m, 2H), 7.06-7.10 (m, IH), 6.93-6.96 (m, IH), 6.77-6.93 (m, IH), 4.81-4.83 (d, 2H), 3.67-3.77 (m, 6H); MS m/z: 405 (M+H4). Calculated for C21H20N6O3: 404.16
Compound (151): Η NMR (methanol-^) δ (ppm) 7,98-8.01 (m, 2H), 6.85-6.98 (m, 5H), 6.55-6.72 (m, 4H), 5.80 (s, 2H), 5.03-5.10 (d, 2H), 4.50 (s, 2H); MS m/z: 419 (M+H4)
Compound (152): Η NMR (DMSO- 5) δ (ppm) 8.60 (s, IH), 8.40-8.44 (m, IH), 8.21-8.29 (m, 2H), 8.05-8.10 (m, IH), 7.80-7.86 (m, IH), 7.08-7.19 (m, 4H), 6.77-6.83(m, IH), 5.50
(s, 2H), 4.80-4.86 (m, 2H); MS m/z: 378 (M+H4)
Compound (153): Η NMR (CDC13) δ (ppm) 8.57-8.60 (d, 2H), 8.10-8.16 (t, IH), 7.84- 7.87 (d, IH), 7.28-7.32 (m, 3H), 7.02-7.04 (m, 5H), 6.76-6.84 (m, IH), 6.58-6.64 (m, IH), 5.32 (s, 2H), 4.82-4.89 (d, 2H); MS m/z: 376 (M+H4)
Compound (154): See Example 9.
Compound (155): Η NMR (DMSO ) 11.00 (s, IH), 9.50 (s, IH), 8.28-8.32 (m, 2H), 7.10-7.28 (m, 5H), 6.92-6.97 (m, IH), 6.47-6.50 (m, IH), 6.17-6.18 (t, IH), 3.747-3.749
(d, 9H); MS m/z: 419 (M+H4). Calculated for C22H22N6O3: 418.18
Compound (156): Η NMR (methanol-^) δ (ppm) 8.25-8.35 (br s, IH), 8.19 (s, IH), 7.41- 7.45 (d, 2H), 6.83-6.96 (m, 5H), 6.16 (s, IH), 3.3-3.80 (m, 9H); MS m/z: 419 (M+H4). Calculated for C22H22N6O3: 418.18
Compound (157): Η NMR (OMSO-d6) δ (ppm) 10.30 (s, IH), 8.32-8.46 (m, 2H), 7.78- 7.93 (m, 4H), 7.00-7.77 (m, 3H), 6.25-6.27 (d, IH, J=0.069), 3.80-3.82 (d, 6H, J=0.033Hz); MS m/z: 414 (M+H4). Calculated for C22HI9N7O2: 413.16 Compound (158): Η NMR (DMSO-fi δ (ppm) 10.50 (s, IH), 9.66 (s, IH), 9.59 (s, IH), 8.14-8.32 (m, 2H), 7.48-7.55 9m, 2H), 7.16 (s, IH), 6.78-7.09 (m, 5H), 6.08 (IH), 3.65 (s, 6H); MS m/z: 389(M+H4). Calculated for C22H21N5O2: 328.14
Compound (159): Η NMR (CDC13) δ (ppm) 10.34 (s, IH), 8,27-8.29 (m, 2H), 7.77-7.78
(d, IH, J=0.03Hz), 7.36 (s, IH), 7.00-7.01 (d, 2H, J=0.03), 6.73-6.82 (m, 2H), 6,45-6.49 (m, IH), 6.14-6.15 (t, IH, J=045Hz), 3.77-3.83 (m, 12H); MS m/z: 449 (M+H4). Calculated for C23H24N6O4: 448.19
Compound (160): Η NMR (CDC13) δ (ppm) 10.56 (s, IH), 8.43-8.50 (m, 2H), 7.45-7.49
(d, 3H), 6.94-6.98 (m, 4H), 6.36-6.38 (m, IH), 3.98-4.03 (t, 6H), 3.19 (br s, 6H); MS m/z: 432 (M+H4). Calculated for C23H25N7O2: 431.21
Compound (161): ΗNMR (CDC13) δ (ppm) 10.19 (s, IH), 8.22-8.24 (m, IH), 8.11 (br s, IH), 6.60-7.39 (m, 10H), 5.91 (s, 2H), 3.81-3.85 (t, 3H); MS m/z: 403 (M+H4).
Calculated for C21H18N6O3: 402.41
Compound (162): Η NMR (CDC13) δ (ppm) 10.07 (s, IH), 8.09-8.16 (m, 2H), 7.31-7.35 (m, IH), 7.22-7.30 (m, 3H), 6.88-6.95 (m, 3H), 6,62-6.75 (m, 3H), 5.84-5.86 (d, 2H), 3.78 (s, 3H); MS m/z: 403 (M+H4). Calculated for C21H18N6O3: 402.41
Compound (163): Η NMR (DMSO-<Q δ (ppm) 10.77 (br s, IH), 10.18 (s, IH), 8.30-8.32 (d, 2H, J=0.06Hz), 7.78 (s, 4H), 7.61-7.62 (d, IH, J=0.021), 1.73-7.16 (t, IH, J=0.028), 6.94-6.97 (m, 2H), 6.06-6.05 (d, 2H, J=0.036); MS m/z: 398 (M+H4). Calculated for C21H15N7O2: 397.13
Compound (164): Η NMR (DMSO- 6) δ (ppm) 10.49 (s, IH), 8.88 (s, IH), 8.25-8.40 (m, 2H), 7,95 (s, IH), 7.64 (s, IH), 6.91-7.13 (m, 4H), 6.49-6.58 (m, IH), 6.03-6.06 (d, 2H), 3.69-3.89 (m, 6H); MS m/z: 433 (M+H4). Calculated for C22H20N6O4: 432.15 Compound (165): Η NMR (methanol-^) δ (ppm) 8.32 (s, IH), 8.09 (s, IH), 7.34 (s, IH), 6.88-7.00 (m, IH), 6.70-6.80 (m, 3H), 6.50-6.70 (m, 2H), 5.90 (d, 2H), 3.71-3.89 (m, 6H); MS m/z: 433 (M+H4). Calculated for C22H20N6O4: 432.15
Compound (166): Η NMR (methanol-^) δ (ppm) 8.09-8.21 (m, 2H), 7.30-7.38 (m, IH),
6.95-6.99 (m, IH), 6.69-6.82 (m, 5H), 6.09 (s, IH), 5.88 (s, 2H), 3.70-3.74 (m, 6H); MS m/z: 433 (M+H4). Calculated for C22H20N6O4: 432.15
Compound (167): Η NMR (DMSO-d6) δ (ppm) 13.28 (s, IH), 11.07 (s, IH), 9.27 (s, IH), 8.23-8.34 (m, 2H), 6.79-7.60 (m, 8H), 6.03 (s, 2H), 2.71 (s, 6H); MS m/z: 416 (M+H4).
Calculated for C22H2,N7O2: 415.18
Compound (168): Η NMR (CDC13) δ (ppm) 10.41 (s, IH), 8.19-8.29 (m, 2H), 7.77-7.80 (m, IH), 7.03-7.04 (d, 3H), 6.72-6.76 (m, IH), 6.51-6.55 (m, 2H), 6.14-6.16 (m, IH), 3.64- 3.90 (m, 12H); MS m/z: 449 (M+H4). Calculated for C23H24N6O4: 448.19
Compound (169): Η NMR (DMSO-^) δ (ppm) 9.64 (s, IH), 9.29 (s, IH), 8.91 (s, IH), 8.14-8.33 (m, 2H), 6.73-7.28 (m, 7H), 6.44-6.56 (m, IH), 6.01 (s, 2H), 4.70 (s, 2H), 3.75- 3.78 (d, 3H, J=0.078Hz); MS m/z: 417 (M+H4). Calculated for C22H20N6O3: 416.16
Compound (170): Η NMR (DMSO-^) δ (ppm) 9.37 (s, IH), 8.91-9.02 (d, IH, J=0.33Hz), 8.15-8.36 (m, 3H), 7.45-7.48 (d, 2H), 6.65-6.98 (m, 6H), 6.02 (s, 2H), 4.69 (s, 2H), 3.76 (s, 3H); MS m z: 417 (M+H ). Calculated for C22H20N6O3' 416.16
Compound (171): Η NMR (OMSO-d6) δ (ppm) 13.78 (s, IH), 9.78 (s, IH), 8.46 (s, IH),
7.90-7.97 (m, 2H), 7.31-7.48 (m, 4H), 6.50-6.83 (m, 4H), 5.83 (s, 2H), 4.43 (s, 2H); MS m/z: 412 (M+H4). Calculated for C22H17N7O2: 411.14
Compound (172): Η NMR (OMSO-d6) δ (ppm) 7.70-7.78 (m, 2H), 7.45 (s, IH), 7.30- 7.35(m, IH), 7.0-7.06 (m, 2H), 6.60-6.68 (m, 2H), 5.61-6.12 (m, 3H), 560-5.65(m, IH), 5.06 (s, 2H), 3.77 (s, 2H), 2.93-3.02 (d, 6H); MS m/z: 447 (M+H4). Calculated for C23H22N6O4: 446.17
Compound (173): Η NMR (methanol-^) δ (ppm) 8.16-8.19 (m, IH), 8.01-8.03 (m, IH), 7.20-7.23 (m, 2H), 6.62-6.84 (m, 6H), 5.87 (s, 2H), 4.58(s, 2H), 2.83-2.86 (m, 6H); MS m/z: 430(M+H4). Calculated for C23H23N7O2: 429.19
Compound (174): Η NMR (methanol-^) δ (ppm) 8.02-8.15 (m, 2H), 6.69-6.81 (m, 2H), 6.60-6.67 (m, 4H), 6.04 (s, IH), 5.45-5.87 (m, 2H), 4.57 (s, 2H), 3.69-3.73 (d, 6H); MS m/z: 447 (M+H4). Calculated for C23H22N6O4: 446.17
Compound (175): Η NMR (DMSO-rf ) δ (ppm) 12.20 (s, IH), 8.04-8.23 (m, 4H), 8.81- 7.90 (m, IH), 6.82-6.97 (d, 3H), 6.67-6.78 (m, 2H), 6.44-6.48 (d, IH, J=0.24Hz), 6.01 (s, 2H), 5.55-4.59 (m, 2H), 3.67-3.88 (m, 6H); MS m/z: 447 (M+H4). Calculated for C23H22N6O4: 446.17
Compound (176): Η NMR (Acetone-d6) δ (ppm) 8.78-8.95 (m, 2H), 8.30-8.60 (m, 2H), 7,95 (s, IH), 7.65-7.70 (m, IH), 7.44-7.48 (m, IH), 7.10-7.38 (m, 3H), 6.91-6.98 (m, IH), 6.55-6.65 (m, IH), 3.90 (s, 3H); MS m/z: 399(M+H4). Calculated for C21HI8N8O: 398.16
Compound (177): Η NMR (methanol-G?,) δ (ppm) 8.51 (s, IH), 8.23-8.50 (m, 2H), 7.91- 7.94 (s, IH), 7.61-7.65 (m, IH), 7.40-7.46 (m, 2H), 6.85-7.08 (m, 4H), 3.65 (s, 3H); MS m/z: 399(M+tr). Calculated for C21H18N8O: 398.16
Compound (178): Η NMR (DMSO- 6) δ (ppm) 14.26 (s, IH), 12.96 (s, IH), 11.24 (s,
IH), 10.17 (s, IH), 8.35-8.72 (m, 3H), 7.58-8.14 (m, 6H), 5.05-7.22 (m, 2H); MS m/z: 394(M+H4). Calculated for C21H15N9: 393.15
Compound (179): Η NMR (methanol-^) δ (ppm) 8.45 (s, IH), 8.35-8.37 (d, IH, J=0.057Hz), 8.23-8.26 (m, IH), 7.88-7.91 (m, 2H), 7.61-7.64 ( , IH), 7.04-7.08 (m, IH), 6.87-6.92 (m, 2H), 5.50-6.54 (m, IH), 3.88(s, 3H), 3.77 (s, 3H); MS m/z: 429 (M+H4).
Calculated for C22H20N8O2: 428.15
Compound (180): Η NMR (methanol-^) δ (ppm) 8.55 (s, IH), 8.32-8.38 (m, IH), 8.23- 8.25 (m, IH), 7.90-7.93 (t, IH), 7.60-7.63 (m, IH), 7.34-7.38 (m, 2H), 7.05-7.08 (m, IH),
6.85-6.90 (m, 3H), 2.87-2.94 (m, 6H); MS m/z: 412 (M+H ). Calculated for C22H21N9: 411.19
Compound (181): Η NMR (methanol-^) δ (ppm) 8.496 (s, IH), 8.33-8.35 (m, IH), 8.22- 8.25 (m, IH), 7.906-7.908 (d, IH), 7.779-7.808 (d, IH), 7.607-7.636 (d, IH), 7.01-7.06 (m,
IH), 6.85-6.89 (m, IH), 6.55-6.65 (m, 2H), 3.81-3.89 (m, 6H); MS m/z: 429 (M+H4). Calculated for C22H20N8O2: 428.17
Compound (182): Η NMR (DMSO- d6) δ (ppm) 8.28 (s, IH), 8.16-8.17 (d, IH), 7.71-7.74 (d, 2H), 7.26-7.32 (t, 2H), 6.96-7.01 (t, IH), 6.76-6.85 (m, 3H), 6.13 (s, IH), 3.69-3.78 (m,
6H); MS m/z: 389 (M+H4). Calculated for C21H20N6O2: 388.16
Compound (183): Η NMR (methanol-^) δ (ppm) 8.36 (s, IH), 8.32-8.33 (m, IH), 7.51 (s, IH), 7.16-7.25 (m, 4H), 7.03-7.07 (m, 1H)„ 6.85-6.90 (m, IH), 6.52-6.60 (m, 2H), 3.78- 3.80 (d, 6H); MS m/z: 389 (M+H4). Calculated for C21H20N6O2: 388.16
Compound (184): Η NMR (DMSO-^) δ (ppm) 13.55 (s, IH), 11.0 (s, IH), 9.6 (s, IH), 8.25-8.44 (m, 2H), 7.00-7.91 (m, 11H ); MS m/z: 329(M+H4). Calculated for C19H16N6: 328.14
Compound (185): Η NMR (DMSO-c δ (ppm) 8.34 (s, IH), 7.89 (s, IH), 6.96-7.40 (m, 9H), 6.60 (s, IH), 3.74-3.80(m, 3H); MS m/z: 359(M+H4). Calculated for C20H18N6O: -358.15 Compound (186): Η NMR (DMSO- 6) δ (ppm) 8.13 (s, IH), 6.65-6.88 (m, 4H), 6.51 (s, 2H), 6.35 (s, 2H), 6.05 (s, IH), 4.75 (s, 2H), 3,75 (m, 12H); MS m/z: 463(M+H4). Calculated for C24H26N6O4: 462.20
Compound (187): Η NMR (DMSO-^) δ (ppm) 13.35 (s, IH), 9.45(s, IH), 8.12 (s, 2H),
7.06-7.25 (m, 2H), 6.70-6.74 (m, IH), 6.37-6.51 (m, 4H), 4.70-4.72 (d, 2H), 3.62-3.72 (m, 9H); MS m/z: 433 (M+H4). Calculated for C23H24N6O3: 432.19
Compound (188): Η NMR (DMSO-d6) δ (ppm) 13.25 (s, IH), 9.32 (s, IH), 8.92-8.99 (d, IH), 8.08-8.39 (m, 2H), 7.40-7.45 (m, 2H), 6.38 -6.86 (m, 6H), 4.66-4.73 (m, 2H), 3.68-
3.71 (m, 9H); MS m/z: 433 (M+H4). Calculated for C23H24N6O3: 432.19
Compound (189): Η NMR (OMSO-d6) δ (ppm) 12.17 (s, IH), 8.09-8.66 (m, 4H), 7.85- 7.98 (m, IH), 6.27-6.70 (m, 6H), 4.67-4,70 (m, 2H), 3.65-3.90 (m, 12H); MS m/z: 463 (M+H4). Calculated for C24H26N6O4: 462.20
Compound (190): Η NMR DMSO-d6) δ (ppm) 11.76 (s, IH), 10.02 (s, IH), 8.74 (s, IH), 8.14-8.18 (m, 2H), 7.61 (m, 4H), 6.72-6.77 (m, IH), 6.38-6.52 (m, 3H), 4.70-4.71 (d, 2H), 3.70 (s, 6H); MS m/z: 428 (M+H4). Calculated for C23H21N7O2: 427.18
Compound (191): Η NMR (DMSO- fi) δ (ppm) 8.72 (s, IH), 8.25-8.28 (m, 2H), 8.09-8.16 (m, IH), 7.99-8.00 (d, IH), 7.79-7.80 (t, IH), 6.87-6.96 (m, IH), 6.70-6.75 (m, IH), 6.35- 6.52 (m, 4H), 4.69-4.71 (d, 2H), 3.69-3.83 (m, 12H); MS m/z: 463 (M+H4). Calculated for C24H26N6O4: 462.20
Compound (192): Η NMR (DMSO- d6) δ (ppm) 9.11 (s, IH), 8.42 (s, IH), 8.10-8.20 (d, 2H), 7.31-7.434 (d, 2H), 6.38-6.67 (m, 6H), 4.69 (s, 2H), 3.69 (s, 6H), 2.81 (s, 6H); MS m/z: 446 (M+H4). Calculated for C24H27N7O2: 445.22 Compound (193): Η NMR (DMSO- d6) δ (ppm) 8.58 (s, IH), 8.42-8.45 (m, IH), 8.10-8.25 (m, 2H), 7.67-7.75 (m, IH), 7.30-7.40 (m, 2H), 6.70-6.82 (m, 2H), 6.00-6.05 (d, IH), 4.76- 4.84 (d, 2H), 3.70-3.75 (m, 6H) ; MS m/z: 404 (M+H4). Calculated for C21H21N7O2: 403.18
Compound (194): Η NMR (methanol-d,) δ (ppm) 8.45 (s, IH), 8.26-8.28 (m, IH), 8.07- 8.08 (m, IH), 7.93-7.95 (m, IH), 7.72-7.74 (d, IH), 7.21-7.26 (m, IH), 6.99-7.08 (m, 2H), 6.83-6.86 (m, IH), 6.56-6.61 (m, IH), 6.37-6.40 (m, IH), 4.69 9s, 2H), 3.65 (s, 3H); MS m/z: 374 (M+H4). Calculated for C20H18N7O: 373.18
Compound (195): Η NMR (DMSO-^) δ (ppm) 9.19 (s, IH), 8.60-8.61 (d, IH), 8.43-8.48 (m, IH), 8.12-8.20 (m, 2H), 7.74-7.77 (m, IH), 7.33-7.44 (m, 3H), 6.70-6.85 (m, 3H) 4.77- 4.79 (d, 2H), 3.71 (s, 3H); MS m/z: 374 (M+H4). Calculated for C20Hι8N7O: 373.18
Compound (196): Η NMR (DMSO- 6) δ (ppm) 8.59 (s, IH), 8.44-8.46 (m, 2H), 8.21 (br, s, IH), 8.09-8.10 (m, IH), 7.85-7.88 (m, IH), 7.73-7.88 9m, IH), 7.31-7.36 (m, IH), 6.63- 6.73 (m, 2H), 6.44-6.69 (m, IH), 4.76-4.78 (m, 2H), 3.67-3.84 (m, 6H); MS m/z: 404 (M+H4). Calculated for C21H21N7O2: 403.18
Compound (197): Η NMR (DMSO- 6) δ (ppm) 8.10-8.12 (m, 2H), 7.93-7.94 (m, 2H),
7.71-7.74 (m, IH), 7.30-7.36 (m, IH), 6.92-6.95 (m, IH), 6.71-6.76 (m, IH), 6.43-6.47 (m, IH), 4,78-4.80 (d, 2H), 3.71-3.83 (m, 6H); MS m/z: 404 (M+H4). Calculated for C21H21N7O2: 403.18
Compound (198): Η NMR (DMSO-^) δ (ppm) 10.06 (s, IH), 8.77-8.79 (d, IH), 8.45-
8.47 (m, IH), 8.17-8.26 (m, 2H), 7.66-7.84 (m, 5H), 7.32-7.37 (m, IH), 6.74-6.79 (m, IH), 4.79-4.81 (d, 2H); MS m/z: 369 (M+H4). Calculated for C20H16N8: 368.15 Compound (199): Η NMR (DMSO-d6) δ (ppm) 9.02 (s, IH), 8.60-8.61 (d, IH), 8.46-8.47 (m, IH), 8.10-8.19 (m, 2H), 7.74-7.77 (d, IH), 7.30-7.37 (m, 3H), 6.66-6.74 (m, 3H), 4.77- 4.79 (d, 2H), 2.82 (s, 6H); MS m/z: 387 (M+H4). Calculated for C21H22N8: 386.20
Compound (200): Η NMR (DMSO-c δ (ppm) 10.89 (s, IH), 10.20 (s, IH), 8.33-8.38
(m, IH), 8.01-8.04 (m, IH), 7.22-7.33 (m, 2H), 7.10-7.22 (m, IH), 7.01-7.09 (m, 3H), 6.62-6.69 (m, IH), 6.21-6.25 (m, IH), 3.78-3.87 (m, 9H); MS m/z: 420 (M+H4) Calculated for C22H21N5O4: 419.43
Compound (201): Η NMR (methanol-d,) δ (ppm) 8.40-8.45 (m, 2H), 7.74-7.80 (m, IH),
7.42-7.45 (d, 2H), 7.08-7.35 (m, 3H), 6.94-6.98 (m, 3H), 6.95-6.98 (m, IH), 4.59 (s, 2H), 3.75 (s, 3H); MS m/z: 373 (M+H4). Calculated for C21H20N6O: 372.17
Compound (202): Η NMR (DMSO- 5) δ (ppm) 8.55-9.35 (m, 3H), 7.80-8.20 (m, 2H), 7.20-7.55 (m, 5H), 6.61-6.96 (m, 4H), 4.79 (s, 2H), 3.80 (s, 3H); MS m/z: 373 (M+H4).
Calculated for C21H20N6O: 372.17
Compound (203): Η NMR (DMSO-c δ (ppm) 11.39 (s, IH), 8.00-8.57 (m, 3H), 7.68- 7.98 (m, 6H), 7.36-7.41 (m, 3H), 6.74-6.83 (m, 2H), 4.70-4.72 (d, 2H); MS m/z: 369 (M+H4). Calculated for C21H17N7: 367.15
Compound (204): Η NMR (DMSO-cQ δ (ppm) 10.69 (s, IH), 7.75 (s, IH ), 7.60-7.62 (d, IH), 7.23-7.32 (m, 5H), 7.11-7.13 (d, IH), 6.92-6.95 (d, 2H), 6.82-6.85 (d, IH), 6.71-6.76 (t, IH), 6.58-6.61 (d, IH), 4.46-4.48 (d, 2H), 3.74-3.76 (d, 6H); MS m/z: 403 (M+H4). Calculated for C23H22N4O3: 402.17
Compound (205): Η NMR (DMSO- 6) δ (ppm) 10.71 (s, IH), 7.82-7.88 (t, IH), 7.60-7.65 (m, IH), 7.10-7.46 (m, 8H), 6.70-6.85 (m, 2H), 6.55-6.62 (m, IH), 5.54-4.58 (m, 2H), 3.78 (s, 3H); MS m/z: 391 (M+H4). Calculated for C22H19FN4O2: 390.15 Compound (206): Η NMR (OMSO-d6) δ (ppm) 7.91-7.94 (t, IH), 7.60-7.62 (d, IH), 7.10-7.41 (m, 8H), 6,67-6.77 (m, 2H), 6.55-6.58 (m, IH), 4.57-4.59 (m, IH), 4,57-4.59 (d, 2H), 3.76 (s, 3H); MS m z: 407 (M+H4). Calculated for C22H19ClN4O2: 406.12
Compound (207): !H NMR (OMSO-d6) δ (ppm) 8.24-8.26 (m, IH), 8.08-8.12 (t, IH),
7.86-7.89 (m, IH), 6.77-7.00 (m, 6H), 6.19-6.20 (t, IH), 6.00 (s, 2H), 3.74 (s, 6H); MS m/z: 404 (M+H4). Calculated for C22H21N5O3: 403.16
Compound (208): MS m/z: 380 (M+H )
Compound (209): Η NMR (CDC13) δ (ppm) 8.32-8.40 (m, 2H), 7.10-7.26 (m, 2H), 6,70- 6.89 (m, 3H), 4.09-4.12 (m, 2H), 3.83 (s, 3H), 3.10-3.17 (m, 4H), 2.54-2.60 (m, 4H), 2.27 (s, 3H); MS m/z: 365 (M+H4)
Compound (210): MS m/z: 395 (M+H4)
Compound (211): Η NMR (OMSO-d6) δ (ppm) 10.63 (s, IH), 7.54-7.55 (d, IH), 7.12- 7.52 (m, 4H), 6.87-6.90 (d, IH), 6.59-6.70 (m, 4H), 3.77 (s, 3H); MS m/z: 283 (M+H ). Calculated for C15Hι4N402: 282.11
Compound (212): Η NMR (methanol-^) δ (ppm) 7.83-7.84 (d, IH), 7.70-7.73 (d, IH), 7.12-7.18 (m, IH), 6.81-6.88 (m, 2H), 6.70-6.73 (m, IH), 6.41-6.45 (m, IH), 3.77-3.87 (d, 6H); MS m/z: 312 (M+H4). Calculated for C16H17N5O2: 311.14
Compound (213): Η NMR (methanol- 4) δ (ppm) 7.71-7.74 (d, IH), 7.30-7.33 (d, 2H),
7.09-7.15 (m, IH), 6.79-6.84 (m, 3H), 6.66-6.71 (m, IH), 2.83-2.85 (d, 6H); MS m/z: 295 (M+H ). Calculated for C16H18N6: 294.16 Compound (214): Η NMR (methanol-^) δ (ppm) 8.28-8.29 (m, IH), 8.10-8.12 (m, IH), 7.84-7.97 (m, 2H), 7.95-7.05 (m, 3H), 3.74-3.79 (m, 4H), 2.52-2.54 (m, 4H), 2.24 (s, 3H); MS m/z: 351 (M+H4)
Compound (215): Η NMR (methanol-c δ (ppm) 8.15-8.22 (m, 3H), 7.82-7.90 (m, IH),
7.50-7.63 (m, 3H), 6.90-6.94 (m, IH), 3.25-3.45 (m, 4H), 2.43-2.48 (m, 4H), 2.15-2.20 (m, 3H); MS m/z: 389(M+H4)
Compound (216): Η NMR (CDC13) δ (ppm) 8.33-8.36 (m, IH), 8.06-8.09 (m, IH), 7.71- 7.74 (m, IH), 7.63 (s, IH), 6.83-6.89 (m, 2H), 6.03 (s, 2H), 3.28-3.32 (m, 4H), 2.46-2.50
(m, 4H), 2.34 (s, 3H); MS m/z: 365 (M+H4)
2-[5-(3-1rifluoromethylphenyl)-lH-imidazol-2-yl]aniline (2l7): See Example 13.
2-(5-(3-Trifluoromethoxyphenyl)-lH- 1.2.41-triazol-3-yl)aniline (218): MS m/z: 321
(M+H4) 2.65g (49%). This material was recrystallised from methanol/water.
2-(5-(2-Chlorophenyl)-lH-[1.2.41-triazol-3-yl)aniline (219): MS m/z: 272 (M+H4) 0.965g (21%). This material was recrystallised from ethanol/water.
2-(5-(3-Methoxyphenyl)-lH-[l .2.4]-triazol-3-yl)aniline (220): MS m/z: 267 (M+H4) 1.2g (28%). This material was recrystallised from methanol.
2-(5-(4-bromophenyl)-lH-[l .2.4]-triazol-3-yl)aniline (221): MS m/z: 316 (M+H4) 1.08g (24%). This material was recrystallised from methanol.
2-(5-(3-bromophenyl)-lH-[1.2.4]-triazol-3-yl)aniline (222): MS m/z: 316 (M+H4) - 1.97g (37%). This material was recrystallised from methanol. 2-(5-(4-Trifluoromethoxyphenyl)-lH-[ 1.2.41-triazol-3-yl)aniline (224): MS m/z: 321 (M+H4); 1.15g (25%). This material was recrystallised from ethanol/water.
2-(5-(4-Trifluoromethylphenyl)-lH-ri.2.41-triazol-3-yl)aniline (225): MS m/z: 305 (M+H+); 1. Ig (37%). This material was recrystallised from methanol.
2-(5-(3-Trifluoromethylρhenyl)- lH-[ 1.2.41-triazol-3-yl)aniline (226): MS m z: 305 (M+H ); l.lg (30%). This material was recrystallised from methanol.
Example 19
Homogeneous Time-Resolved Fluorescence (HTRF) Assay for VEGFR-2 (KDR) Kinase Inhibition
Representative compounds of the invention were tested for their inhibition of VEGFR (KDR) tyrosine kinase. The percent inhibition and IC50 values of selected compounds were determined. These results are summarized in Table 5.
Table 5
KDR Enzymatic Assay Cmpd. No. % Inhibition IC50 (μM)
1 91
2 67
3 85
4 69
5 27
6 41
7 18
8 34
9 60
11 71
12 55
13 34
14 26 Cmpd. No. % Inhibition IC50(μM)
15 83
16 90
17 19
18 70
19 77 4
20 52
21 8
22 61 3.6
23 75 2.3
10 24 70 1.3
25 74 1.8
26 86
27 72 0.52
28 69 2.3
15 34 66
42 66
50 31
51 48 15
52 53 11
20 53 52 11
54 20
55 64 4.5
56 50
58 40
25 60 69 4.1
61 4.1
62 79 1.8
64 10
76 62
30 77 40
78 7
79 17
87 18
88 39
35 89 67
90 78
91 71
93 26
102 65 Cmpd. No. % Inhibition IC50 (μM)
117 10
118 81
119 11
120 3
121 6
125 12
126 12
127 6
128 4
10 129 8
130 4
132 8
133 5
134 5
15 135 5
136 3
137 24
138 43
139 7
20 140 4
141 9
142 3
143 24
144 25
25 145 3
146 85
147 0.27
148 30
149 33
30 150 245
151 90
152 8
155 19
156 39
35 157 18
159 25
160 28
161 42
162 11
40 163 14 Cmpd. No. % Inhibition ICso (μM)
164 51
165 51
166 72
167 47.5
168 46
169 55
170 63
171 55
172 61
10 173 58
174 59
175 72
176 82
178 35
15 179 70
180 84
181 84
182 9
183 29
20 185 73
186 18
187 12
188 18
189 41
25 190 14
191 41
192 23
193 79
194 81
30 195 85
196 81
200 -2
201 74
202 81
35 203 42
204 14
208 - 2 •
212 54
216 20
40 VEGFR tyrosine kinase inhibition is determined by measuring the phosphorylation level of poly-Glu-Ala-Tyr-biotin (pGAT-biotin) peptide in a Homogeneous Time- Resolved Fluorescence (HTRF) assay. Into a black 96-well Costar plate is added 2 μl/well of 25x compound in 100% DMSO (final compound concentration in the 50-μl kinase reaction is typically 1 nM to 10 μM). Next, 38 μl of reaction buffer (25 mM Hepes pH 7.5, 5 mM MgC12, 5 mM MnC12, 2 mM DTT, 1 mg/ml BSA) containing 0.5 pmoles polyGAT-biotin and 3-4 ng KDR enzyme is added to each well. After 5-10 min preincubation, the kinase reaction is initiated by the addition of 10 μl of 10 μM ATP in reaction buffer, after which the plate is incubated at room temperature for 45 min. The reaction is stopped by the addition of 50 μl of KF buffer (50 mM Hepes pH 7.5, 0.5 M KF,
1 mg/ml BSA) containing 100 mM EDTA and 0.36 μg/ml PY20K (Eu-cryptate labeled anti-phosphotyrosine antibody, CIS bio international). After 30 min, 100 μl of 5 nM SV- XL (modified- APC-labeled Streptavidin, CIS bio international) in KF buffer is added, and after an addition 2-hr incubation at room temperature, the plate is read in a RUBYstar HTRF Reader.
Example 20 Cell-based assay for VEGFR-2 (KDR) Kinase Inhibition Representative compounds of the invention were tested using the ELISA Cell-based assay for KDR inhibition. The results are reported in Table 6.
Table 6
Cell-Based Phosphorylation
Cmpd. No. % Inhibition IC50 (μM)
1 7 788 14
2 34
3 38
4 50 30
5 10
6 30
7 58 30
9 47 Cmpd. No. % Inhibition IC50(μM)
10 36
11 0
12 70 5
13 63 30
14 15
15 75 10
16 91 10
17 76 30
18 77 1
10 76 53 10
77 15
78 0
156 70
157 57
15 159 67
161 68
164 69 20
165 60
166 68
20 167 62
168 71
169 63
170 67
171 67
25 172 70 4.7
173 68
174 68 5.6
175 64
176 66 2.6
30 179 68
180 59
181 66 1.1
201 64
202 60
35 203 19
205 9
207 193
212 65 Transfection of 293 cells with DNA expressing FGFR1/KDR chimera: DNA for transfection was diluted to a final concentration of 5 μg/ml DNA in 1XBBS, 125 mM CaCl2 and incubated at room temperature for 30 min. 293 cells were seeded in 15 cm tissue culture plates using 2 xlO7 cells per plate and incubated for 4 hrs, followed by dropwise addition of 3 ml of DNA solution. The plates were incubated overnight.
The next morning, the cells were trypsinized, collected by centrifugation, resuspended (4 x 105 cell/ml), divided into wells of 48 well tissue culture plates (1 ml/well) and incubated overnight. Compounds of the invention were added to individual wells to a final concentration of 10-30 μM and incubated for 2 hours. Generally, 10 mM stock solution were diluted 1/300-1/1000, yielding a final DMSO concentration of
0.1-0.3%. Cells were lysed by resuspension in Lysis buffer (150 mM NaCI, 50 mM Hepes pH 7.5, 0.5% Trition X-100, 10 mM NaPPi, 50 mM NaF, 1 mM NajVOJ and rocked for lh at 4°C. Cells were lysed by adding in 100 μl lysis buffer per well.
ELISA for Detection of Tyrosine-phosphorylated Chimeric Receptor: 96 well ELISA plates were coated using 100 μl/well of 10 μg/ml αFGFRl, and incubated overnight at 4°C. αFGFRl is prepared in a buffer made with 16 ml 0.2M Na2CO3 and 34 ml 0.2M NaHCO3 and the pH adjusted to 9.6. Concurrent with lysis of the transfected cells, αFGFRl coated ELISA plates are washed three times with PBS+0.1% Tween-20, blocked by addition of 200 μl/well of 3% BSA in PBS and incubated for lh. Blocking solution is removed from the wells. 80 μl of lysate is then transferred to the coated and blocked wells and incubated for lh at 4°C. The plates are washed three times with PBS+0.1% Tween-20.
To detect bound phosphorylated chimeric receptor, 100 μl of anti-phosphotyrosine antibodies (RC20:HRPO, Transduction Laboratories) were added per well (final concentration 0.5 μg/ml in PBS) and incubated for lh. The plates were washed six times with PBS+0.1% Tween-20. Enzymatic activity of HRP was detected by adding 50 μl/well of equal amounts of the Kirkegaard & Perry Laboratories (KPL) Substrate A and Substrate B. (KPL cat. #54-61-0). The reaction was stopped by the addition of 50 μl/well 0. IN H2SO4 and absorbance is detected at 450nm The above examples are intended to be illustrative only, hi particular, the invention is not intended to be limited to the methods, protocols, conditions and the like specifically recited herein, insofar as those skilled in the art would be able to substitute other conditions, methods, amounts, materials, etc. based on the present disclosure to arrive at compounds within the scope of this disclosure. While the present invention is described with respect to particular examples and preferred embodiments, the present invention is not limited to these examples and embodiments. In particular, the compounds of the present invention are not limited to the exemplary species' recited herein. Moreover, the methods of the present invention are not limited to treating only the exemplified diseases and conditions, but rather any disease or condition that may be treated by regulation of kinases. Additionally, the methods of synthesis of the present invention are not limited to the methods exemplified in the example. The methods of the present invention include methods of making any of the compounds set forth in the present invention that those skilled would be able to make in view of the present disclosure, and are not limited to the exemplified method. For example, methods encompassed by the present invention may involve the use of a different starting material depending on the desired final compound, different amounts of various ingredients, or substitution of different ingredients such as other reactants or catalysts that would be suitable depending on the starting material and result to be achieved.

Claims

What is claimed is:
A compound of Formula (I):
R,
Figure imgf000119_0001
wherein :
Xj and X2 are atoms or radicals independently selected from the group consisting of oxygen, sulfur, nifrogen, radicals of formula C-R3 and radicals of formula N-R3, with the proviso that at least one of Xt and X2 is oxygen, sulfur, nifrogen or a diradical of formula N-R3, wherein:
R3 is an atom or radical selected from the group consisting of:
1) hydrogen,
2) halogen,
3) alkyl, optionally substituted with one or more substituents selected from R4;
4) alkenyl, optionally substituted with one or more substituents selected from R4;
5) alkynyl, optionally substituted with one or more substituents selected from R4; wherein R4 is an atom or radical selected from the group consisting of: a) halogen; b) alkyl, which may be optionally substituted with one or. more halogen, hydroxy or lower alkoxy; c) alkenyl, which may be optionally substituted with one or more halogen, hydroxy or lower alkoxy; d) nitro; e) cyano; f) oxo; g) vinyl; h) styryl; i) a group of formula -C(O)R5, -CO2R5, -OR5, -SR5, -SOR5, -
SO2R5, -NR5R6, -NCO2R5, or -OCO2R5 where R5 and R6 are atoms or radicals independently selected from the group consisting of hydrogen, lower alkyl, aralkyl, aryl and heteroaryl;
X3 is selected from the group consisting of oxygen, sulfur, nifrogen and diradicals of formula N-R3,
Yj and Y2 are atoms independently selected from the group consisting of nitrogen and carbon,
Rt is a radical selected from the group consisting of:
Figure imgf000120_0001
wherein Wj is nitrogen or C-R^, W2 is nifrogen or C-R^, W3 is nifrogen or C-Rw3, W4 is nifrogen or C-R^, W5 is nitrogen or C-Rw5, W6 is nifrogen or C-R^, W7 is nifrogen or C-R^, Wj is nifrogen or C-R^ and W9 is nitrogen or C-R^ , each Rwj, ^, Rw3, Rw4, R^, R^, R^, Rw8 and Rw9 being an atom or radical independently selected from the group consisting of:
1) hydrogen,
2) halogen,
3) nitro, 4) cyano,
5) alkyl, optionally substituted with one or more substituents selected from R4,
6) alkenyl, optionally substituted with one or more substituents selected from R4,
7) alkynyl, optionally substituted with one or more substituents selected from R4,
8) aralkyl, optionally substituted with one or more substituents selected
Figure imgf000121_0001
9) phenyl, optionally substituted with 1 to 5 substituents selected from R4,
10) a group of the formula -CO2R5, -COR5, -OR5, -SR5, -SOR5, -SO2R6, -NR5R6,
11) pyridyl, optionally substituted with 1 to 4 substituents selected from R4,
12) pyrazinyl, optionally substituted with 1 to 3 substituents selected
Figure imgf000121_0002
13) pyrimidinyl, optionally substituted with 1 to 3 substituents selected from R4,
14) indazolyl, optionally substituted with 1 to 5 substituents selected
Figure imgf000121_0003
15) tetrazolyl, and
14) heterocyclic radicals of formulae :
(RA
Figure imgf000121_0004
wherein X4 is O, S, or N-R4, a is 0 to 3, b is 0 to 2, c is O or 1, or together, one or more of the combinations R^ and Rw2, Rw2 and R^, Rw3 and R^, R^ and R^, R^ and R^, Rw7 and R^, and R^ and R^ form a fused 5- or 6- membered carbocyclic ring or heterocyclic ring having one or two heteroatoms selected from nitrogen, oxygen and sulfur, Z is selected from the group consisting of oxygen, sulfur, -S(O)-, -S(O)2-, - CR5R6-, -CR5R6O-, CR5R6NR3- and -NR3- R2 is a radical of formula -OR7a, -SR7a, -S(O)R7a, -CR5R6R7a, -CR5R6-OR7a wherein R7a is a radical selected from the group consisting of:
1) -CH2-R8,
2) -CH2CH2-R8,
3) -CH2CH2CH2-R8, and
4) -R8, wherein R8 is a cyclic radical selected from the group consisting of: a) aromatic carbocyclic radicals, optionally substituted with 1 to 5 substituents wherein the substituents are selected from R4 or two adjacent substituents can form a 5, 6 or 7 membered fused carbocyclic or heterocyclic ring optionally substituted with one or more substituents selected from R4, and b) aromatic and non-aromatic heterocyclicyl radicals, optionally substituted with 1 to 5 substituents wherein the substituents are either selected from R4 or two adjacent substituents can form a 5, 6 or 7 membered fused carbocyclic or heterocyclic ring optionally substituted with one or more substituents selected from R4, or
R2 is a radical selected from the group
Figure imgf000122_0001
and -NR7aR7b and:
R7a and R^ are both hydrogen,
R7a and R^ together form a 6 membered ring heterocycle, optionally substituted with one or more substituents selected from the group R4, or Rrt, is hydrogen or a radical selected from R4 and R7a is a radical selected from the group consisting of:
1) -CH2-R8,
2) -CH2CH2-R8,
3) -CH2CH2CH2-R8, and
4) -R8, wherein R8 is a cyclic radical selected from the group consisting of: a) aromatic carbocyclic radicals, optionally substituted with 1 to 5 substituents wherein the substituents are selected from R4 or two adjacent substituents can form a 5, 6 or 7 membered fused carbocyclic or heterocyclic ring optionally substituted with one or more substituents selected from R4, and b) aromatic and non-aromatic heterocyclicyl radicals, optionally substituted with 1 to 5 substituents wherein the substituents are either selected from R4 or two adjacent substituents can form a 5, 6 or 7 membered fused carbocyclic or heterocyclic ring optionally substituted with one or more substituents selected from R4.
2. The compound of claim 1 wherein R2 is a radical of formula -NH-R8, -NHCH2-R8, - NHCH2CH2-R8 or -NHCH2CH2CH2-R8, wherein R8 is selected from the group consisting of optionally substituted phenyl radicals, optionally substituted bicyclic aromatic carbocyclic radicals, optionally substituted polycyclic aromatic carbocyclic radicals, optionally substituted monocyclic aromatic heterocyclic radicals, optionally substituted bicyclic aromatic heterocyclic radicals and optionally substituted polycyclic aromatic heterocyclic radicals.
3. The compound of claim 2 wherein R8 is selected from the group consisting of phenyl, optionally substituted with 1 to 5 substituents selected from R4; pyridinyl, optionally substituted with 1 to 4 substituents selected from R4; pyrazinyl, optionally substituted with 1 to 3 substituents selected from R4; pyrimidinyl, optionally substituted with 1 to 3 substituents selected from R4; indazolyl, optionally substituted with 1 to 5 subsitutents selected from R4; tetrazolyl; and aromatic heterocyclic radicals of formula:
(R4)a
Figure imgf000124_0001
wherein X, R4 and a-c are as previously defined.
4. The compound of claim 1 having the Formula (la):
Figure imgf000124_0002
wherein Wj, W2, W3, W4, Rl5 R2 and R3 are as previously defined.
5. The compound of claim 4 having the Formula (la'):
Figure imgf000124_0003
wherein Wl5 W6, R^, R^, R^, and R7a are as previously defined. The compound of claim 4 having the Formula (la"):
Figure imgf000125_0001
Wj, R^, R^, R^, RW8, ^, R7a, R-Tb and Z are as previously defined.
7. A process comprising: a) providing a hydrazide having a formula selected from the group consisting of
Figure imgf000125_0002
or salt thereof, b) providing a complementary amidine having a formula selected from the group consisting of
Figure imgf000126_0001
or salt thereof, wherein Rl9 R2, R3, Wl5 W2, W3 and W4 are as defined in claim 1, c) contacting the hydrazide and the amidine for a period of time sufficient to substantially convert at least one of the hydrazide and amidine to a compound of Formula (la):
Figure imgf000126_0002
and d) isolating the compound.
8. The process of claim 7 wherein the hydrazide is of Formula (H) and the amidine is of Formula (HI) .
9. The process of claim 7 wherein the hydrazide is of Formula (IV) and the amidine is of Formula (V).
10. The process of claim 7 wherein providing the amidine comprises: a) contacting a nitrile with a lower alcohol under acidic conditions to form an imidate or salt thereof, and b) contacting the imidate or salt thereof with ammonia to form the amidine.
11. The process of claim 7 wherein providing the hydrazide comprises: a) contacting a carboxylic acid ester selected from the group consisting of unsubstituted or aryl substituted orthoamino benzene carboxylic acid esters and unsubstituted or aryl substituted (2-amino)-3 -pyridinyl carboxylic acid esters, with an aldehyde to form an imine, b) reducing the imine to a second carboxylic acid ester selected from the group consisting of optionally aryl substituted, N substituted 2-amino benzene carboxylic acid esters and N substituted 3 -pyridinyl carboxylic acid esters. c) and converting the second carboxylic acid ester to the hydrazide with hydrazine.
12. The compound of claim 1 having the Formula (lb):
Figure imgf000127_0001
wherein Rl5 R2, Wl5 W2, W3 and W4 are as previously defined.
13. The compound of claim 12 having the Formula (lb'):
Figure imgf000128_0001
wherein Wl5 W2, W3, W4, R^, Rw6, Rw7, R^, R^, R7a and R^ are as previously defined.
14. A process comprising: a) providing a hydrazide of Formula (H) :
Figure imgf000128_0002
wherein R2 is a radical of formula -NR^R^,
b) providing an isothiocyanate of Formula (VI):
Figure imgf000128_0003
c) contacting the hydrazide and isothiocyanate for a period of time sufficient to substantially convert at least one of the hydrazide and isothiocyanate to an intermediate compound, and d) contacting the intermediate compound with a coupling agent to convert it into a 1,3,4-oxadiazole of Formula (lb'):
Figure imgf000129_0001
defined in claim 13.
15. The compound of claim 1 having the Formula (lc):
Figure imgf000129_0002
wherein:
1) Xj is nitrogen and X2 is C-R3, or
2) Xj is C-R3 and X2 is nitrogen, and
Rj, R2, W1( W2, W3 and W4 are as previously defined.
16. The compound of claim 1 having the Formula (lc'):
Figure imgf000130_0001
R^, R^ and R^ are as previously defined.
17. The compound of claim 1 having the Formula (Id):
wherein:
1) Xj is nitrogen and X2 is -CR3, or
2) Xj is -CR3 and X2 is nitrogen, and
R1? R2, R3, Wl9 W2, W3 and W4 are as previously defined.
18. A process comprising: a) providing an α-halo carbonyl compound having a formula selected from the group consisting of:
Figure imgf000130_0003
b) providing a complementary amidine having a formula selected from the group consisting of:
Figure imgf000131_0001
c) contacting the α-halo carbonyl compound and the amidine for a period of time sufficient to substantially convert at least one of the hydrazide and amidine to a compound of Formula (Id):
Figure imgf000131_0002
and d) isolating the compound, wherein R R2, Xl5 X2 Wl5 W2, W3 and W4 are as defined in claim 17 and hal is bromine or iodine.
19. The compound of claim 17 having the Formula (Id'):
Figure imgf000131_0003
wherein R3, Rw5, Rv/6 and R^ are as previously defined.
0. A process comprising: a) providing an α-halo carbonyl compound of Formula (HT):
Figure imgf000132_0001
b) providing an amidine of Formula (IX'):
Figure imgf000132_0002
c) contacting the α-halo carbonyl compound and the amidine for a period of time sufficient to substantially convert at least one of the hydrazide and amidine to a 2-(2-nifrophenyl)-4-aryl imidazole, and d) reducing the 2-(2-nitrophenyl)-4-aryl imidazole compound to a compound of Formula (Id'):
Figure imgf000132_0003
wherein R3, Rw5, Rw6 and R^ are as defined in claim 19 and hal is bromine or iodine.
21. The compound of claim 1 in a condensed state.
22. The compound of claim 21 wherein the condensed state is a solid.
23. The compound of claim 22 wherein the solid is amorphous.
24. The compound of claim 22 wherein the solid is crystalline.
25. The compound of claim 24 wherein the crystalline solid state is a solvate of the compound and a solvent.
26. The compound of claim 25 wherein the solvent is water.
27. The compound of claim 21 wherein the condensed state is a salt of the compound.
28. The compound of claim 1 that is a solute in a liquid.
29. The compound of claim 28 wherein the liquid is a body fluid of a mammal selected from the group consisting of blood, bile and gastric fluid.
30. The compound of claim 1 in at least 98% purity by weight.
31. A mixture of two or more compounds of claim 30.
32. A pharmaceutical composition made by a process comprising contacting a pharmaceutical carrier and a compound of claim 30.
33. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutical carrier.
34. A pharmaceutical dosage form comprising the pharmaceutical composition of claim 33.
35. The pharmaceutical dosage form of claim 34 that is selected from the group consisting of tablets, capsules, troches, lozenges and soft gelatin capsules.
36. A method of influencing the progression of an angiogenic dependent disease in a mammal comprising administering to the mammal an effective anti-angiogenic amount of a compound of Formula (I) as defined in claim 1.
37. The method of claim 36 wherein the influence is mediated by restriction of the blood supply to diseased cells.
38. The method of claim 37 wherein the influence on the progression of the angiogenic dependent disease is arrest of neovascularization leading to the eradication of the disease from the mammal.
39. The method of claim 37 wherein the influence on the progression of the angiogenic dependent disease is partial restriction of the blood supply to diseased cells, resulting in an increase in life expectancy of the mammal.
40. The method of claim 36 wherein the angiogenic dependent disease is selected from the group consisting of malignant tumors, malignant neoplasms, highly vascular tumors and neoplasms, brain cancer, genitourinary tract cancer, lymphatic cancer, stomach cancer, renal cancer, colon cancer, larynx cancer, lung cancer and bone cancer, epidermoid tumors, squamous tumors, colorectal tumors, prostate tumors, breast tumors, lung tumors, pancreatic tumors, thyroid tumors, ovarian tumors, liver tumors, squamous cell carcinoma, basal cell carcinoma, human malignant keratinocytes, Kaposi's sarcoma, neuroblastomas, capillary hemangioblastomas, meningiomas, cerebral metastases, melanoma, gastrointestinal and renal carcinomas and sarcomas, rhabdomyosarcoma, glioblastoma multiforme, histiocytic lymphoma, and leiomyosarcoma. neovascular glaucoma, proliferative retinopathy, diabetic retinopathy, retrolental fibroplastic retinopathy, macular degeneration, corneal graft rejection, atherosclerosis, rheumatoid arthritis, insulin-dependent diabetes mellitus, multiple sclerosis, myasthenia gravis, Chron's disease, autoimmune nephritis, primary biliary cirrhosis, psoriasis, acute pancreatitis, allograph rejection, allergic inflammation, contact dermatitis, delayed hypersensitivity reactions, inflammatory bowel disease, septic shock, osteoporosis, osteoarthritis, cognition defects induced by neuronal inflammation, hemangiomas, angiofibromas, Osier- Weber syndrome, restinosis, fungal, parasitic and viral infections, breast carcinoma, lung carcinoma, colorectal carcinoma, pancreatic carcinoma, glioma, lymphoma, leukemia, multiple myeloma, lymphoma, acute myelogenous leukemia, chronic myelogenous leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, erythrocytic leukemia, monocytic leukemia, Hodgkin's lymphoma and non-Hodgkin's lymphoma.
41. A method of inhibiting VEGF receptors in a mammalian patient by administering to a mammalian patient a pharmaceutical composition comprising a compound of Formula (I) as defined in claim 1 and a pharmaceutical carrier.
42. A method of freating cancer comprising administering to a patient afflicted with cancer a therapeutically effective amount of a compound of Formula (I) as defined in claim 1.
43. The method of claim 42 wherein the therapeutically beneficial effect derives from inhibition of angiogenesis.
44. The method of claim 43 wherein inhibition of angiogenesis is caused by inhibition of VEGF receptor tyrosine kinase activity in cells adjacent to the cancer.
PCT/US2003/038512 2002-12-10 2003-12-05 Anti-angiogenic compounds and their use in cancer treatment WO2004052280A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003293376A AU2003293376A1 (en) 2002-12-10 2003-12-05 Anti-angiogenic compounds and their use in cancer treatment

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US43200702P 2002-12-10 2002-12-10
US60/432,007 2002-12-10
US72649603A 2003-12-04 2003-12-04
US10/726,496 2003-12-04

Publications (2)

Publication Number Publication Date
WO2004052280A2 true WO2004052280A2 (en) 2004-06-24
WO2004052280A3 WO2004052280A3 (en) 2004-08-12

Family

ID=32511622

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/038512 WO2004052280A2 (en) 2002-12-10 2003-12-05 Anti-angiogenic compounds and their use in cancer treatment

Country Status (2)

Country Link
AU (1) AU2003293376A1 (en)
WO (1) WO2004052280A2 (en)

Cited By (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1606283A2 (en) * 2003-03-03 2005-12-21 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
WO2006034116A1 (en) * 2004-09-17 2006-03-30 Vertex Pharmaceuticals Incorporated Diaminotriazole compounds useful as protein kinase inhibitors
WO2006053903A2 (en) * 2004-11-19 2006-05-26 Rheinische Friedrich-Wilhelms Universität Low-molecular inhibitors of cytohesin-family guanine nucleotide exchange factors
WO2006064375A2 (en) * 2004-12-16 2006-06-22 Ab Science Aminoaryl substituted five-membered ring heterocyclic compounds for the treatment of diseases
EP1757290A1 (en) 2005-08-16 2007-02-28 Zentaris GmbH Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors
WO2007123939A2 (en) * 2006-04-19 2007-11-01 Laboratoires Serono S.A. Novel arylamino n-heteraryls as mek inhibitors
WO2007123936A1 (en) * 2006-04-19 2007-11-01 Laboratoires Serono Sa Novel heteroaryl-substituted arylaminopyridine derivatives as mek inhibitors
WO2007149395A2 (en) * 2006-06-20 2007-12-27 Amphora Discovery Corporation 2,5-substituted oxazole derivatives as protein kinase inhibitors for the treatment of cancer
WO2008035726A1 (en) * 2006-09-21 2008-03-27 Eisai R & D Management Co., Ltd. Pyridine derivative substituted by heteroaryl ring, and antifungal agent comprising the same
WO2008057280A1 (en) * 2006-10-27 2008-05-15 Amgen Inc. Multi-cyclic compounds and methods of use
JP2008517024A (en) * 2004-10-20 2008-05-22 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 3-allylaminopiperidine derivatives
DE102007002717A1 (en) 2007-01-18 2008-07-24 Merck Patent Gmbh Heterocyclic indazole derivatives
WO2008093674A1 (en) * 2007-01-29 2008-08-07 Santen Pharmaceutical Co., Ltd. Novel thiadiazole derivative having kinase inhibitory activity
DE102007022565A1 (en) 2007-05-14 2008-11-20 Merck Patent Gmbh Heterocyclic indazole derivatives
WO2009053102A1 (en) 2007-10-26 2009-04-30 Syngenta Participations Ag Novel imidazole derivatives
WO2009053101A1 (en) 2007-10-26 2009-04-30 Syngenta Participations Ag Novel imidazole derivatives
EP2091329A1 (en) * 2006-12-05 2009-08-26 Sun, Chung-ming Indazole compounds
WO2009127615A1 (en) * 2008-04-14 2009-10-22 Syngenta Participations Ag Novel imidazole derivatives having microbiocidal activity
DE102008038221A1 (en) 2008-08-18 2010-02-25 Merck Patent Gmbh 7-azaindole derivatives
DE102008038222A1 (en) 2008-08-18 2010-02-25 Merck Patent Gmbh Indazol-5-carboxylic acid derivatives
WO2010020305A1 (en) 2008-08-18 2010-02-25 Merck Patent Gmbh Oxadiazole derivatives for treating diabetes
US7691882B2 (en) 2005-10-31 2010-04-06 Eisai R&D Management Co., Ltd. Heterocycles substituted pyridine derivatives and antifungal agent containing thereof
US7799782B2 (en) 2003-03-03 2010-09-21 Array Biopharma Inc. P38 inhibitors and methods of use thereof
US7829585B2 (en) 2005-03-30 2010-11-09 Eisai R&D Management Co., Ltd. Antifungal agent containing pyridine derivative
US7932272B2 (en) 2003-09-30 2011-04-26 Eisai R&D Management Co., Ltd. Antifungal agent containing heterocyclic compound
US8039639B2 (en) 2006-01-31 2011-10-18 Array Biopharma Inc. Kinase inhibitors and methods of use thereof
US20110257196A1 (en) * 2008-06-16 2011-10-20 Yan Lu Compounds for treatment of cancer
EP2431035A1 (en) 2010-09-16 2012-03-21 Æterna Zentaris GmbH Novel Triazole Derivatives with Improved Receptor Activity and Bioavailability Properties as Ghrelin Antagonists of Growth Hormone Secretagogue Receptors
US8188119B2 (en) 2008-10-24 2012-05-29 Eisai R&D Management Co., Ltd Pyridine derivatives substituted with heterocyclic ring and γ-glutamylamino group, and antifungal agents containing same
US8507530B2 (en) 2007-04-27 2013-08-13 Eisai R&D Management Co., Ltd. Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same
US8513287B2 (en) 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
JP5284788B2 (en) * 2006-09-21 2013-09-11 エーザイ・アール・アンド・ディー・マネジメント株式会社 Heteroaryl ring-substituted pyridine derivatives and antifungal agents containing them
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
WO2014181287A1 (en) * 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
WO2017047602A1 (en) * 2015-09-18 2017-03-23 科研製薬株式会社 Biaryl derivative and medicine containing same
US9751869B2 (en) 2013-03-15 2017-09-05 Bristol-Myers Squibb Company LXR modulators
IT201600092051A1 (en) * 2016-09-13 2018-03-13 Alessandro Antonelli MEDICAL COMPOUND FOR TREATMENT OF THYROID CANCER
US9981915B2 (en) 2014-05-06 2018-05-29 University Of Tennessee Research Foundation Compounds for treatment of cancer
JP2018145180A (en) * 2017-03-01 2018-09-20 科研製薬株式会社 Pharmaceuticals comprising biaryl derivatives or salts thereof
WO2018206778A1 (en) * 2017-05-12 2018-11-15 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Phenyl-heterocycle-phenyl derivatives for use in the treatment or prevention of melanoma
JP2020518669A (en) * 2017-05-03 2020-06-25 ビバーチェ セラピューティクス，インク． Non-fused tricyclic compound
US10865196B2 (en) 2008-06-16 2020-12-15 University Of Tennessee Research Foundation Compounds for treatment of cancer
WO2021043208A1 (en) * 2019-09-06 2021-03-11 Impact Therapeutics, Inc 3, 5-disubstituted pyrazole compounds as kinase inhibitors and uses thereof
CN114044774A (en) * 2021-12-06 2022-02-15 北京超维知药科技有限公司 EGFR inhibitor and preparation method and application thereof
CN115279368A (en) * 2019-11-20 2022-11-01 维瓦斯治疗公司 Heteroaryl compounds
US11497751B2 (en) * 2018-01-25 2022-11-15 Redx Pharma Plc Modulators of Rho-associated protein kinase
WO2023018313A1 (en) * 2021-08-13 2023-02-16 Bisichem Co., Ltd. Fused ring heteroaryl compounds and use thereof
CN116041277A (en) * 2023-01-18 2023-05-02 中国药科大学 Phenyl and biphenyl substituted five-membered heterocyclic compound, preparation method, pharmaceutical composition and application thereof
WO2024152710A1 (en) * 2022-01-30 2024-07-25 上海市第十人民医院 Glutaminyl cyclase inhibitor and use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5438066A (en) * 1992-11-04 1995-08-01 Zeneca Limited Oxa- and thiadiazole derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5438066A (en) * 1992-11-04 1995-08-01 Zeneca Limited Oxa- and thiadiazole derivatives

Cited By (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1606283A4 (en) * 2003-03-03 2007-05-23 Array Biopharma Inc P38 inhibitors and methods of use thereof
EP1606283A2 (en) * 2003-03-03 2005-12-21 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US7799782B2 (en) 2003-03-03 2010-09-21 Array Biopharma Inc. P38 inhibitors and methods of use thereof
US8518983B2 (en) 2003-03-03 2013-08-27 Array Biopharma Inc. P38 inhibitors and methods of use thereof
US7932272B2 (en) 2003-09-30 2011-04-26 Eisai R&D Management Co., Ltd. Antifungal agent containing heterocyclic compound
US7329652B2 (en) 2004-09-17 2008-02-12 Vertex Pharamaceuticals Incorporated Diaminotriazole compounds useful as protein kinase inhibitors
WO2006034116A1 (en) * 2004-09-17 2006-03-30 Vertex Pharmaceuticals Incorporated Diaminotriazole compounds useful as protein kinase inhibitors
JP2008513488A (en) * 2004-09-17 2008-05-01 バーテックス ファーマシューティカルズ インコーポレイテッド Diaminotriazole compounds useful as inhibitors of protein kinases
JP2008517024A (en) * 2004-10-20 2008-05-22 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 3-allylaminopiperidine derivatives
US8524911B2 (en) 2004-10-20 2013-09-03 Merck Serono Sa 3-arylamino pyridine derivatives
US8841459B2 (en) 2004-10-20 2014-09-23 Merck Serono Sa 3-arylamino pyridine derivatives
US8163788B2 (en) * 2004-11-19 2012-04-24 Rheinische Friedrich-Wilhelms Universitat Bonn Low-molecular inhibitors of cytohesin-family guanine nucleotide exchange factors
WO2006053903A2 (en) * 2004-11-19 2006-05-26 Rheinische Friedrich-Wilhelms Universität Low-molecular inhibitors of cytohesin-family guanine nucleotide exchange factors
WO2006053903A3 (en) * 2004-11-19 2006-12-07 Univ Bonn Low-molecular inhibitors of cytohesin-family guanine nucleotide exchange factors
WO2006064375A2 (en) * 2004-12-16 2006-06-22 Ab Science Aminoaryl substituted five-membered ring heterocyclic compounds for the treatment of diseases
US7829585B2 (en) 2005-03-30 2010-11-09 Eisai R&D Management Co., Ltd. Antifungal agent containing pyridine derivative
US7829724B2 (en) 2005-08-15 2010-11-09 Zentaris Gmbh Triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors
US8710089B2 (en) 2005-08-15 2014-04-29 Zentaris Gmbh Triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors
EP1757290A1 (en) 2005-08-16 2007-02-28 Zentaris GmbH Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors
US8841327B2 (en) 2005-10-31 2014-09-23 Eisai R&D Management Co., Ltd. Heterocycles substituted pyridine derivatives and antifungal agent containing thereof
US7691882B2 (en) 2005-10-31 2010-04-06 Eisai R&D Management Co., Ltd. Heterocycles substituted pyridine derivatives and antifungal agent containing thereof
US8153662B2 (en) 2005-10-31 2012-04-10 Eisai R&D Management Co., Ltd. Heterocycles substituted pyridine derivatives and antifungal agent containing thereof
US8158657B2 (en) 2005-10-31 2012-04-17 Eisai R&D Management Co., Ltd. Heterocycles substituted pyridine derivatives and antifungal agent containing thereof
US8039639B2 (en) 2006-01-31 2011-10-18 Array Biopharma Inc. Kinase inhibitors and methods of use thereof
US8802703B2 (en) 2006-04-19 2014-08-12 Merck Serono S.A. Arylamino N-heteraryl compounds as MEK inhibitors
WO2007123936A1 (en) * 2006-04-19 2007-11-01 Laboratoires Serono Sa Novel heteroaryl-substituted arylaminopyridine derivatives as mek inhibitors
JP2009534386A (en) * 2006-04-19 2009-09-24 ラボラトワール セローノ ソシエテ アノニム Novel heteroaryl-substituted arylaminopyridine derivatives as MEK inhibitors
US8076486B2 (en) 2006-04-19 2011-12-13 Merck Serono S.A. Heteroaryl-substituted arylaminopyridine derivatives as MEK inhibitors
WO2007123939A3 (en) * 2006-04-19 2007-12-21 Applied Research Systems Novel arylamino n-heteraryls as mek inhibitors
WO2007123939A2 (en) * 2006-04-19 2007-11-01 Laboratoires Serono S.A. Novel arylamino n-heteraryls as mek inhibitors
US7772233B2 (en) 2006-04-19 2010-08-10 Merck Serono, S.A. Arylamino N-heteroaryl compounds as MEK inhibitors
WO2007149395A3 (en) * 2006-06-20 2008-01-31 Amphora Discovery Corp 2,5-substituted oxazole derivatives as protein kinase inhibitors for the treatment of cancer
WO2007149395A2 (en) * 2006-06-20 2007-12-27 Amphora Discovery Corporation 2,5-substituted oxazole derivatives as protein kinase inhibitors for the treatment of cancer
US8183264B2 (en) 2006-09-21 2012-05-22 Eisai R&D Managment Co., Ltd. Pyridine derivative substituted by heteroaryl ring, and antifungal agent comprising the same
WO2008035726A1 (en) * 2006-09-21 2008-03-27 Eisai R & D Management Co., Ltd. Pyridine derivative substituted by heteroaryl ring, and antifungal agent comprising the same
JP5284788B2 (en) * 2006-09-21 2013-09-11 エーザイ・アール・アンド・ディー・マネジメント株式会社 Heteroaryl ring-substituted pyridine derivatives and antifungal agents containing them
US8822514B2 (en) 2006-10-27 2014-09-02 Amgen Inc. Multi-cyclic compounds and methods of use
WO2008057280A1 (en) * 2006-10-27 2008-05-15 Amgen Inc. Multi-cyclic compounds and methods of use
US8236823B2 (en) 2006-10-27 2012-08-07 Amgen Inc. Multi-cyclic compounds and methods of use
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
EP2091329A4 (en) * 2006-12-05 2011-02-23 Univ Nat Chiao Tung Indazole compounds
EP2091329A1 (en) * 2006-12-05 2009-08-26 Sun, Chung-ming Indazole compounds
DE102007002717A1 (en) 2007-01-18 2008-07-24 Merck Patent Gmbh Heterocyclic indazole derivatives
WO2008086854A1 (en) 2007-01-18 2008-07-24 Merck Patent Gmbh 5-([1,3,4] oxadiazol-2-yl)-1h-indazol and 5-([1,3,4] thiadiazol-2-yl)-1h-indazol derivatives as sgk inhibitors for the treatment of diabetes
US8063034B2 (en) 2007-01-29 2011-11-22 Santen Pharmaceutical Co., Ltd. Oxadiazole derivatives and thiadiazole derivatives having neovascularization inhibitory activity
WO2008093674A1 (en) * 2007-01-29 2008-08-07 Santen Pharmaceutical Co., Ltd. Novel thiadiazole derivative having kinase inhibitory activity
WO2008093677A1 (en) 2007-01-29 2008-08-07 Santen Pharmaceutical Co., Ltd. Novel oxadiazole derivatives and thiadiazole derivatives having neovascularization inhibiting activity
JP2008266294A (en) * 2007-01-29 2008-11-06 Santen Pharmaceut Co Ltd Novel oxadiazole derivative and novel thiadiazole derivative each having angiogenesis inhibitory activity
KR101475540B1 (en) * 2007-01-29 2014-12-22 산텐 세이야꾸 가부시키가이샤 Novel oxadiazole derivatives and thiadiazole derivatives having neovascularization inhibiting activity
CN103224493A (en) * 2007-01-29 2013-07-31 参天制药株式会社 Novel oxadiazole derivatives and thiadiazole derivatives having neovascularization inhibitory activity
US8507530B2 (en) 2007-04-27 2013-08-13 Eisai R&D Management Co., Ltd. Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same
DE102007022565A1 (en) 2007-05-14 2008-11-20 Merck Patent Gmbh Heterocyclic indazole derivatives
WO2009053102A1 (en) 2007-10-26 2009-04-30 Syngenta Participations Ag Novel imidazole derivatives
WO2009053101A1 (en) 2007-10-26 2009-04-30 Syngenta Participations Ag Novel imidazole derivatives
US8513287B2 (en) 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
WO2009127615A1 (en) * 2008-04-14 2009-10-22 Syngenta Participations Ag Novel imidazole derivatives having microbiocidal activity
US10865196B2 (en) 2008-06-16 2020-12-15 University Of Tennessee Research Foundation Compounds for treatment of cancer
US10301285B2 (en) 2008-06-16 2019-05-28 Gtx, Inc. Compounds for treatment of cancer
US20110257196A1 (en) * 2008-06-16 2011-10-20 Yan Lu Compounds for treatment of cancer
US9334242B2 (en) 2008-06-16 2016-05-10 Gtx, Inc. Compounds for treatment of cancer
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
DE102008038222A1 (en) 2008-08-18 2010-02-25 Merck Patent Gmbh Indazol-5-carboxylic acid derivatives
DE102008038221A1 (en) 2008-08-18 2010-02-25 Merck Patent Gmbh 7-azaindole derivatives
WO2010020305A1 (en) 2008-08-18 2010-02-25 Merck Patent Gmbh Oxadiazole derivatives for treating diabetes
US8188119B2 (en) 2008-10-24 2012-05-29 Eisai R&D Management Co., Ltd Pyridine derivatives substituted with heterocyclic ring and γ-glutamylamino group, and antifungal agents containing same
US11465987B2 (en) 2010-03-01 2022-10-11 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
AU2010347233B2 (en) * 2010-03-01 2015-06-18 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
WO2012035124A1 (en) 2010-09-16 2012-03-22 Æterna Zentaris Gmbh Novel triazole derivatives with improved receptor activity and bioavailability properties as ghrelin antagonists of growth hormone secretagogue receptors
EP2431035A1 (en) 2010-09-16 2012-03-21 Æterna Zentaris GmbH Novel Triazole Derivatives with Improved Receptor Activity and Bioavailability Properties as Ghrelin Antagonists of Growth Hormone Secretagogue Receptors
US9751869B2 (en) 2013-03-15 2017-09-05 Bristol-Myers Squibb Company LXR modulators
WO2014181287A1 (en) * 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
US9981915B2 (en) 2014-05-06 2018-05-29 University Of Tennessee Research Foundation Compounds for treatment of cancer
US10155728B2 (en) 2014-05-06 2018-12-18 Gtx Inc. Compounds for treatment of cancer
JPWO2017047602A1 (en) * 2015-09-18 2018-07-12 科研製薬株式会社 Biaryl derivative and medicament containing the same
US10647675B2 (en) 2015-09-18 2020-05-12 Kaken Pharmaceutical Co., Ltd. Biaryl derivative and medicine containing same
WO2017047602A1 (en) * 2015-09-18 2017-03-23 科研製薬株式会社 Biaryl derivative and medicine containing same
RU2760373C2 (en) * 2015-09-18 2021-11-24 Какен Фармасьютикал Ко., Лтд. Biaryl derivative and drug containing it
IT201600092051A1 (en) * 2016-09-13 2018-03-13 Alessandro Antonelli MEDICAL COMPOUND FOR TREATMENT OF THYROID CANCER
JP2018145180A (en) * 2017-03-01 2018-09-20 科研製薬株式会社 Pharmaceuticals comprising biaryl derivatives or salts thereof
JP2020518669A (en) * 2017-05-03 2020-06-25 ビバーチェ セラピューティクス，インク． Non-fused tricyclic compound
WO2018206778A1 (en) * 2017-05-12 2018-11-15 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Phenyl-heterocycle-phenyl derivatives for use in the treatment or prevention of melanoma
JP2020519646A (en) * 2017-05-12 2020-07-02 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ Phenyl-heterocycle-phenyl derivatives for use in the treatment or prevention of melanoma
AU2018265584B2 (en) * 2017-05-12 2023-09-28 Ludwig-Maximilians-Universität München Phenyl-heterocycle-phenyl derivatives for use in the treatment or prevention of melanoma
US11180518B2 (en) 2017-05-12 2021-11-23 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Phenyl-heterocycle-phenyl derivatives for use in the treatment or prevention of melanoma
US11497751B2 (en) * 2018-01-25 2022-11-15 Redx Pharma Plc Modulators of Rho-associated protein kinase
US11878020B2 (en) 2018-01-25 2024-01-23 Redx Pharma Plc Modulators of Rho-associated protein kinase
CN114728945A (en) * 2019-09-06 2022-07-08 上海瑛派药业有限公司 3, 5-disubstituted pyrazole compounds as kinase inhibitors and application thereof
WO2021043208A1 (en) * 2019-09-06 2021-03-11 Impact Therapeutics, Inc 3, 5-disubstituted pyrazole compounds as kinase inhibitors and uses thereof
CN114728945B (en) * 2019-09-06 2024-01-16 上海瑛派药业有限公司 3, 5-disubstituted pyrazole compounds as kinase inhibitors and uses thereof
CN115279368A (en) * 2019-11-20 2022-11-01 维瓦斯治疗公司 Heteroaryl compounds
CN115279368B (en) * 2019-11-20 2024-05-24 维瓦斯治疗公司 Heteroaryl compounds
WO2023018313A1 (en) * 2021-08-13 2023-02-16 Bisichem Co., Ltd. Fused ring heteroaryl compounds and use thereof
CN114044774A (en) * 2021-12-06 2022-02-15 北京超维知药科技有限公司 EGFR inhibitor and preparation method and application thereof
CN114044774B (en) * 2021-12-06 2024-04-09 光武惠文生物科技(北京)有限公司 EGFR inhibitor and preparation method and application thereof
WO2024152710A1 (en) * 2022-01-30 2024-07-25 上海市第十人民医院 Glutaminyl cyclase inhibitor and use thereof
CN116041277A (en) * 2023-01-18 2023-05-02 中国药科大学 Phenyl and biphenyl substituted five-membered heterocyclic compound, preparation method, pharmaceutical composition and application thereof

Also Published As

Publication number Publication date
AU2003293376A1 (en) 2004-06-30
AU2003293376A8 (en) 2004-06-30
WO2004052280A3 (en) 2004-08-12

Similar Documents

Publication Publication Date Title
WO2004052280A2 (en) Anti-angiogenic compounds and their use in cancer treatment
AU2002364549B2 (en) Vanilloid receptor ligands and their use in treatments
JP6525437B2 (en) Antifibrotic pyridinone
US20150353538A1 (en) Compounds and therapeutic uses thereof
JP4394442B2 (en) Spiro-hydantoin compounds useful as anti-inflammatory agents
EP2493862B1 (en) Imidazole derivatives as ido inhibitors
JP4555082B2 (en) Vanilloid receptor ligands and their use in therapy
US20100311748A1 (en) Heterocyclic amides useful for the treatment of cancer and psoriasis
US20110105509A1 (en) Indole based receptor crth2 antagonists
CN103804358B (en) One class Diarylhydantoin derivant, its preparation method, pharmaceutical composition and application
EP2152079A1 (en) Heterocyclic compounds and uses thereof
CA2985542A1 (en) Triazole agonists of the apj receptor
SK12052003A3 (en) N-(2-arylethyl) benzylamines as antagonists of 5-HT6 receptor
WO2007061923A2 (en) Glucokinase activators
TW202140467A (en) Small molecule sting antagonists
EP2318370A1 (en) Fluorinated heteroaryls
JP2004523546A (en) Quinazolines as MMP-13 inhibitors
US20130317027A1 (en) Compounds and therapeutic uses thereof
WO2005000813A1 (en) Heteroarylamino-phenylketone derivatives and their use as kinase inhibitors
CA3047002A1 (en) Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
JP2007533635A (en) Vanilloid receptor ligands and their use in therapy
JP6500092B2 (en) Triazole compounds as T-type calcium channel blockers
TW200914438A (en) 3-disubstituted indol-2-one derivatives, preparation thereof and therapeutic application thereof
US20080171751A1 (en) Triazole Compounds Suitable for Treating Disorders that Respond to Modulation of the Dopamine D3 Receptor
CA1317948C (en) Omega-¬(hetero)alkyl|benz¬cd|-indol-2-amines

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP